1

February 16th, 2021

Immune system and blood-brain barrier-wide biomarker analyses provide causal evidence for autoimmunity in dementia

Joni V. Lindbohm, MD, PhD;^{1,2} Nina Mars, MD, PhD;³ Pyry N. Sipilä, MD, PhD;² Prof. Archana Singh-Manoux;^{1,4} Heiko Runz, MD, PhD;^{5,6} FinnGen; ³ Prof. Gill Livingston;^{7,8} Prof. Sudha Seshadri;^{9,10,11,12} Prof. Ramnik Xavier;^{13,14} Prof. Aroon D. Hingorani;^{15,16,17} Prof. Samuli Ripatti;^{2,3,18}* Prof. Mika Kivimäki^{1,2}*

¹ Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, UK

²Clinicum, Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland

³ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

⁴ Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Paris, France

⁵ Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/EMBL, Heidelberg, Germany

⁶ Translational Biology, Biogen Inc, Cambridge, MA, USA

⁷ Division of Psychiatry, University College London, London, UK

⁸ Camden and Islington NHS Foundation Trust, London, UK

⁹ Glenn Biggs Institute of Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.

¹⁰ Boston University School of Public Health, Boston, MA, USA.

¹¹ New York University Grossman School of Medicine, New York, NY, USA.

¹² Boston University School of Medicine, Boston, MA, USA.

¹³ Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

¹⁴ Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

¹⁵ Invotestraisof Condioxasew as Science as University is dollar of the analysis of the second of

2

¹⁶ University College London, British Heart Foundation Research Accelerator, London, UK.

¹⁷ Health Data Research UK, London, UK.

¹⁸Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA

* Authors contributed equally

Correspondence to Dr Joni Lindbohm, Clinicum, Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland; E-mail address: joni.lindbohm@helsinki.fi; Telephone: +358 9 1911 Fax: +358 9 191 27 600

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

3

Abstract

Immune system and blood brain barrier (BBB) dysfunction are implicated in the development of Alzheimer's disease and other dementias, but their causal role remains unknown. We performed Mendelian randomization (MR) for over 43,643 immune system and BBB-related biomarkers and identified 126 potential causal risk factors for dementias. A phenome-wide analysis using MR-based polygenic risk score in FinnGen study (N=339,233) for these risk factors revealed a common genetic background for dementias and autoimmune diseases which was supported by further HLA analyses. Pathway analyses linked the 126 proteins to amyloid- β , tau and α -synuclein pathways, increased inflammatory responses, and altered self-tolerance mechanisms. In inverse-probability-weighted analyses simulating randomized controlled drug trials in observational data, anti-inflammatory and immunosuppressive medications were associated with reduced dementia risk (p<0.01 for methotrexate and TNF- α inhibitors). These converging results from different research lines suggest that autoimmunity is a modifiable component in diseases causing dementia.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

4

1 Background

2 3 Dysregulation of peripheral and central immune systems and chronic neuroinflammation occur in 4 diseases, such as severe infections and autoimmune diseases that relate to increased risk of 5 dementia.¹⁻³ In central immune system, neuroinflammation can closely relate to sustained activation of microglia, the resident immune cells in the central nervous system (CNS), and lead to 6 neurodegeneration and increased deposition of plaques and tangles.¹⁻³ When CNS encounters 7 8 infections, trauma, or toxins, microglia are key in the acute immune response and in this phase are 9 neuroprotective. When the microglia activation continues, this leads to chronic production of pro-10 inflammatory products including reactive oxygen species, nitric oxide, and cytokines.¹⁻³ This in turn may exacerbate disease-specific pathology, such as amyloid β and tau protein in Alzheimer's 11 12 disease, and neurodegeneration.¹

13

14 In addition, the peripheral immune system and blood brain barrier are thought to be important in the development of dementias.^{1,4} Because of the crosstalk between the central and peripheral immune 15 16 system and BBB, the causal factors linking inflammation to dementias may originate from any of 17 these systems. Chronic peripheral inflammation, from low-grade systemic inflammation^{5,6} and 18 infections,⁷ can disrupt BBB so that it allows neurotoxic and pro-inflammatory plasma components and pathogens to enter CNS.⁴ Dysfunctional BBB may also promote peripherally driven 19 20 neuroinflammation by increasing endothelial adhesion molecules and chemokines and migration of 21 peripheral leukocytes to CNS.⁴ These processes expose CNS to prolonged neuroinflammation and 22 subsequent neurodegeneration,¹ although the role of centrally and peripherally driven CNS autoimmunity in dementias remains unclear.⁸⁻¹¹ In addition, there is limited data to confirm the 23 causal nature of these hypothesised mechanisms.¹⁻³ 24

25

Mendelian randomization (MR), using large GWAS libraries for unconfounded genetic proxies for biomarkers, and triangulation, combining multiple research methods with different sources of strengths and biases to identify convergent evidence, improve validity of causal estimates and success rate in drug development.^{12,13} Although a range of studies on the immune system and BBB have been conducted,¹⁻⁴ to the best of our knowledge, there are currently no published large-scale, immune system and BBB-wide MR analyses, confirmed by triangulation to identify novel drug targets and risk factors for dementias.

33

34 In this study, we analyse biomarkers of immune system and BBB (Figure 1) and use MR to study 35 potential causal associations with five outcomes (Alzheimer's disease, Parkinson's diseases, 36 frontotemporal dementia, vascular dementia, and poor cognitive performance) and triangulate the 37 results. We identify several novel associations between inflammatory and immune checkpoint-38 related biomarkers and dementias. Using single nucleotide polymorphisms (SNPs) strongly 39 associated with these biomarkers, we create MR-based polygenic risk scores (PRS) for the diseases. 40 In phenome-wide association analyses (PheWAS) for the PRSs, we observe shared genetic risk 41 factors with autoimmune diseases and dementias, which are supported by HLA analysis. In line 42 with this, our pathway analyses for risk factors identified in MR show enrichment in inflammatory 43 and self-tolerance related processes, which are in close interaction with amyloid β , tau protein, and 44 α -synuclein. Lastly, using inverse-probability-weighted (IPW) survival analysis to simulate a

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

5

45 randomized controlled trial design in observational data with up to 20 years of follow-up, we

46 identify anti-inflammatory medications which may lower the risk of dementias. In summary, we

47 detect several novel risk factors and potential drug targets for dementia-causing diseases in a

48 triangulation framework and propose that dementias may have an autoimmune component which is

49 modifiable with anti-inflammatory medication. These findings are set out in **Figure 2**.

50

51

52 **Results**

53

54 Mendelian randomization and proteomics analyses

55 In the discovery step, we used MR to identify potential causal risk factors for dementias. The MR-

base search provided 30,913 components for the immune system and 12,730 components for BBB;

57 254 immune system components and 132 BBB components passed the false discovery rate (FDR)

58 of 5% (Figure 1). After removal of duplicates, 126 unique biomarkers were associated (p-value

59 <0.000502) with neurodegenerative diseases in MR analyses using Wald ratio (when only 1 or 2

60 SNPs was available) or inverse variance-weighted method (when 3 or more SNPs were available)

61 (Figure 3A and B). MR sensitivity analyses showed no strong evidence of reverse causality, and

62 evidence of horizontal pleiotropy for only two outcomes. (STable 1 and SFigures 1A and B). The

63 126 biomarkers (FDR <5%) showed few off-target associations, mainly with type 1 diabetes and

- 64 LDL-C. (**SFigure 2**).
- 65

66 While most biomarkers were disease-specific, 8 were associated with Alzheimer's disease, vascular

67 dementia, and poor cognitive performance. The SNPs for the latter biomarkers were centred within

68 500 kilobases (kb) from *APOE* gene, one of the strongest genetic risk factors for late-onset

69 Alzheimer's disease (**SFile 1**). To differentiate the effects of these biomarkers from *APOE*, we

round studied dementia outcomes and plasma proteins measured within the Whitehall II cohort (N=6,235).

71 Out of the 8 proteins, 2 were associated with all-cause dementia in a 20-year follow-up and 1

72 (IFIT2) of these remained after adjustment of APOE status (SFigure 3; data on dementia subtypes

73 were not available).

74

75 The 118 outcome-specific biomarkers did not show similar enrichment around high-risk genes for

76 Alzheimer's disease such as APP, PSEN1, PSEN2, ADAM10, TREM2, PLD3, and UNC5C. Instead,

they were characterized by inflammatory, chemokine, complement, and adhesion processes (C1Q,

78 C1R, C4B, CCL1, CDHR5, GPNMB, IL1β, IL17, IL27, IL37, LTBR, PTP1B, SIGIRR), antigen

79 presenting and immune checkpoints (HLA-DR, HLA-DQ, BAFFR, C1R, C1Q, CD11, CD19,

80 CD20, CD33, CD40, CX3CR1, PD-1, and PDL-1), and BBB tight junction related biomarkers

- 81 (TJP, AIMP1, BIN1).
- 82

83 Polygenic risk score and HLA analysis

84 To study the diseases that share common genetic background with dementias, we created MR-based

- 85 polygenetic risk score (PRS) using the SNPs of the 126 biomarkers for dementias and then run a
- 86 phenome-wide association analysis (PheWAS) (Figure 4). After linkage disequilibrium (LD)
- 87 pruning and SNP matching in FinnGen (N=339,233), 92 SNPs were available for a PRS for

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

6

88 Alzheimer's disease (the number of SNPs for other outcomes was insufficient, ≤25). The PRS was

- 89 strongly and positively associated with risk of all types of dementia-causing diseases (except
- 90 Parkinson's disease) and autoimmune disorders, such as rheumatic diseases, type 1 diabetes and its
- 91 complications. The PRS was also associated with increased risk of thyroiditis, coronary heart
- 92 disease, hyperlipidaemia, and the likelihood of having medications for Crohn's disease (indicating
- disease severity), but reduced risk of cancers. We studied whether HLA-types that predispose to
- autoimmune diseases are also associated with dementias. These analyses showed 21 directionally
- 95 consistent HLA association with dementias and at least one autoimmune disease (Figure 5A-E).
- 96

97 Pathway analyses

- 98 To identify pathways the 126 biomarkers are involved in, we performed analyses based on KEGG,
- 99 ClueGO, and ConsensusPathDB databases. The findings provided further support for the
- 100 autoimmune component in dementias. KEGG and ClueGO analyses showed that the identified
- 101 biomarkers increased MHC-II-mediated antigen presentation in several processes, HLA-DR
- 102 expression across all hematopoietic cell lines, neuronal adhesion molecule CNTN2, and PD-L1 in
- 103 T-cell-antigen interactions that reduces self-tolerance. The biomarkers also decreased barrier
- 104 protecting IL-17F, self-tolerance increasing PDCD1 in T-cell-antigen interactions, and antiviral
- 105 complement factor B and IFNAR1 (**SFigures 4A-H and 5**). ConsensusPathDB analyses showed
- 106 that all of the 42 plasma proteins included in the 126 biomarkers had physical interactions with or
- 107 were in a biological pathway within zero to two molecule distance from amyloid precursor protein, 108 tau protein, or α -synuclein (**SFigure 6A-R**).
- 108 109

110 Inverse probability-weighted analyses

111 To evaluate the autoimmune hypothesis in relation to modifiability and drug repurposing, we used 112 inverse probability-weighted (IPW) analyses in FinnGen and studied whether commonly used anti-113 inflammatory and immunosuppressive medications are likely to reduce the risk of dementias (Table 114 1). We validated the IPW protocol with a positive control, by replicating the randomized controlled 115 trial (RCT) effect between statin medication and myocardial infarction and used anti-inflammatory medications as negative control.¹⁴⁻¹⁷ Supporting the autoimmune hypothesis, risk of dementia-116 causing diseases was reduced with methotrexate and TNF- α inhibitors. Methotrexate appeared to 117 118 decrease risk only in those with above-average MR-based autoimmune PRS (50% cut-off). To 119 identify rare medications not detectable in FinnGen with sufficient power, we additionally searched 120 the OpenTargets database. This search identified 64 drugs that target 18 of the 126 proteins, 121 suggesting that these may have potential for repurposing to treatment of dementias (SFile 2).

122

123 **Discussion**

124

125 Using triangulation across Mendelian randomization, plasma proteomics, polygenic risk scores,

- 126 HLA type, pathway, and IPW analyses, we identified causal support for 126 risk factors and
- 127 potential drug targets for dementia-causing diseases. Of these 118 were novel MR associations.
- 128 Most of the identified risk factors and targets were outcome specific, and included inflammatory,
- 129 self-tolerance, and/or BBB tight junction related biomarkers. A phenome-wide analysis of PRS
- 130 from SNPs associated with the identified risk factors showed that Alzheimer's disease share genetic
- 131 background with autoimmune diseases, such as rheumatoid arthritis and type 1 diabetes. The

7

132 autoimmune hypothesis was also supported by HLA analyses showing 21 HLA-type associations 133 common to dementias and autoimmune diseases. Pathway analyses linked the 126 biomarkers to

134 autoimmunity via antigen presentation and reduced self-tolerance and showed that all 42 plasma

- 135 proteins of the 126 biomarkers are closely related to α-synuclein, amyloid precursor, and tau protein pathways that characterize Alzheimer's and Parkinson's diseases and dementia with Levy bodies. 136
- 137 The autoimmune hypothesis was further supported by IPW analyses mimicking randomized
- 138 controlled drug trial in observational data. They suggested anti-inflammatory medication use may
- potentially reduce the risk of these illnesses. 139
- 140

141 Several lines of earlier and current evidence support the hypothesis that diseases causing dementia 142 have an autoimmune component (Figure 2). Epidemiological studies have shown higher rates of 143 cognitive impairment, Alzheimer's diseases, Parkinson's disease, vascular, and frontotemporal 144 dementia in rheumatic disease patients.¹⁸⁻²² Diabetes is a recognized risk factor for Alzheimer's disease²³ and individuals with type 1 diabetes have higher rate of cognitive decline, Alzheimer's 145 disease, and vascular dementia.^{24,25} Thyroiditis, which often has an autoimmune origin, increases 146 risk of dementias.^{10,26} In agreement with these findings, we showed that MR-based Alzheimer's 147 disease PRS increased risk of all these autoimmune diseases. In addition, the PRS was associated 148 149 with reduced risk of cancers, which is a well-described beneficial side effect of reduced selftolerance commonly harnessed in cancers medications.²⁷ 150

151

152 Furthermore, risk factors, course of disease, and clinical picture in dementias and autoimmune 153 diseases have several similarities. Alzheimer's and autoimmune diseases are more common in women^{9,28,29} and the diseases share inflammatory risk factors such as smoking and obesity.^{9,23,30,31} 154 Infections increase risk for autoimmune diseases,³² rate of cognitive decline,¹ and dementias even 155 156 20 years before the diagnosis,⁷ and can acutely trigger rheumatoid arthritis, type 1 diabetes and the formation of autoantibodies against CNS that lead to tissue degeneration.^{8,9,11} Interestingly, many 157 inflammation-related biomarkers in our analyses influenced pathways closely related to amyloid 158 159 precursor protein, tau protein, or α -synuclein suggesting that they may contribute to proteinopathies 160 that characterize of Alzheimer's and Parkinson's disease and dementia with Levy bodies. This 161 process has some similarities with AA form of amyloidosis in rheumatic arthritis in which uncontrolled inflammation accumulates amyloid to a range of tissues³³ and with islet amyloidosis in 162 diabetes that leads to tissue degeneration.³⁴ Two MR studies suggested inflammatory risk factor 163 may not be causally linked to dementias.^{35,36} However, those studies did not focus on processes that 164 control self-tolerance and they may have used inflammatory markers that are only responses to 165 166 these processes and thus prone to produce null finding or reverse causation in MR analyses.

167

168 Common cellular mechanisms between autoimmune disease and dementias

169 At cellular level, loss of central tolerance in central immune organs and subsequent escape of

autoreactive B- and T-cells to periphery^{37,38} are thought to predispose to autoimmune diseases 170

together with certain HLA alleles.^{9,39,40} Conversion to disease may occur after complex interplay 171

172 between inflammation, infections, and tissue damage, with subsequent failure of peripheral self-

173 tolerance mechanisms such as ignorance, anergy, suppression, inhibition, and antigen

174 presentation.^{37,38} Our results link all of these mechanism to the development of dementias.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

8

BBB normally controls tightly the access of toxins, pathogens, and peripheral molecules and cells to CNS.⁴ This keeps peripheral lymphocytes "ignorant" of CNS structures and prevents activation of autoreactive cells against CNS.³⁸ However, chronic antigen exposure and activation of innate and adaptive immune systems impair BBB by releasing pro-inflammatory cytokines, prostaglandins, and histamine leading to endothelial damage and upregulation of adhesion molecules.^{4,41} This exposes CNS to autoreactive peripheral lymphocytes that lose their ignorance.³⁸ The prolonged

- 182 inflammation also leads to reduced anergy, which allows more potentially self-reactive T-
- 183 lymphocytes to proliferate.³⁸
- 184

Our MR analyses support these processes. We showed that higher plasma levels of the integral part 185 of BBB, the tight junction component (TJP1⁴²), and proteins degrading it (AIMP1⁴³ and BIN1⁴⁴), 186 187 increased the risk of dementias. Moreover, pro-inflammatory C1Q, C1R, CD20, CD11, CDHR5, 188 GPNMB, and IL1 β^{45-49} elevated risk of dementias, whereas anti-inflammatory C4B, IL27, IL37, PTP1B, and SIGGIRR⁵⁰⁻⁵⁴ and barrier protecting IL-17F⁵⁵ reduced the risk. In suppression and 189 inhibition, regulatory T-cells suppress, or molecules on B- and T-cells inhibit activation of 190 lymphocytes at peripheral checkpoints.³⁸ Our MR analyses identified several checkpoint regulators 191 192 including BAFFR, C1R, C1Q, CD11, CD19, CD20, CD22, CD33, CD40, CX3CR1, LTBR, PD-1,

- and PDL-1^{37,48,56-64} as potential causal risk factors for poor cognitive performance and dementias,
 uncovering the importance of checkpoint control and autoreactive lymphocytes in dementias.
- 195

196 HLA analyses were also consistent with the autoimmunity hypothesis. After the increase in BBB 197 permeability, peripherally driven neuroinflammation activates central neuroinflammatory responses in astrocytes and microglia.^{1,4} The chronic neuroinflammation, pathogens, and tissue damage 198 199 initiate antigen presentation in HLA receptors on antigen-presenting cells in CNS that can activate the autoreactive B- and T-cells and initiate self-sustaining autoimmunity^{11,40} against CNS structures. 200 Supporting this we identified 21 shared HLA-types between autoimmune diseases and dementias. 201 202 Similarly, MR and pathway analyses supported causal status of HLA-DR and HLA-DQ cell types 203 in dementias.

- 205 The autoreactive cells can be activated via bystander activation, or HLA-mediated molecular mimicry and epitope spreading.^{8-10,38} In bystander activation, sustained or excessive immune 206 207 response can bypass normal T-cell antigen presentation to B-cells and activate autoreactive B-cell 208 to plasma cell that produces autoantibodies. In molecular mimicry, autoreactive T- and B-cells first 209 target foreign antigens, and then cross-react with similar self-antigens expressed by host cells. In 210 epitope spreading, cryptic epitopes (parts of dying cells, and intrinsic or foreign DNA or RNA) normally invisible to immune system become visible after tissue damage, which activates 211 212 autoreactive B- and T cells on these epitopes.
- 213

204

Our results also provide support for these mechanisms. In MR analyses, we observed that higher levels of naïve and memory CD20 B-cells, the main drug target for B-cell induced autoimmune diseases,⁶⁵ increases risk for Alzheimer's diseases. Similarly, higher levels of CD19, a co-receptor on B-cells that can lead to autoimmunity when hyperactivated,⁶⁶ increased Parkinson's diseases risk. We also observed that higher levels of IgG against Epstein-Barr virus' nuclear antigen, a marker of active infection that can mimic CNS structures,^{67,68} elevated Alzheimer's diseases risk. In

9

addition, IFIT2 that intercepts foreign RNA and protects against central viral infections,⁶⁹ reduced 220 the risk of all dementia causing diseases except Parkinson's diseases. Moreover, the pathway 221 222 analyses suggested that many proteins (COPS6, SOCS3, PSMB5, TOLLIP, TRIM21, PRPF40A, NOC4L, RPS6, IK, KRR1, and MTO1)⁷⁰⁻⁸⁰ involved in intracellular pathways from DNA, RNA, 223 224 and protein processing to antigen presentation may be linked with amyloid β , tau protein, and α synuclein.

- 225
- 226

227 The identified 8 proteins with SNPs located near APOE gene were associated with increased BBB permeability, inflammation, neurotoxicity, and lipid transport disturbances, ^{42,56,69,81-84} which are all 228 processes linked to APOE in Alzheimer's disease.⁸⁵ Our results suggest that the 8 proteins may be 229 linked to the effects of APOE. Another novel result was that higher levels of CD33, one of the top 230 231 GWAS hits for Alzheimer's diseases⁸⁶ and target receptor on microglia for an ongoing trial 232 (NCT03822208) including mild to moderate Alzheimer's diseases patients, increased the risk of 233 disease even when expressed on peripheral leukocytes.

234

Anti-inflammatory medications and dementias 235

236 Our IPW analyses on use of anti-inflammatory medications, including records of filled drug 237 prescriptions in initially dementia-free individuals at baseline followed up to 20 years supported the 238 modifiability of dysfunctional autoimmune processes. We replicated protective associations between TNF-α inhibitors.⁸⁷ methotrexate.⁸⁸ and Alzheimer's disease. As novel findings we showed 239 that methotrexate may be protective only for Alzheimer's and Parkinson's disease among those 240 241 with high MR-based PRS. These findings are plausible on a cellular level for BBB degradation and 242 neuroinflammation. TNF- α is a gatekeeper of inflammatory responses and endothelial 243 permeability.⁸⁹ Methotrexate, in turn, modulates a range of inflammatory and immune responses in 244 nearly every cell types forming the foundations for treatment of rheumatoid arthritis.⁹ NSAIDs and antihistamines appeared to decrease risk for all dementias but the validation using a negative control 245 246 outcome (coronary heart disease) suggested that the IPW model for these medications was 247 insufficient to replicate trial design.

248

Randomized controlled trials of TNF- α inhibitors in Alzheimer's disease patients have not shown 249 benefits in 1 to 2 year follow-up.^{90,91} However, in autoimmune diseases, early initiation of anti-250 251 inflammatory medication is of paramount importance suggesting that the trials of medication for people with established dementia may be too late.⁹ 252

253

254 **Strengths and limitations**

Our triangulation approach has several strengths. By using a broad set of immune system and BBB 255

- 256 biomarkers we were able to study these systems comprehensively without restrictions to specific 257 predefined hypotheses. Our findings are based on MR, a promising approach to examine causality,¹²
- 258 and on analyses using plasma proteomics, PRS, HLA, pathway, and IPW analyses in two
- 259 independent cohorts and a range of databases. Plasma protein analyses allowed us to adjust effect
- 260 estimates for APOE which was not possible in Mendelian randomization analyses for some
- 261 proteins. PRS and HLA analyses used data from the FinnGen study with a sample size of 340,000
- providing sufficient statistical power for the identification of shared novel risk alleles between 262
- 263 dementias and autoimmune disease. We used ConsensusPathDB, which is one of the most

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

10

264 comprehensive collection of databases on molecular pathways and interactions.⁹² The medication
 265 analyses used IPW survival analysis that is suggested to provide more reliable causal estimates than
 266 traditional survival analyses of observational data.⁹³

267

Our study has also several limitations. Although we explored over 40,000 biomarkers related to the 268 269 immune system and BBB, we may have missed some biomarkers due to limitations in search 270 protocol or lack of SNPs. Our plasma protein analyses were limited by lack of data on dementia subtypes. The PRS and PheWAS analyses were done with samples with European ancestry and may 271 272 not apply to non-European ancestries. Due to limited number of SNPs included in PRS, we may 273 have missed important immune system and BBB related associations in our phenome-wide analyses. Nonetheless, the Alzheimer's MR-based PRS associated strongly with all types of 274 275 dementia (except Parkinson's disease) and a range of outcomes related to type 1 diabetes and 276 rheumatic diseases suggesting that at least these findings are robust. The IPW analyses on 277 medications may include some bias due to a limited number of covariates for simulation of 278 randomized control trial. However, major bias is unlikely for the main findings since the analysis 279 protocol was validated by a positive- and negative-control analyses.

280 281

282 Conclusions

283

In summary, this study provides novel insights into autoimmunity, BBB, and inflammatory
dysfunctions that may contribute to the development of dementias. As the inflammatory
components are potentially modifiable with anti-inflammatory medications, the present results also
raise hypotheses on several novel drug targets for dementia-causing diseases which need to be
validated in future experimental studies. Randomized controlled trials on early initiation of these
medications for high-risk individuals are warranted while antigen-specific prevention strategies may
offer new avenues in search of treatment for dementias.

293 Methods

294

292

295 Mendelian randomization

The SNPs for biomarkers and outcomes were searched from MR-base database.⁹⁴ Immune system 296 297 and BBB search terms were identified using identifiers of cell types, receptors, proteins, metabolites, and genes. The identifiers were searched from several publications^{3,4,6,23,36,38,40,95,96} and 298 from Uniprot⁹⁷ with search terms "immune" and "blood brain barrier". Outcomes included all 299 300 cohorts with following diseases: all types of Alzheimer's disease, Parkinson's disease, vascular 301 dementia, frontotemporal dementia, dementia in general, and progression of dementia. (SMethods). Poor cognitive performance was chosen as an intermediate outcome. Two sample MR was used to 302 analyse associations between biomarkers and outcomes.¹² First analyses estimated effects with 303 Wald ratio or inverse variance-weighted analyses.⁹⁴ For biomarker-outcome pairs that passed FDR 304 of 5% and shared over two common SNPs we performed sensitivity analyses with weighted 305

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

11

median, simple mode, MR Egger, and backward Mendelian randomization¹² with TwoSampleMR
 and MRInstruments R packages.

308

To assess off-target effects of the observed causal biomarkers, we performed a phenome-wide MR
 analysis for each biomarker, using GWAS summary statistics for 210 UK Biobank endpoints
 conducted by Neale lab and with recognized dementia risk factors.^{23,98}

- 312
- 313
- 314

315 Plasma protein analyses

316 Plasma protein measurements in Whitehall II study were available for 6,235 individuals of whom 310 developed dementia and the methods have been describe before (**SMethods**).^{6,99,100} In brief, the 317 plasma proteins were measured using the SomaScan version 4.0 and 4.1 assays.^{6,101,102} The assays 318 319 were validated against external reference population and protein-specific conversion coefficients 320 were used to balance the technical differences between versions 4.0 and 4.1. Using DNA extracted from whole blood, a standard PCR assay determined APOE genotype using the salting out 321 322 method.^{103,104} In analyses, proteins were transformed to a normal distribution by inverse rank-based 323 normal transformation. The analyses used plasma samples measured in 1995/1997 and the follow-324 up ended at onset of dementia, death, or 1st of October 2019, which ever occurred first. Cox regression models adjusted for age, sex, and APOE estimated associations between the proteins and 325 dementia.¹⁰⁵ The proportionality assumption in all Cox models was assessed with Schoenfeld 326 residuals and with log-log plots.¹⁰⁵ We used statistical software R (3.6.0 and 4.1.0) for these 327 328 analyses.

329

330 Polygenic risk score and IPW analyses

FinnGen Data Freeze 8 contains 339,233 individuals, and is a collection of prospective
epidemiological and disease-based cohorts, and hospital biobank samples and links genotypes by
the unique national personal identification numbers to nationwide health registries, including the
national hospital discharge (available from 1968), death (1969–), cancer (1953–) and medication
reimbursement (1964–) and purchase (1995–) registries. Genotyping and imputation is described in
SMethods.

337

PRS was constructed from SNPs that were associated with the 126 MR identified causal biomarkers 338 339 for dementias. The SNPs were LD-pruned with clumping cut-off $R^2 = 0.01$ in 500kb window with R package TwoSampleMR. The available SNPs were searched from FinnGen genotypes and the 340 341 final scores were generated with PLINK v2.00aLM3 by calculating the SNP-biomarker beta 342 weighted sum of risk alleles for each SNP. The PRS was scaled to zero mean and unit variance, and 343 we analysed its phenome-wide associations across 2401 disease endpoints. The association between 344 PRS and endpoints were studied with logistic regression, adjusting for birth year, sex, and ten first 345 principal components of ancestry.

346

The IPW analyses⁹³ were done in FinnGen and included participants aged over 45 without any dementia-causing disease at baseline (N = 90,512). ATC codes for anti-inflammatory medication use were obtained from linkage to national medication purchase registry (data starts from 1995) and

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

12

in each analyses we included only new medication users to simulate trial design.¹⁰⁶ A model

including a range of baseline and time-varying variables and informative censoring estimated the

352 weights (**SMethods**). The analyses used time-varying Cox models and assumptions were assessed

- similar to plasma proteins. The follow-up started in 1997 and ended at onset of dementia, death, or 354 31^{st} of December 2019, which ever occurred first. We used R (4.1.2) and ipw package for these
- 355 analyses.
- 356

357 HLA analyses

The analyses were done using HLA alleles, imputed with high accuracy using a Finnish-specific reference panel, which has been previously described in detail.¹⁰⁷ After filtering based on a HLA carrier frequency of ≥ 0.01 and posterior probability of ≥ 0.6 , we assessed the association between HLA alleles and dementias and autoimmune diseases using logistic regression adjusted for birth year, sex, and ten first principal components of ancestry.

363

364 **Pathway analyses**

365 KEGG pathway analysis was done with Generally Applicable Gene-set Enrichment (GAGE),¹⁰⁸

using MR betas and p-values as input for expression ratios. GO term enrichment analyses were
 done with ClueGO version 2.5.8¹⁰⁹ in Cytoscape version 3.7.2¹¹⁰ (SMethods). The hypergeometric
 test used all the 76 plasma proteins or surface receptors of the 126 biomarkers as input and all

immune system and BBB related proteins from Uniprot⁹⁷ as background, with correction for 5%
 FDR. The shortest interaction path analyses were done with ConsensusPathDB.⁹² a web based

- analysis tool containing several biomedical databases.
- 372

373 **Open Targets analyses**

374 Medications that change the levels of the 126 biomarkers were searched from Open Targets375 database using Uniprot protein and Entrez gene symbols.

376

377 378

379

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

13

394 Ethics statement

In the Whitehall II study, research ethics approvals were renewed at each wave; the most recent
approval was obtained from the University College London Hospital Committee on the Ethics of
Human Research (reference number 85/0938). Written, informed consent from participants was
obtained at each contact.

399

400 Patients and control subjects in FinnGen provided informed consent for biobank research, based on

- 401 the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish
- 402 Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were
- 403 collected based on study-specific consents and later transferred to the Finnish biobanks after
- 404 approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare
- and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The
- 406 Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement
- 407 number for the FinnGen study is Nr HUS/990/2017.
- 408
- 409 The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers:
- 410 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
- 411 THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
- 412 THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:
- 413 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution
- 414 (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA
- 415 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020),
- 416 Findata permit numbers THL/2364/14.02/2020,
- 417 THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020,
- 418 THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020,
- 419 THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021,
- 420 THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021,
- 421 THL/4235/14.06.00/2021 and Statistics Finland (permit numbers: TK-53-1041-17 and
- 422 TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021).
- 423
- 424 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 8
- 425 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67,
- 426 BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service
- 427 Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154 and amendment
- 428 #1 (August 17 2020), AB20-5926 and amendment #1 (April 23 2020), Biobank Borealis of
- 429 Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020,
- 430 Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central
- 431 Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.
- 432

433 Acknowledgments and Funding Sources

- 434 We want to acknowledge the participants and investigators of FinnGen study. The FinnGen project
- 435 is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the
- 436 following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers
- 437 Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp &

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

14

438 Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US

- 439 Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer
- 440 Ingelheim. Following biobanks are acknowledged for delivering biobank samples to FinnGen:
- 441 Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank
- 442 (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
- 443 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
- 444 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
- 445 US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland
- 446 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-
- 447 FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank
- 448 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank
- 449 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are
- 450 members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB
- 451 (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank
- 452 data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by
- 453 FINBB.

454

- 455 The study was supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research
- 456 Council (S011676, K013351, R024227), the National Institute on Aging (National Institutes of
- 457 Health; R01AG056477 and RF1AG062553), the British Heart Foundation (RG/16/11/32334), the
- 458 Academy of Finland (311492), NordForsk (75021), and SomaLogic, Inc. JVL was supported by
- 459 Academy of Finland (339568). NM was supported by the Academy of Finland (331671). PNS was
- supported by the Emil Aaltonen Foundation. MK was supported by the Wellcome Trust
- 461 (221854/Z/20/Z), UK Medical Research Council (MR/S011676, MR/R024227), US National
- 462 Institute on Aging (R01AG062553, R01AG056477), Academy of Finland (311492), Helsinki
- 463 Institute of Life Science (H970), and the Finnish Work Environment Fund (190424). SR was
- 464 funded by Academy of Finland (285380 and 312062), Sigrid Jusélius Foundation and University of
- 465 Helsinki HiLIFE Fellow grants 2017-2020.
- 466
- 467 FinnGen consortium authors are listed in FinnGen Banner Authors file.
- 468
- 469

470 Author Contributions

- 471 JVL, NM, SR, and MK generated the hypothesis and designed the study. JVL wrote the first draft
- 472 of the report, did the primary analyses, with support from NM, and performed literature searches.
- 473 All authors interpreted the data and critically commented and reviewed the report. JVL and MK had
- 474 full access to pseudonymised data from the Whitehall II. JVL, NM, and SR had full access to
- 475 pseudonymised data from the FinnGen study.
- 476

477 **Competing interests**

- 478 In Whitehall II study part of the proteins were measured as academic–industry partnership project
- 479 beween UCL and SomaLogic, Inc. which provided expertise in plasma proteins and funded 2240
- 480 SOMAscan assays. PNS reports a grant from the Emil Aaltonen foundation, during the conduct of
- 481 the study. MK reports grants from Wellcome Trust, UK Medical Research Council, US National

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

482 Institute on Aging, Academy of Finland, Helsinki Institute of Life Science, and the Finnish Work

483 Environment Fund, during the conduct of the study.

485 Data sharing

- 486 Data, protocols, and other metadata of the Whitehall II and FinnGen studies are available according
- to the data sharing policies of these studies. Pre-existing data access policy for Whitehall II specify
- that research data requests can be submitted to each steering committee; these will be promptly
- reviewed for confidentiality or intellectual property restrictions and will not unreasonably be
- 490 refused. Detailed information on data sharing can be found here:
- 491 https://www.ucl.ac.uk/epidemiology-health-care/research/epidemiology-and-public-
- 492 health/research/whitehall-ii/data-sharing Individual-level patient or protein data may further be
- 493 restricted by consent, confidentiality, or privacy laws/considerations. The FinnGen data may be
- 494 accessed through Finnish Biobanks' FinBB portal (www.finbb.fi).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

16

526 **References**

- Bettcher, B.M., Tansey, M.G., Dorothée, G. & Heneka, M.T. Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. *Nat Rev Neurol* 17, 689-701 (2021).
- 532 2. Kinney, J.W., *et al.* Inflammation as a central mechanism in Alzheimer's disease.
 533 *Alzheimers Dement (N Y)* 4, 575-590 (2018).
- 5343.Tan, E.K., *et al.* Parkinson disease and the immune system associations, mechanisms and535therapeutics. *Nat Rev Neurol* 16, 303-318 (2020).
- 536 4. Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R. & Zlokovic, B.V. Blood-Brain
 537 Barrier: From Physiology to Disease and Back. *Physiological Reviews* 99, 21-78 (2019).
- 5. Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* 14, 576-590 (2018).
- 541 6. Lindbohm, J.V., *et al.* Plasma proteins, cognitive decline, and 20-year risk of dementia in
 542 the Whitehall II and Atherosclerosis Risk in Communities studies. *Alzheimer's & dementia*:
 543 *the journal of the Alzheimer's Association* (2021).
- 544 7. Sipilä, P.N., *et al.* Hospital-treated infectious diseases and the risk of dementia: a large,
 545 multicohort, observational study with a replication cohort. *Lancet Infect Dis* 21, 1557-1567
 546 (2021).
- 547 8. Op de Beeck, A. & Eizirik, D.L. Viral infections in type 1 diabetes mellitus--why the β
 548 cells? *Nat Rev Endocrinol* 12, 263-273 (2016).
- 549 9. Smolen, J.S., et al. Rheumatoid arthritis. Nature Reviews Disease Primers 4, 18001 (2018).
- 550 10. Stassi, G. & De Maria, R. Autoimmune thyroid disease: new models of cell death in autoimmunity. *Nat Rev Immunol* 2, 195-204 (2002).
- 11. Prüss, H. Autoantibodies in neurological disease. *Nat Rev Immunol* **21**, 798-813 (2021).
- Holmes, M.V., Richardson, T.G., Ference, B.A., Davies, N.M. & Davey Smith, G.
 Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. *Nat Rev Cardiol* 18, 435-453 (2021).
- 556 13. Munafo, M.R. & Davey Smith, G. Robust research needs many lines of evidence. *Nature*557 553, 399-401 (2018).
- Law, M.R., Wald, N.J. & Rudnicka, A.R. Quantifying effect of statins on low density
 lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-*Bmj* 326, 1423 (2003).
- 15. Bally, M., *et al.* Risk of acute myocardial infarction with NSAIDs in real world use:
 bayesian meta-analysis of individual patient data. *Bmj* **357**, j1909 (2017).
- Thanigaimani, S., Phie, J., Krishna, S.M., Moxon, J. & Golledge, J. Effect of disease
 modifying anti-rheumatic drugs on major cardiovascular events: a meta-analysis of
 randomized controlled trials. *Sci Rep* 11, 6627 (2021).
- 566 17. Ridker, P.M., *et al.* Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
 567 *New England Journal of Medicine* 380, 752-762 (2018).
- 568 18. Broce, I., *et al.* Immune-related genetic enrichment in frontotemporal dementia: An analysis
 569 of genome-wide association studies. *PLoS Med* 15, e1002487 (2018).
- 570 19. Chou, R.C., Kane, M., Ghimire, S., Gautam, S. & Gui, J. Treatment for Rheumatoid
 571 Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. *CNS Drugs* 30, 1111-1120 (2016).
- Wallin, K., *et al.* Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. *J Alzheimers Dis* **31**, 669-676 (2012).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Zhou, M., Xu, R., Kaelber, D.C. & Gurney, M.E. Tumor Necrosis Factor (TNF) blocking
 agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid
 arthritis and psoriasis. *PLoS One* 15, e0229819 (2020).
- 578 22. Li, X., Sundquist, J. & Sundquist, K. Subsequent risks of Parkinson disease in patients with
 autoimmune and related disorders: a nationwide epidemiological study from Sweden.
 580 *Neurodegener Dis* 10, 277-284 (2012).
- 581 23. Livingston, G., *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet
 582 Commission. *Lancet (London, England)* 396, 413-446 (2020).
- Jacobson, A.M., *et al.* Cognitive performance declines in older adults with type 1 diabetes:
 results from 32 years of follow-up in the DCCT and EDIC Study. *Lancet Diabetes Endocrinol* 9, 436-445 (2021).
- 586 25. Lacy, M.E., *et al.* Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes.
 587 *Diabetes Care* 41, 2339-2345 (2018).
- 588 26. Sipilä, P.N., *et al.* Long-term risk of dementia following hospitalization due to physical diseases: A multicohort study. *Alzheimer's & dementia : the journal of the Alzheimer's*590 *Association* 16, 1686-1695 (2020).
- 591 27. Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by
 592 CTLA-4 blockade. *Science* 271, 1734-1736 (1996).
- 593 28. Krischer, J.P., *et al.* The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age,
 594 Sex, and Family History on the Progression From Multiple Autoantibodies to Type 1
 595 Diabetes: A TEDDY Study Report. *Diabetes* 66, 3122-3129 (2017).
- 596 29. Gleicher, N. & Barad, D.H. Gender as risk factor for autoimmune diseases. *J Autoimmun* 28, 1-6 (2007).
- 598 30. Corbin, K.D., *et al.* Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and
 599 Mechanisms. *Endocr Rev* 39, 629-663 (2018).
- 800 31. Rasouli, B., *et al.* Smoking and the Risk of LADA: Results From a Swedish Population801 Based Case-Control Study. *Diabetes Care* 39, 794-800 (2016).
- 32. Nielsen, P.R., Kragstrup, T.W., Deleuran, B.W. & Benros, M.E. Infections as risk factor for autoimmune diseases A nationwide study. *J Autoimmun* 74, 176-181 (2016).
- Berfetto, F., *et al.* Systemic amyloidosis: a challenge for the rheumatologist. *Nature Reviews Rheumatology* 6, 417-429 (2010).
- 606 34. Rojas, J., *et al.* Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes
 607 Therapy. *J Diabetes Res* 2018, 9601801 (2018).
- 608 35. Fani, L., *et al.* Circulating biomarkers of immunity and inflammation, risk of Alzheimer's disease, and hippocampal volume: a Mendelian randomization study. *Translational*610 *Psychiatry* 11, 291 (2021).
- 611 36. Walker, K.A., *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways
 612 associated with dementia risk. *Nature Aging* 1, 473-489 (2021).
- 613 37. von Boehmer, H. & Melchers, F. Checkpoints in lymphocyte development and autoimmune
 614 disease. *Nat Immunol* 11, 14-20 (2010).
- 615 38. Theofilopoulos, A.N., Kono, D.H. & Baccala, R. The multiple pathways to autoimmunity.
 616 *Nat Immunol* 18, 716-724 (2017).
- Buzzetti, R., Zampetti, S. & Maddaloni, E. Adult-onset autoimmune diabetes: current
 knowledge and implications for management. *Nat Rev Endocrinol* 13, 674-686 (2017).
- 619 40. Dendrou, C.A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat Rev*620 *Immunol* 18, 325-339 (2018).
- 41. Abbott, N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. *Cell Mol Neurobiol* 20, 131-147 (2000).
- 42. Furuse, M., *et al.* Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. *J Cell Biol* **127**, 1617-1626 (1994).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

monocyte-activating polypeptide II in the rat hippocampus following status epilepticus. Int J

Thomas, S., et al. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell

18

Li, C., Ma, W., Zhao, Y. & Wang, H. Changes in the expression of endothelial

625

626 627

628

43.

44.

Mol Med 47, 699-707 (2021).

- 629 Barrier Function. Dig Dis Sci 61, 423-432 (2016). 630 45. Carmona, F.D., et al. Novel identification of the IRF7 region as an anticentromere 631 autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 71, 114-119 (2012). Dalakas, M.C., Alexopoulos, H. & Spaeth, P.J. Complement in neurological disorders and 632 46. 633 emerging complement-targeted therapeutics. Nat Rev Neurol 16, 601-617 (2020). 634 47. Migliorini, P., Italiani, P., Pratesi, F., Puxeddu, I. & Boraschi, D. The IL-1 family cytokines 635 and receptors in autoimmune diseases. Autoimmun Rev 19, 102617 (2020). 636 48. Nowatzky, J., Manches, O., Khan, S.A., Godefroy, E. & Bhardwaj, N. Modulation of human 637 Th17 cell responses through complement receptor 3 (CD11 b/CD18) ligation on monocyte-638 derived dendritic cells. J Autoimmun 92, 57-66 (2018). 639 49. Saade, M., Araujo de Souza, G., Scavone, C. & Kinoshita, P.F. The Role of GPNMB in 640 Inflammation. Front Immunol 12, 674739 (2021). 641 Berdnikovs, S., et al. PTP1B deficiency exacerbates inflammation and accelerates leukocyte 50. 642 trafficking in vivo. J Immunol 188, 874-884 (2012). 643 51. Kamitaki, N., et al. Complement genes contribute sex-biased vulnerability in diverse 644 disorders. Nature 582, 577-581 (2020). Meka, R.R., Venkatesha, S.H., Dudics, S., Acharya, B. & Moudgil, K.D. IL-27-induced 645 52. 646 modulation of autoimmunity and its therapeutic potential. Autoimmun Rev 14, 1131-1141 647 (2015).648 Xu, W.D., Zhao, Y. & Liu, Y. Insights into IL-37, the role in autoimmune diseases. 53. 649 Autoimmun Rev 14, 1170-1175 (2015). 650 Cavalli, G. & Dinarello, C.A. Suppression of inflammation and acquired immunity by IL-54. 651 37. Immunol Rev 281, 179-190 (2018). 652 55. McGeachy, M.J., Cua, D.J. & Gaffen, S.L. The IL-17 Family of Cytokines in Health and 653 Disease. Immunity 50, 892-906 (2019). 654 Brink, R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 18, 276-283 (2006). 56. 655 57. Choi, J.W., et al. The prognostic significance of VISTA and CD33-positive myeloid cells in 656 cutaneous melanoma and their relationship with PD-1 expression. Scientific Reports 10, 657 14372 (2020). 658 58. Wang, O., et al. Transient BAFF Blockade Inhibits Type 1 Diabetes Development in 659 Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to 660 Deletion by Anti-CD20 Cotherapy. J Immunol 199, 3757-3770 (2017). 661 59. Yamauchi, T., et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of 662 response to immune checkpoint inhibitors. Nature Communications 12, 1402 (2021). 663 Dörner, T., Shock, A. & Smith, K.G. CD22 and autoimmune disease. Int Rev Immunol 31, 60. 664 363-378 (2012). 665 Gommerman, J.L. & Summers deLuca, L. LTBR and CD40: working together in dendritic 61. 666 cells to optimize immune responses. Immunol Rev 244, 85-98 (2011). 667 62. Maldini, C.R., Ellis, G.I. & Riley, J.L. CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18, 605-616 (2018). 668
- 669 63. Schittenhelm, L., Hilkens, C.M. & Morrison, V.L. β(2) Integrins As Regulators of Dendritic
 670 Cell, Monocyte, and Macrophage Function. *Front Immunol* 8, 1866 (2017).
- 671 64. Wang, J. & Fu, Y.X. The role of LIGHT in T cell-mediated immunity. *Immunol Res* 30, 201-214 (2004).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19

673 65. Meffre, E. & O'Connor, K.C. Impaired B-cell tolerance checkpoints promote the 674 development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev 292, 90-675 101 (2019). 676 Hobeika, E., Nielsen, P.J. & Medgyesi, D. Signaling mechanisms regulating B-lymphocyte 66. 677 activation and tolerance. J Mol Med (Berl) 93, 143-158 (2015). 678 67. Gate, D., et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's 679 disease. Nature 577, 399-404 (2020). 680 Xiao, D., et al. A meta-analysis of interaction between Epstein-Barr virus and HLA-68. 681 DRB1*1501 on risk of multiple sclerosis. Scientific Reports 5, 18083 (2015). Das Sarma, J., et al. Ifit2 deficiency restricts microglial activation and leukocyte migration 682 69. 683 following murine coronavirus (m-CoV) CNS infection. PLoS Pathog 16, e1009034 (2020). 684 70. Bech-Otschir, D., et al. COP9 signalosome-specific phosphorylation targets p53 to 685 degradation by the ubiquitin system. *Embo j* **20**, 1630-1639 (2001). 686 Bertram, K., et al. Cryo-EM Structure of a Pre-catalytic Human Spliceosome Primed for 71. 687 Activation. Cell 170, 701-713.e711 (2017). 688 Choudhary, B., Marx, O. & Norris, A.D. Spliceosomal component PRP-40 is a central 72. 689 regulator of microexon splicing. Cell Rep 36, 109464 (2021). 690 Groettrup, M., et al. A role for the proteasome regulator PA28alpha in antigen presentation. 73. 691 Nature 381, 166-168 (1996). Kamura, T., et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-692 74. 693 Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18, 3055-3065 (2004). 694 75. Lu, K., Psakhye, I. & Jentsch, S. Autophagic clearance of polyO proteins mediated by 695 ubiquitin-Atg8 adaptors of the conserved CUET protein family. Cell 158, 549-563 (2014). 696 76. Sturm, M., Cheng, J., Baßler, J., Beckmann, R. & Hurt, E. Interdependent action of KH 697 domain proteins Krr1 and Dim2 drive the 40S platform assembly. Nat Commun 8, 2213 698 (2017). 699 77. Wada, K. & Kamitani, T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res 700 Commun 339, 415-421 (2006). 701 78. Yamashita, D., et al. hDREF regulates cell proliferation and expression of ribosomal protein 702 genes. Mol Cell Biol 27, 2003-2013 (2007). 703 79. Zhu, X., et al. Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory 704 and Conventional T Cells. Cell Rep 27, 1205-1220.e1204 (2019). 705 Li, X., Li, R., Lin, X. & Guan, M.X. Isolation and characterization of the putative nuclear 80. 706 modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 707 S rRNA A1555G mutation. J Biol Chem 277, 27256-27264 (2002). 708 Estefanía, E., et al. Human KIR2DL5 is an inhibitory receptor expressed on the surface of 81. 709 NK and T lymphocyte subsets. J Immunol 178, 4402-4410 (2007). 710 Adly, A.A.M., Ismail, E.A., Tawfik, L.M., Ebeid, F.S.E. & Hassan, A.A.S. Endothelial 82. 711 monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: 712 Relation to micro-vascular complications. Cytokine 76, 156-162 (2015). 713 83. Dolan, J., et al. The extracellular leucine-rich repeat superfamily; a comparative survey and 714 analysis of evolutionary relationships and expression patterns. BMC Genomics 8, 320 715 (2007). 716 84. García-Heredia, J.M. & Carnero, A. The cargo protein MAP17 (PDZK1IP1) regulates the 717 immune microenvironment. Oncotarget 8, 98580-98597 (2017). 718 85. Yamazaki, Y., Zhao, N., Caulfield, T.R., Liu, C.C. & Bu, G. Apolipoprotein E and 719 Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15, 501-518 720 (2019). 721 86. Naj, A.C., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are 722 associated with late-onset Alzheimer's disease. Nat Genet 43, 436-441 (2011).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .


20

723 Torres-Acosta, N., O'Keefe, J.H., O'Keefe, E.L., Isaacson, R. & Small, G. Therapeutic 87. 724 Potential of TNF-α Inhibition for Alzheimer's Disease Prevention. J Alzheimers Dis 78, 619-725 626 (2020). 726 Judge, A., et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis 88. 727 patients. Alzheimers Dement (NY) 3, 612-621 (2017). 728 89. Chen, A.Y., Wolchok, J.D. & Bass, A.R. TNF in the era of immune checkpoint inhibitors: 729 friend or foe? Nature Reviews Rheumatology 17, 213-223 (2021). 730 Aisen, P.S., et al. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease 90. 731 ProgressionA Randomized Controlled Trial. JAMA 289, 2819-2826 (2003). 732 91. Butchart, J., et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, 733 double-blind, phase 2 trial. Neurology 84, 2161-2168 (2015). 734 92. Herwig, R., Hardt, C., Lienhard, M. & Kamburov, A. Analyzing and interpreting genome 735 data at the network level with ConsensusPathDB. Nature Protocols 11, 1889-1907 (2016). 736 Hernán, M.A. & Robins, J.M. Using Big Data to Emulate a Target Trial When a 93. 737 Randomized Trial Is Not Available. Am J Epidemiol 183, 758-764 (2016). 738 94. Hemani, G., et al. The MR-Base platform supports systematic causal inference across the 739 human phenome. Elife 7(2018). 740 Akiyama, H., et al. Inflammation and Alzheimer's disease. Neurobiology of aging 21, 383-95. 741 421 (2000). 742 O'Brien, J.T. & Thomas, A. Vascular dementia. Lancet (London, England) 386, 1698-1706 96. 743 (2015). 744 97. UniProt, C. UniProt: a worldwide hub of protein knowledge. Nucleic acids research 47, 745 D506-D515 (2019). 746 98. http://www.nealelab.is/uk-biobank/. 747 99. Kivimaki, M., et al. Validity of Cardiovascular Disease Event Ascertainment Using Linkage 748 to UK Hospital Records. Epidemiology (Cambridge, Mass.) 28, 735-739 (2017). 749 100. Sommerlad, A., et al. Accuracy of general hospital dementia diagnoses in England: 750 Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. Alzheimer's & 751 dementia : the journal of the Alzheimer's Association 14, 933-943 (2018). 752 101. Gold, L., et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. 753 *PloS one* **5**, e15004 (2010). 754 Williams, S.A., et al. Plasma protein patterns as comprehensive indicators of health. Nature 102. 755 medicine 25, 1851-1857 (2019). 756 103. Bolla, M.K., Wood, N. & Humphries, S.E. Rapid determination of apolipoprotein E 757 genotype using a heteroduplex generator. Journal of lipid research 40, 2340-2345 (1999). 758 Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting 104. 759 DNA from human nucleated cells. Nucleic acids research 16, 1215 (1988). 760 Cox, D.R. Regression Models and Life-Tables. Journal of the Royal Statistical 105. 761 *Society.Series B (Methodological)* **34**, 187-220 (1972). 762 106. Dickerman, B.A., García-Albéniz, X., Logan, R.W., Denaxas, S. & Hernán, M.A. Avoidable 763 flaws in observational analyses: an application to statins and cancer. Nat Med 25, 1601-1606 764 (2019). 765 Ritari, J., Hyvärinen, K., Clancy, J., Partanen, J. & Koskela, S. Increasing accuracy of HLA 107. 766 imputation by a population-specific reference panel in a FinnGen biobank cohort. NAR 767 Genom Bioinform 2, Iqaa030 (2020). 768 Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D. & Woolf, P.J. GAGE: generally 108. 769 applicable gene set enrichment for pathway analysis. BMC Bioinformatics 10, 161 (2009). 770 109. Bindea, G., et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene 771 ontology and pathway annotation networks. *Bioinformatics* 25, 1091-1093 (2009).

- Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular 110. interaction networks. Genome Res 13, 2498-2504 (2003).

Figure 1. Flowchart of the study design. HLA, human leukocyte antigen; KEGG, Kyoto Encyclopedia of Genes and Genomes; PRS, polygenic risk score; SNP, single nucleotide polymorphism.

1) Biomarker discovery step: two-sample Mendelian randomization analyses



2) Validation step for the 126 biomarkers: triangulation analyses




Figure 2. The autoimmune hypothesis of diseases causing dementias, the supporting evidence from current analyses are listed at each mechanism. BBB, blood brain barrier; CD, cluster of differentiation; CNS, central nervoussystem; HLA, Human Leukocyte Antigen; cluster of differentiation; IPW, inverse probability weighted;





Figure 3A. Wald ratio or inverse variance weighted Mendelian randomization estimates for outcome-specific biomarkers.



27

Figure 3B. Wald ratio or inverse variance weighted Mendelian randomization estimate for biomarkers that associated with at least three outcomes. These biomarkers localized around APOE gene. Biomarkers outcome pairs with no common SNPs available are on grey colour.





Figure 4. Phenome-wide association analyses for a Mendelian randomization-based polygenic risk score constructed only from SNPs that associated with levels of causal Alzheimer's disease biomarkers in Mendelian randomization Wald ratio or inverse variance weighted analyses. Upward pointing triangle means risk increasing and downward risk decreasing. Larger triangle indicates larger effect size.





Outcomes

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .


30

Figure 5A-E. Association between different HLA-allele subclasses (y-axis) and dementia causing diseases, autoimmune diseases and their complications (x-axis). The HLA-types with at least one directionally consistent association with autoimmune diseases are bolded. Left side of the panel describes dementias and right side autoimmune diseases and their complications. *, false discovery rate p < 0.02; **, p < 0.01.






B)




-0.6 -0.3 0.0 0.3 0.6

31



E)





perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

33

Table 1. Associations between dementias and anti-inflammatory medications from inverse probability weighted (IPW) analyses in the FinnGen study. The positive control IPW analyses validate the analysis protocol by replicating association between statin medication and coronary heart disease. The negative control IPW analyses validate the associations between each anti-inflammatory medication and dementias by replicating the null finding between anti-inflammatory medications and coronary heart disease.

The baseline variables in IPW analyses were birth year, sex, ten principal components and timevarying variables statin, ACE-blocker, AT-blocker, renin-blocker, calcium channel blocker, any diuretic, insulin, metformin, other diabetes drug, depression medication, antipsychotic, and anticoagulant use as well as time varying any cancer, myocardial infarction, atrial fibrillation, heart failure, venous thromboembolism, ischemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, obesity, sleep apnoea, and chronic obstructive pulmonary diseases, with informative censoring included. Because of limited number of participants, TNF- α inhibitors users in dementias include also baseline users, other analyses include only medication-free individuals at baseline. The estimates for randomized control trials are from references 14 to 17. Secondary prevention randomized control trial was used for methotrexate because no primary prevention trial was available. MR-PRS, Mendelian randomization based polygenic risk score for Alzheimer's disease; NSAID, non-steroidal anti-inflammatory drugs; TNF- α , tumor necrosis factor α ; IPW, inverse probability weighted analyses; RCT, randomized control trials.

Medication	Disease	HR and 95% CIs	p-value
Statins			
Positive control for IPW			
protocol	Coronary heart disease IPW	0.38 (0.19 to 0.78)	0.009
	Coronary heart disease RCT	0.39 (0.29 to 0.49)	<0.001
Methotrexate	Alzheimer ´s disease	0.71 (0.56 to 0.90)	0.004
Methotiexate	Alzheimer's disease MR-PRS ≥50%	0.64 (0.49 to 0.88)	0.004
	Alzheimer's disease MR-PRS <50%	0.84 (0.59 to 1.19)	0.005
	Vascular dementia	0.64 (0.39 to 1.19)	0.330
	Parkinson's disease	0.48 (0.29 to 0.81)	0.205
	Parkinson 's disease MR-PRS ≥50%	0.20 (0.05 to 0.83)	0.000
	Parkinson 's disease MR-PRS <50%	0.61 (0.08 to 4.37)	0.622
Negative control	Coronary heart disease IPW	0.97 (0.84 to 1.11)	0.647
Negative control	Coronary heart disease RCT	0.96 (0.79 to 1.16)	0.862
		0.70 (0.77 to 1.10)	0.002
TNF- α inhibitors	Alzheimer´s disease	0.32 (0.14 to 0.76)	0.010
	Vascular dementia	0.27 (0.04 to 1.91)	0.188
	Parkinson´s disease	0.26 (0.04 to 1.82)	0.173
Negative control	Coronary heart disease IPW	1.03 (0.55 to 1.95)	0.916
-	Coronary heart disease RCT	1.09 (0.77 to 1.56)	0.645
NSAIDs	Alzheimer's disease	0.37 (0.35 to 0.40)	<0.001
	Vascular dementia	0.25 (0.20 to 0.32)	<0.001
	Parkinson's disease	0.65 (0.57 to 0.75)	<0.001
Negative control	Coronary heart disease IPW	0.38 (0.34 to 0.41)	< 0.001
	Coronary heart disease RCT	1.48 (1.00 to 2.26)	0.059
Antihistamines	Alzheimer 's disease	0.54 (0.48 to 0.61)	<0.001
Antinistanines	Vascular dementia	0.43 (0.29 to 0.64)	<0.001
	Parkinson's disease	0.70 (0.56 to 0.89)	0.003
Negative control	Coronary heart disease IPW	0.59 (0.51 to 0.69)	0.009
Negative control	Coronary heart disease RCT	No RCT available	0.007
Corticosteroids	Alzheimer's disease	0.65 (0.40 to 1.06)	0.085
	Vascular dementia	1.02 (0.32 to 3.21)	0.972
	Parkinson´s disease	0.50 (0.12 to 2.18)	0.358
Negative control	Coronary heart disease IPW	0.55 (0.25 to 1.23)	0.556
5	Coronary heart disease RCT	No RCT available	
Salazines	Alzheimer´s disease	0.89 (0.71 to 1.11)	0.296
	Vascular dementia	0.82 (0.41 to 1.66)	0.583
	Parkinson´s disease	0.69 (0.42 to 1.11)	0.128
Negative control	Coronary heart disease IPW	1.06 (0.89 to 1.27)	0.490
	Coronary heart disease RCT	No RCT available	

35

Supplementary Table 1. Significant backward Mendelian randomization results with p-value below 0.05. These hazard ratios were not stronger than observed in forward Mendelian randomization analyses in Supplementary Figure 1A and B.

Exposure	Outcome	Number of SNPs	HR (95% CIs)	p-value
Alzheimer's disease	FSC-A on plasmacystoid dendritic cell	20	0.85 (0.73 to 0.98)	0.0275
Late-onset Alzheimer's disease	Protein S100-A13	13	0.51 (0.41 to 0.63)	<0.001

36

Supplementary Figure 1A. Mendelian randomization sensitivity analyses for one standard deviation change in biomarker levels associated with late onset Alzheimer's diseases and with at least 3 SNPs available. The source of outcome and MR-base outcome identifier is described below the biomarker. Black = inverse variance weighted, grey = weighted median, blue = simple mode, red = Egger Mendelian randomization.

Biomarker	Number of SNPs	HR	95% CIs	p-value
Protein S100-A13 Lambert et al. (ebi-a-GCST002	245)	0.45 0.40 0.37 0.38	(0.26 to 0.76) (0.36 to 0.45) (0.34 to 0.39) (0.11 to 1.34)	0.0030 <0.001 <0.001 0.2280
Protein S100-A13 FinnGen (finn-a-AD_LO_EXMC		0.38 0.57 0.51 0.47 0.44	(0.36 to 0.89) (0.43 to 0.61) (0.42 to 0.54) (0.18 to 1.07)	0.0140 <0.001 <0.001 0.1449
Siglec-3 (CD33) Lambert et al. (ebi-a-GCST002		1.10 1.11 1.11 1.14	(1.06 to 1.15) (1.07 to 1.15) (1.07 to 1.15) (1.08 to 1.22)	<0.001 <0.001 0.0029 0.0122
Siglec-3 (CD33) FinnGen (finn-a-AD_LO)		1.46 1.40 1.53 1.35	(1.04 to 2.06) (0.94 to 2.07) (0.95 to 2.48) (0.48 to 3.82)	0.0305 0.0971 0.1811 0.6251
CD33 on CD33+ HLA DR+ CD14dim Lambert et al. (ebi-a-GCST002245) CD33 on CD33dim HLA DR- Lambert et al. (ebi-a-GCST002245) CD33 on basophil		1.07 1.08 1.08 1.11	(1.03 to 1.11) (1.04 to 1.11) (1.05 to 1.11) (1.06 to 1.17)	<0.001 <0.001 0.0367 0.1425
	245) 6 6 6	1.07 1.08 1.09 1.14	(1.04 to 1.11) (1.05 to 1.11) (1.05 to 1.12) (1.07 to 1.20)	<0.001 <0.001 0.0035 0.0124
Lambert et al. (ebi-a-GCST002 SSC-A on plasmacytoid Dendr	, 55 55 56	1.06 1.07 1.07 1.13	(1.03 to 1.10) (1.04 to 1.10) (1.04 to 1.11) (1.06 to 1.20)	<0.001 <0.001 0.0087 0.0306
Lambert et al. (ebi-a-GCST002 HLA DR on plasmacytoid Deno	245) 4 4 4	0.79 0.77 0.77 1.02	(0.70 to 0.89) (0.66 to 0.91) (0.64 to 0.92) (0.61 to 1.70)	<0.001 0.0016 0.0653 0.9382
Lambert et al. (ebi-a-GCST002 HLA DR on Dendritic Cell		0.92 0.92 0.92 0.91	(0.89 to 0.95) (0.88 to 0.95) (0.88 to 0.95) (0.88 to 0.95) (0.86 to 0.96)	<0.001 <0.001 0.0245 0.0767
Lambert et al. (ebi-a-GCST002245) Leucine-rich repeat neuronal protein 1 Lambert et al. (ebi-a-GCST002245) Leucine-rich repeat neuronal protein 1 FinnGen (finn-a-AD_LO_EXMORE)	protein 1	0.91 0.91 0.91 0.89	(0.88 to 0.95) (0.87 to 0.94) (0.86 to 0.95) (0.83 to 0.95)	<0.001 <0.001 0.0151 0.0427
	protein 1	→ 3.31 → 3.16 → 3.15 → 2.86	(2.83 to 3.88) (2.96 to 3.39) (2.93 to 3.38) (2.40 to 3.41)	<0.001 <0.001 <0.001 <0.001
	PRE) 4 4 4 4 4	→ 2.27 → 2.28 → 2.29 ↓ 2.42	(2.04 to 2.53) (2.06 to 2.53) (2.07 to 2.54) (2.04 to 2.86)	<0.001 <0.001 <0.001 0.0094
	0.2 0.5 1	2 4		

37

Supplementary Figure 1B. Mendelian randomization sensitivity analyses for one standard deviation change in biomarker levels associated with other dementias than late onset Alzheimer's diseases and with at least 3 SNPs available. The source of outcome and MR-base outcome identifier is described below the Biomarker. Black = inverse variance weighted, grey = weighted median, blue = simple mode, red = Egger Mendelian randomization.


Outcome	Biomarker	Number of SNPs	HR 95% Cls p-value
Alzheimer's disease	Monocyte percentage of white cells Lambert et al. (ieu-a-298)		0.46 (0.33 to 0.64) <0.001 0.46 (0.34 to 0.61) <0.001 0.52 (0.38 to 0.71) 0.0526 0.67 (0.38 to 1.19) 0.3997
	Sum basophil neutrophil counts Lambert et al. (ieu-a-298)		0.10 (0.04 to 0.25) <0.001 0.14 (0.05 to 0.38) <0.001 0.17 (0.05 to 0.55) 0.1001 0.53 (0.01 to 18.89) 0.7862
	FSC-A on plasmacytoid Dendritic Cell Kunkle et al. (ieu-b-2)		0.75 (0.65 to 0.86) <0.001 0.77 (0.64 to 0.92) 0.0045 0.77 (0.64 to 0.93) 0.1100 0.53 (0.28 to 1.02) 0.3099
	Monocyte percentage Lambert et al. (ieu-a-298)		0.42 (0.26 to 0.67) <0.001 0.43 (0.32 to 0.58) <0.001 0.44 (0.33 to 0.60) 0.0333 0.81 (0.42 to 1.56) 0.6444
	Zinc-alpha-2-glycoprotein Lambert et al. (ieu-a-297)		1.12 (1.04 to 1.21) 0.0046 1.13 (1.04 to 1.22) 0.0037 1.13 (1.04 to 1.23) 0.0699
	Zinc-alpha-2-glycoprotein Kunkle et al. (leu-b-2)	4	1.08 (1.00 to 1.15) 0.0379
Atypical or mixed Alzheimer's disease	Leucine-rich repeat neuronal protein 1 FinnGen (finn-a-AD_AM_EXMORE)		1.08 (1.07 to 1.16) 0.0312 1.10 (1.02 to 1.19) 0.0907 1.11 (0.96 to 1.29) 0.3053 1.98 (1.55 to 2.52) <0.001 2.01 (1.69 to 2.40) <0.001 2.03 (1.71 to 2.42) 0.0041
Early onset Alzheimer's disease	Leucine-rich repeat neuronal protein 1 FinnGen (finn-a-AD_EO_EXMORE)		2.09 (1.35 to 3.23) 0.0802
Dementia in Alzheimer disease	Leucine-rich repeat neuronal protein 1 FinnGen (finn-a-F5_ALZHDEMENT)		2.24 (1.82 to 2.76) <0.001
Dementia	Leucine-rich repeat neuronal protein 1		2.04 (1.85 to 2.25) <0.001
Vascular dementia	FinnGen (finn-a-F5_DEMENTIA)	4 4 4 4	1.70 (1.52 to 1.91) <0.001
	FinnGen (finn-a-F5_VASCDEM)		1.53 (1.33 to 1.77) <0.001
Parkinson's disease	CX3CR1 on monocyte Nalls et al. (ieu-b-7)		0.85 (0.79 to 0.91) <0.001 0.84 (0.79 to 0.90) <0.001 0.84 (0.78 to 0.92) 0.0571 0.86 (0.65 to 1.13) 0.4680
	CX3CR1 on CD14+ CD16+ monocyte Nalls et al. (ieu-b-7)	3 3 3 3 3 3	0.85 (0.80 to 0.91) <0.001 0.86 (0.80 to 0.92) <0.001 0.86 (0.80 to 0.92) 0.0512 0.91 (0.77 to 1.07) 0.4526
	CX3CR1 on CD14+ CD16- monocyte Nalls et al. (ieu-b-7)	3 3 3 3	0.86 (0.81 to 0.91) <0.001 0.86 (0.81 to 0.92) <0.001 0.86 (0.80 to 0.92) 0.0557 0.84 (0.63 to 1.13) 0.4544
	Transmembrane glycoprotein NMB Nalis et al. (ieu-b-7)		1.25 (1.03 to 1.52) 0.0271 1.25 (1.11 to 1.40) <0.001

medRxiv preprint doi: https://doi.org/10.1101/2022.02.17.22271136; this version posted February 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

38

Supplementary Figure 2. Phenome-wide association analyses for the 126 biomarkers, effect size describes one standard deviation change in biomarker levels. All biomarker and outcomes pairs that passed false discovery rate correction of 5% are presented. Most biomarkers associated with only few outcomes and the grey boxes indicate no association after false discovery rate correction of 5% or lack of common SNPs.



39


Supplementary Figure 3. Plasma protein associations with dementia for one standard deviation change in protein levels from the Whitehall II cohort. The analyses included 8 proteins that had SNPs clustered around APOE and associated with at least three dementia subtypes in Mendelian randomization analyses. Analyses are first adjusted for age and sex and then additionally for APOE status.

Protein measured from plasma		HR	95% CIs	p-value
Endothelial monocyte-activating polypeptide 2	- • -	1.02	(0.91 to 1.14)	0.750
Endothelial monocyte-activating polypeptide 2 APOE adjusted		1.11	(0.97 to 1.27)	0.140
Interferon-induced protein with tetratricopeptide repeats 2	-	0.79	(0.70 to 0.88)	<0.001
Interferon-induced protein with tetratricopeptide repeats 2 APOE adjusted	-•-	0.84	(0.73 to 0.97)	0.010
Killer cell immunoglobulin-like receptor 2DL5A	_	1.03	(0.90 to 1.18)	0.640
Killer cell immunoglobulin-like receptor 2DL5A	-	0.95	(0.85 to 1.07)	0.390
Killer cell immunoglobulin-like receptor 2DL5A APOE adjusted		0.98	(0.83 to 1.17)	0.860
Killer cell immunoglobulin-like receptor 2DL5A APOE adjusted	-	0.96	(0.83 to 1.09)	0.480
Leucine-rich repeat neuronal protein 1:Cytoplasmic domain		1.38	(1.23 to 1.54)	<0.001
Leucine-rich repeat neuronal protein 1:Cytoplasmic domain APOE adjusted	_ + _	1.01	(0.83 to 1.22)	0.930
Leucine-rich repeat neuronal protein 1:Extracellular domain		1.08	(0.95 to 1.24)	0.250
Leucine-rich repeat neuronal protein 1:Extracellular domain APOE adjusted	-•-	1.08	(0.91 to 1.28)	0.390
Tight junction protein ZO-1	_	0.96	(0.86 to 1.08)	0.520
Tight junction protein ZO-1 APOE adjusted	-	0.95	(0.83 to 1.09)	0.460
Tumor necrosis factor receptor superfamily member 13C		1.00	(0.88 to 1.14)	0.950
	Ţ	1.00	· · · · · · · · · · · · · · · · · · ·	
Tumor necrosis factor receptor superfamily member 13C APOE adjusted		1.01	(0.87 to 1.18)	0.870
ValinetRNA ligase	-	0.99	(0.89 to 1.11)	0.930
ValinetRNA ligase APOE adjusted	-•-	0.95	(0.84 to 1.09)	0.490
	0.5 0.75 1.5 2			


40

Supplementary Figures 4 A-H. KEGG functional pathway enrichment analyses for all proteins and receptors that associated with dementias in Mendelian randomization analyses. The estimated causal betas were used in place of log fold change.


A)




B)





C)





43















Supplementary Figure 5. ClueGO enrichment analyses for all the 76 proteins and receptors in the biomarkers that had evidence of causal association in Mendelian randomization analyses. All proteins that associated with Uniprot search terms "immune system" and "blood brain barrier" were used as a background dataset. GO-terms in blue were enriched in cluster where most significant associations were observed for cell adhesion molecules. In the red cluster, the most significant GO-term associations were observed for hematopoietic cell lineage. Big dots describe the GO-terms and small dots the genes associated with these terms.




Supplementary Figures 6A-R. ConsensusPathDB shortest interaction path analyses for the 42 proteins that were causally associated with dementia causing diseases in Mendelian randomization analyses. Figures A-N include biomarkers for amyloid and tau and O-R for α -synuclein pathways.











Microtubule-associated protein tau (MAPT)














Supplementary methods 1

2

3 Mendelian randomization analyses

The SNPs for biomarkers and outcomes were searched from MR-base database.¹ Immune system 4 and BBB search terms were identified using identifiers of cell types, receptors, proteins, and genes. 5 The identifiers were searched from several publications²⁻¹⁰ and from Uniprot¹¹ with search terms 6 "immune" and "blood brain barrier". Outcomes included all cohorts with following dementia-7 causing diseases: all types of Alzheimer's disease, Parkinson's disease, vascular dementia, 8 9 frontotemporal dementia, dementia in general, and progression of dementia. Poor cognitive performance was chosen as an intermediate outcome. Two sample Mendelian randomization was 10 used to analyse associations between biomarkers and outcomes.¹² First analyses estimated effects 11 with Wald ratio or inverse variance-weighted analyses.¹ For biomarker-outcome pairs that passed 12 FDR of 5% and shared over two common SNPs we performed sensitivity analyses with weighted 13 median, simple mode, MR Egger, and backward Mendelian randomization¹² with TwoSampleMR 14

15 and MRInstruments R packages.

16 To assess off-target effects of the observed causal biomarkers, we performed a phenome-wide

Mendelian randomization analyses for each biomarker, using GWAS summary statistics for 210 17

- UK Biobank endpoints conducted by Neale lab and with recognized dementia risk factors.^{5,13} All 18
- analyses used European ancestry as reference, clumping cut-off R2 = 0.01 and a 10,000kb window. 19
- 20 LD proxies were searched with R2 = 0.6 and a proxy split size of 500. The biomarkers and outcome
- alleles were harmonized by inferring from positive strand alleles using allele frequencies for 21
- 22 palindromes. We used statistical software R (3.6.0 and 4.1.0) for these analyses. Novelty of our
- 23 Mendelian randomization findings was evaluated with Pubmed search using following search terms: (Mendelian randomization) AND (dementia OR Alzheim* OR Parkin* OR cognitive
- 24
- 25 decline) AND (Entrez gene symbol OR Uniprot protein identifier) without limitations.
- 26

27 Plasma proteins and Whitehall II study

Plasma protein measurements in Whitehall II study were available for 6,235 individuals of whom 28

29 310 developed dementia. The participants are linked to the National Health Services (NHS)

Hospital Episode Statistics (HES) database, and the British National mortality register using 30

individual NHS identification numbers for linkage.¹⁴ The NHS provides nearly complete health care 31

coverage for all individuals legally resident in the UK. Incident dementia was defined using the 32

33 WHO International Classification of Diseases, version 10 (ICD-10) codes F00, F01, F03, G30, and

34 G31 and ICD-9 codes 290.0-290.4, 331.0-331.2, 331.82, and 331.9. We also conducted informant

35 interviews and checked participants' medications at each screening (in 1996-1998, 2011-2013 and

2016-2017) for dementia-related medication. Sensitivity and specificity of dementia assessment 36

37 based on HES data is 0.78 and 0.92.15

The plasma proteins were measured using the SomaScan version 4.0 and 4.1 assays.^{4,16,17} The 38

39 assays were validated against external reference population and protein-specific conversion

coefficients were used to balance the technical differences between versions 4.0 and 4.1. The 40

- analyses used plasma samples measured in 1995/1997 and stored in 0.25 mL aliquots at -80°C. 41
- Earlier studies describe performance of the SomaScan assay and the modified aptamer binding in 42
- detail.^{4,16,17} In brief, the assay uses a mix of thousands of slow off-rate modified aptamers 43
- 44 (SOMAmers) that bind to proteins in participants' plasma samples where the specificity is ensured
- with two-step process analogous to a conventional immunoassay. The specificity of the aptamer 45
- reagents is good and has been tested in several ways.^{4,18,19} Median intra- and inter-assay coefficients 46
- of variation for SomaScan version 4 are ~5% and assay sensitivity is comparable to that of typical 47
- 48 immunoassays, with a median lower limit of detection in the femtomolar range.
- 49
- 50 In the Whitehall II study, standard self-administered questionnaires provided data on age and sex.
- 51 Using DNA extracted from whole blood, a standard PCR assay determined APOE genotype using
- the salting out method.^{20,21} Two blinded independent observers read the genotype and any 52
- discrepancies were resolved by repeating the PCR analysis. 53
- 54 In analyses, proteins were transformed to a normal distribution by inverse rank-based normal
- transformation. The follow-up ended at onset of dementia, death, or 1st of October 2019, which ever 55
- occurred first. Age, sex, and APOE adjusted Cox regression models estimated associations between 56
- the proteins and dementia.²² The proportionality assumption in all Cox models was assessed with 57
- Schoenfeld residuals and with log-log plots.²² We used statistical software R (3.6.0 and 4.1.0) for 58 59 these analyses.
- 60

Polygenic risk score and IPW analyses 61

62 FinnGen Data Freeze 8 contains 339,233 individuals, and represents approximately 7% of Finnish adult population. FinnGen is a collection of prospective epidemiological and disease-based cohorts, 63 64 and hospital biobank samples and links genotypes by the unique national personal identification numbers to nationwide health registries, including the national hospital discharge (available from 65 66 1968), death (1969–), cancer (1953–) and medication reimbursement (1964–) and purchase (1995–) registries. The registry-based follow-up ended on Dec 31, 2019. Alzheimer's disease was defined 67 with ICD-10 codes under F00 and G30, ICD-9 codes under 3310, ICD-8 code under 29010, and 68 69 medication purchase code N06D. Vascular dementia was defined with ICD-10 codes under F01 and ICD-9 codes under 4378. Parkinson's disease was defined with ICD-10 codes under G20, ICD-9 70

- codes under 3320A, ICD-8 code under 34200, and reimbursements code 110. 71
- 72
- 73 FinnGen samples were genotyped with Illumina and Affymetrix arrays (Illumina Inc., San Diego,
- 74 and Thermo Fisher Scientific, Santa Clara, CA, USA), and genotype calls were made with the
- 75 GenCall or zCall (for Illumina) and the AxiomGT1 algorithm for Affymetrix data. Individuals with
- 76 ambiguous gender, high genotype missingness (>5%), excess heterozygosity (+-4SD) and non-
- 77 Finnish ancestry were excluded, as well as all variants with high missingness (>2%), low Hardy-
- 78 Weinberg equilibrium p-value (<1e-6) and minor allele count (MAC < 3). Array data pre-phasing
- 79 was carried out with Eagle $2.3.5^{23}$ with the number of conditioning haplotypes set to 20,000.
- 80 Genotype imputation was done using the population-specific SISu v3 imputation reference with

81 3,775 high-coverage (25-30x) whole-genome sequences in Finns, described in detail at

82 https://doi.org/10.17504/protocols.io.xbgfijw.

83

84 The PRS were constructed from SNPs that were associated with the Mendelian randomization causal 126 biomarkers for dementias. The SNPs were LD-pruned with clumping cut-off R2 = 0.0185 86 in 500kb window with R package TwoSampleMR. The available SNPs were searched from FinnGen genotypes and the final scores were generated with PLINK v2.00aLM3 by calculating the 87 SNP-biomarker beta weighted sum of risk alleles for each SNP. The PRS was scaled to zero mean 88 89 and unit variance, and we analysed its phenome-wide associations across 2401 disease endpoints. 90 The association between PRS and endpoints were studied with logistic regression, adjusting for 91 birth year, sex, and ten first principal components of ancestry.

92

93 We used IPW analyses to emulate randomized control trials on the effect of preventive antiinflammatory medication on risk of dementias in FinnGen.²⁴ These analyses included participants 94 aged over 45 without any dementia-causing disease at baseline (N = 90,512) ATC codes for anti-95 inflammatory medication use were searched from medication purchase registry that starts from 96 97 1995. To simulate trial design and to avoid immortal time bias, each analyses included only new 98 medication users. In IPW analyses, we assumed that when medication is initiated, it is continued 99 until end of follow-up to simulate intention to treat analyses and thus to provide conservative 100 estimates. The baseline variables in IPW analyses were birth year, sex, ten principal components of ancestry and time-varying variables statin, ACE-blocker, AT-blocker, renin-blocker, calcium 101 102 channel blocker, any diuretic, insulin, metformin, other diabetes drug, depression medication, 103 antipsychotic, and anticoagulant use as well as time varying any cancer, myocardial infarction, atrial fibrillation, heart failure, venous thromboembolism, ischemic stroke, intracerebral 104 105 haemorrhage, subarachnoid haemorrhage, obesity, sleep apnoea, and chronic obstructive pulmonary 106 diseases, with informative censoring included. The positive control analyses on statin medication used these same variables but did not include statin as time-varying covariate. We used R (4.1.2) for 107 108 these analyses.

109

110 HLA analyses

The analyses were done using imputed HLA alleles, imputed with high accuracy using a Finnishspecific reference panel, which has been previously described in detail.²⁵ After filtering based on a HLA carrier frequency of ≥ 0.01 and posterior probability of ≥ 0.6 , we assessed the association between HLA alleles and dementias and autoimmune diseases using logistic regression, adjusting for birth year, sex, and ten first principal components of ancestry.

116

117 Pathway analyses

118 KEGG pathway analysis was used for studying the effect of the biomarkers on validated pathways

119 with Generally Applicable Gene-set Enrichment (GAGE),²⁶ using Mendelian randomization Wald

- ratios or inverse variance weight betas and p-values as input for expression ratios. GO term
- enrichment analyses were done with ClueGO version 2.5.8²⁷ in Cytoscape version 3.7.2.²⁸ The
- hypergeometric test used all the 76 plasma proteins or surface receptors of the 126 biomarkers as
- input and all immune system and BBB related proteins from Uniprot¹¹ as background, with
- correction for 5% FDR. The shortest interaction path analyses were done with ConsensusPathDB,²⁹
- a web based analysis tool containing a range of biomedical databases. ConsensusPathDB was used
- to decipher the potential common pathways between the biomarkers and amyloid β , tau protein, and
- α-synuclein.

Open Targets analyses

- Medications that change the levels of the 126 biomarkers were searched from Open Targets database using Uniprot protein and Entrez gene symbols.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.17.22271136; this version posted February 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

153 Supplementary references

- 154
- 155 1. Hemani, G., *et al.* The MR-Base platform supports systematic causal inference across the 156 human phenome. *Elife* **7**(2018).
- 157 2. Akiyama, H., *et al.* Inflammation and Alzheimer's disease. *Neurobiology of aging* 21, 383158 421 (2000).
- Dendrou, C.A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat Rev Immunol* 18, 325-339 (2018).
- 4. Lindbohm, J.V., *et al.* Plasma proteins, cognitive decline, and 20-year risk of dementia in
 the Whitehall II and Atherosclerosis Risk in Communities studies. *Alzheimer's & dementia : the journal of the Alzheimer's Association* (2021).
- 164 5. Livingston, G., *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet
 165 Commission. *Lancet (London, England)* 396, 413-446 (2020).
- 166 6. O'Brien, J.T. & Thomas, A. Vascular dementia. *Lancet (London, England)* 386, 1698-1706
 (2015).
- Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R. & Zlokovic, B.V. Blood-Brain
 Barrier: From Physiology to Disease and Back. *Physiological Reviews* 99, 21-78 (2019).
- Tan, E.K., *et al.* Parkinson disease and the immune system associations, mechanisms and therapeutics. *Nat Rev Neurol* 16, 303-318 (2020).
- 172 9. Theofilopoulos, A.N., Kono, D.H. & Baccala, R. The multiple pathways to autoimmunity.
 173 *Nat Immunol* 18, 716-724 (2017).
- Walker, K.A., *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways
 associated with dementia risk. *Nature Aging* 1, 473-489 (2021).
- 176 11. UniProt, C. UniProt: a worldwide hub of protein knowledge. *Nucleic acids research* 47, D506-D515 (2019).
- Holmes, M.V., Richardson, T.G., Ference, B.A., Davies, N.M. & Davey Smith, G.
 Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. *Nat Rev Cardiol* 18, 435-453 (2021).
- 181 13. <u>http://www.nealelab.is/uk-biobank/</u>.
- 182 14. Kivimaki, M., *et al.* Validity of Cardiovascular Disease Event Ascertainment Using Linkage
 183 to UK Hospital Records. *Epidemiology (Cambridge, Mass.)* 28, 735-739 (2017).
- 184 15. Sommerlad, A., *et al.* Accuracy of general hospital dementia diagnoses in England:
 185 Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. *Alzheimer's &*
- 186 *dementia : the journal of the Alzheimer's Association* **14**, 933-943 (2018).
- 187 16. Gold, L., *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery.
 188 *PloS one* 5, e15004 (2010).
- 189 17. Williams, S.A., *et al.* Plasma protein patterns as comprehensive indicators of health. *Nature medicine* 25, 1851-1857 (2019).
- 18. Emilsson, V., *et al.* Co-regulatory networks of human serum proteins link genetics to disease. *Science (New York, N.Y.)* 361, 769-773 (2018).
- 19. Tin, A., *et al.* Reproducibility and Variability of Protein Analytes Measured Using a
 194 Multiplexed Modified Aptamer Assay. *The journal of applied laboratory medicine* 4, 30-39
 195 (2019).
- Bolla, M.K., Wood, N. & Humphries, S.E. Rapid determination of apolipoprotein E
 genotype using a heteroduplex generator. *Journal of lipid research* 40, 2340-2345 (1999).
- 198 21. Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting 199 DNA from human nucleated cells. *Nucleic acids research* **16**, 1215 (1988).
- 200 22. Cox, D.R. Regression Models and Life-Tables. *Journal of the Royal Statistical* 201 Society.Series B (Methodological) 34, 187-220 (1972).

- 202 23. Loh, P.R., et al. Reference-based phasing using the Haplotype Reference Consortium panel. 203 Nat Genet 48, 1443-1448 (2016).
- 204 24. Hernán, M.A. & Robins, J.M. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol 183, 758-764 (2016). 205
- Ritari, J., Hyvärinen, K., Clancy, J., Partanen, J. & Koskela, S. Increasing accuracy of HLA 206 25. 207 imputation by a population-specific reference panel in a FinnGen biobank cohort. NAR 208 Genom Bioinform 2, Iqaa030 (2020).
- Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D. & Woolf, P.J. GAGE: generally 209 26.
- applicable gene set enrichment for pathway analysis. BMC Bioinformatics 10, 161 (2009). 210
- 211 27. Bindea, G., et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 25, 1091-1093 (2009). 212
- 213 Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular 28. 214 interaction networks. Genome Res 13, 2498-2504 (2003).
- Herwig, R., Hardt, C., Lienhard, M. & Kamburov, A. Analyzing and interpreting genome 215 29. data at the network level with ConsensusPathDB. Nature Protocols 11, 1889-1907 (2016). 216

217

Supplementary file 1. Distance from APOE gene

SNP	Beta exposure Exposure	Outcome	Chromosome	Position	Distance from start of APOE	Distance from end of APOE
rs12461065	0.1574 ValinetRNA ligase id:prot-a-3191	Alzheimer's disease (more excluded) id:finn-a-AD_EXMORE	19	45 102 050	- 306 961 -	310 600
rs395908	0.3382 EMAP-2 id:prot-c-2714_78_2	Alzheimer's disease id:ieu-b-2	19	45 380 961	- 28 050 -	31 689
rs429358	0.3499 Killer cell immunoglobulin-like receptor 2DL5A id:prot-a-1643	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930 -	709
rs429358	1.1769 Leucine-rich repeat neuronal protein 1 id:prot-a-1792	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930 -	709
rs429358	0.3527 PDZK1-interacting protein 1 id:prot-a-2242	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930 -	709
rs429358	0.2148 Tight junction protein ZO-1 id:prot-a-2983	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930 -	709
rs438811	-1.2435 Protein S100-A13 id:prot-a-2616	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 418 790	9 779	6 140
rs5167	0.2454 BAFF Receptor id:prot-c-5383_14_3	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.3319 Endothelial monocyte-activating polypeptide 2 id:prot-a-65	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.277 Melanoma-associated antigen 3 id:prot-a-1828	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.2145 Transmembrane protein 59-like id:prot-a-3014	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.8678 ValinetRNA ligase id:prot-a-3191	Alzheimer's disease (more excluded) id:finn-a-AD_EXMORE	19	44 980 181	- 428 830 -	432 469
rs59325138	0.1436 Interferon-induced protein with tetratricopeptide repeats 2 id:p	ro Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 416 291	7 280	3 641
rs7412	-0.4743 Cadherin-related family member 5 id:prot-a-490	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 412 079	3 068 -	571
rs7412	0.7212 Cell surface glycoprotein CD200 receptor 2 id:prot-a-424	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 412 079	3 068 -	571
rs7412	-0.3721 Disintegrin and metalloproteinase domain-containing protein 11	ic Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 412 079	3 068 -	571
rs7412	-0.5043 Pregnancy-specific beta-1-glycoprotein 5 id:prot-a-2404	Alzheimer disease (more excluded) id:finn-a-G6_ALZHEIMER_	E 19	44 921 921	- 487 090 -	490 729

Supplementary File 2. Drugs available in the Open Targets database that act on the biomarkers that associated with dementias and are hypothized to reduce the risk. In total 64 different drugs were identified.

Drug_ID	Drug_name	Туре	Mechanism_of_action	Action_type	Disease_ID	Disease_name_originally_used_for Phase	Status	Source
CHEMBL2107842	ALBINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00097435%22
CHEMBL2107842	ALBINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00759200%22,https://clinicaltrials.gov/sea
CHEMBL2107842	ALBINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chronic hepatitis B virus infection	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00964665%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_000095	chronic lymphocytic leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_0000403	diffuse large B-cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_0000574	lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00004101%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_1001469	Mantle cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	MONDO_0018906	follicular lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1000657	rectum cancer	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04130854%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1001968	soft tissue sarcoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03719430%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	5	MONDO_0007576	esophageal cancer	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03165994%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	•	EFO_0000756	melanoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02706353%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_0002617	metastatic melanoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT03597282%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1000044	pancreatic adenocarcinoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03214250%22
CHEMBL2109266	AVE-9633	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	MONDO_0004643	myeloid leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00543972%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000616	neoplasm	3	http://www.whocc.no/atc_ddd_index/?code=L01XX70
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0011057	neurotoxicity	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04150913%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02601313%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04314843%22,https://clinicaltrials.gov/sea
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02926833%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000574	lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04608487%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02348216%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0044889	high grade B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02348216%22
CHEMBL4594618	BREXUCABTAGENE AUTOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02601313%22
CHEMBL4594618	BREXUCABTAGENE AUTOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03624036%22
CHEMBL4594618	BREXUCABTAGENE AUTOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02614066%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000540	immune system disease	4	http://www.whocc.no/atc_ddd_index/?code=L04AC08
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_208650	Cryopyrin-associated periodic syndron	4	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003106	pneumonia	3 Completed	https://clinicaltrials.gov/search?id=%22NCT04362813%22

CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003914	atherosclerosis
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001999	systemic juvenile idio
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_1451	CINCA syndrome
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	DOID_13406	pulmonary sarcoidosis
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000275	atrial fibrillation
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000756	melanoma
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001071	lung carcinoma
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001359	type I diabetes mellitu
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001360	type II diabetes mellit
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002506	osteoarthritis
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003780	Behcet's syndrome
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004214	Abdominal Aortic Ane
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004246	mucocutaneous lympl
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004265	peripheral arterial dis
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004274	gout
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0005531	urticaria
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0007135	adult-onset Still's dise
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0008518	polymyalgia rheumati
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1000906	dry eye syndrome
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001165	Schnitzler syndrome
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001345	Hepatitis, Alcoholic
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	HP_0000999	Pyoderma
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	MONDO_0100096	COVID-19
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_232	Sickle cell anemia
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_309025	Mevalonate kinase de
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_342	Familial Mediterranea
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000198	myelodysplastic syndr
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000341	chronic obstructive pu
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000685	rheumatoid arthritis
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001365	age-related macular d
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002517	pancreatic ductal ader
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002609	juvenile idiopathic art

3 Completed https://clinicaltrials.gov/search?id=%22NCT01327846%22 stemic juvenile idiopathic arthritis 3 Terminated https://clinicaltrials.gov/search?id=%22NCT00886769%22 3 Terminated https://clinicaltrials.gov/search?id=%22NCT00770601%22 Imonary sarcoidosis 2 Completed https://clinicaltrials.gov/search?id=%22NCT02888080%22 https://clinicaltrials.gov/search?id=%22NCT01805960%22 2 Terminated 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT03484923%22 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04789681%22 pe I diabetes mellitus 2 Completed https://clinicaltrials.gov/search?id=%22NCT00947427%22 pe II diabetes mellitus 2 Terminated https://clinicaltrials.gov/search?id=%22NCT00900146%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01160822%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT02756650%22 bdominal Aortic Aneurysm 2 Terminated https://clinicaltrials.gov/search?id=%22NCT02007252%22 ucocutaneous lymph node syndrome 2 Withdrawn https://clinicaltrials.gov/search?id=%22NCT02980263%22 2 Terminated https://clinicaltrials.gov/search?id=%22NCT01731990%22 eripheral arterial disease https://clinicaltrials.gov/search?id=%22NCT00819585%22,https://clinicaltrials.gov/sea 2 Completed 2 Unknown status https://clinicaltrials.gov/search?id=%22NCT01635127%22 https://clinicaltrials.gov/search?id=%22NCT02204293%22 lult-onset Still's disease 2 Terminated 2 Terminated https://clinicaltrials.gov/search?id=%22NCT01364389%22 lymyalgia rheumatica 2 Completed https://clinicaltrials.gov/search?id=%22NCT01250171%22 hnitzler syndrome 2 Completed https://clinicaltrials.gov/search?id=%22NCT01390350%22,https://clinicaltrials.gov/sea 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03775109%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01302795%22 https://clinicaltrials.gov/search?id=%22NCT04365153%22 2 Completed 2 Completed https://clinicaltrials.gov/search?id=%22NCT02961218%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01303380%22 evalonate kinase deficiency amilial Mediterranean fever 2 Completed https://clinicaltrials.gov/search?id=%22NCT01148797%22,https://clinicaltrials.gov/sea yelodysplastic syndrome 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04810611%22,https://clinicaltrials.gov/sea nronic obstructive pulmonary disease 1 Completed https://clinicaltrials.gov/search?id=%22NCT00581945%22 neumatoid arthritis 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00505089%22 ge-related macular degeneration 1 Completed https://clinicaltrials.gov/search?id=%22NCT00503022%22 ancreatic ductal adenocarcinoma 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04581343%22 uvenile idiopathic arthritis 1 Completed https://clinicaltrials.gov/search?id=%22NCT00426218%22

CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003060	non-small cell lun
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0009322	proliferative diabe
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	HP_0001945	Fever
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	MONDO_0007254	breast cancer
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000681	renal cell carcinon
CHEMBL2109286	COLTUXIMAB RAVTANSINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblast
CHEMBL2109286	COLTUXIMAB RAVTANSINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cel
CHEMBL2109286	COLTUXIMAB RAVTANSINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0005952	non-Hodgkins lym
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003073	asymptomatic mye
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000203	monoclonal gamm
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000209	T-cell acute lymph
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000220	acute lymphoblast
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000222	acute myeloid leu
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000249	Alzheimer's diseas
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000574	lymphoma
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000616	neoplasm
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0002690	systemic lupus ery
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0005761	lupus nephritis
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0006738	plasmacytoma
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0007160	autoimmune throi
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0009441	Waldenstrom mad
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001115	POEMS syndrome
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001469	Mantle cell lymph
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001875	amyloidosis
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001951	colorectal carcinor
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0008315	prostate cancer
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0018906	follicular lymphon
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_000095	chronic lymphocyt
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000183	Hodgkins lymphor
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000198	myelodysplastic s
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000304	breast adenocarci
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000311	cancer

on-small cell lung carcinoma roliferative diabetic retinopathy 1 Terminated 1 Unknown status 1 Recruiting enal cell carcinoma 0 Recruiting cute lymphoblastic leukemia 2 Terminated ffuse large B-cell lymphoma 2 Completed on-Hodgkins lymphoma 1 Completed 3 Recruiting symptomatic myeloma onoclonal gammopathy 2 Active, not recruiting -cell acute lymphoblastic leukemia 2 Not yet recruiting cute lymphoblastic leukemia 2 Recruiting cute myeloid leukemia 2 Active, not recruiting Izheimer's disease 2 Recruiting 2 Completed 2 Withdrawn stemic lupus erythematosus 2 Not yet recruiting 2 Recruiting 2 Recruiting utoimmune thrombocytopenic purpu 2 Recruiting /aldenstrom macroglobulinemia 2 Recruiting OEMS syndrome 2 Recruiting lantle cell lymphoma 2 Terminated 2 Completed 2 Active, not recruiting lorectal carcinoma 2 Withdrawn ostate cancer 2 Terminated ollicular lymphoma hronic lymphocytic leukemia 1 Recruiting odgkins lymphoma 1 Suspended yelodysplastic syndrome 1 Recruiting reast adenocarcinoma 1 Suspended 1 Completed

1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03064854%22 https://clinicaltrials.gov/search?id=%22NCT01589029%22 https://clinicaltrials.gov/search?id=%22NCT02775994%22 https://clinicaltrials.gov/search?id=%22NCT03742349%22 https://clinicaltrials.gov/search?id=%22NCT04028245%22 https://clinicaltrials.gov/search?id=%22NCT01440179%22 https://clinicaltrials.gov/search?id=%22NCT01472887%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00796731%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03937635%22 https://clinicaltrials.gov/search?id=%22NCT03236428%22 https://clinicaltrials.gov/search?id=%22NCT04972942%22 https://clinicaltrials.gov/search?id=%22NCT03384654%22 https://clinicaltrials.gov/search?id=%22NCT02807558%22 https://clinicaltrials.gov/search?id=%22NCT04070378%22 https://clinicaltrials.gov/search?id=%22NCT02927925%22 https://clinicaltrials.gov/search?id=%22NCT03207542%22 https://clinicaltrials.gov/search?id=%22NCT04810754%22 https://clinicaltrials.gov/search?id=%22NCT04868838%22 https://clinicaltrials.gov/search?id=%22NCT04166565%22 https://clinicaltrials.gov/search?id=%22NCT04703621%22 https://clinicaltrials.gov/search?id=%22NCT03679624%22 https://clinicaltrials.gov/search?id=%22NCT04396496%22 https://clinicaltrials.gov/search?id=%22NCT02413489%22 https://clinicaltrials.gov/search?id=%22NCT02816476%22 https://clinicaltrials.gov/search?id=%22NCT02060188%22 https://clinicaltrials.gov/search?id=%22NCT03035357%22 https://clinicaltrials.gov/search?id=%22NCT02413489%22 https://clinicaltrials.gov/search?id=%22NCT03447808%22 https://clinicaltrials.gov/search?id=%22NCT03432741%22 https://clinicaltrials.gov/search?id=%22NCT03537599%22 https://clinicaltrials.gov/search?id=%22NCT03432741%22 https://clinicaltrials.gov/search?id=%22NCT03098550%22

CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000330	childhood ad
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000519	glioblastom
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000673	prostate ade
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001378	multiple my
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003060	non-small ce
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0004599	acute graft v
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0005952	non-Hodgkiı
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0006475	plasma cell l
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001051	mycosis fun
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0019465	nodal margi
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	Orphanet_85443	ALamyloido
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000349	clear cell rer
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000403	diffuse large
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0006544	bladder tran
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymph
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000309	Burkitts lym
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell I
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicularlyn
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003086	kidney disea
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0002462	glomerulone
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001378	multiple my
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0004254	membranou
CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent	Binding agent	EFO_0000222	acute myelo
CHEMBL1743020	FORALUMAB	Antibody	T cell surface glycoprotein CD3 inhibitor	Inhibitor	EFO_0000384	Crohn's dise
CHEMBL1743020	FORALUMAB	Antibody	T cell surface glycoprotein CD3 inhibitor	Inhibitor	EFO_0004599	acute graft v
CHEMBL2108342	GEMTUZUMAB	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000222	acute myelo
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000616	neoplasm
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000220	acute lymph
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000224	acute promy
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_000095	chronic lymp
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000198	myelodyspla

nildhood acute myeloid leukemia 1 Recruitina ioblastoma multiforme rostate adenocarcinoma ultiple myeloma on-small cell lung carcinoma cute graft vs. host disease on-Hodgkins lymphoma asma cell leukemia vcosis fungoides odal marginal zone B-cell lymphoma Lamyloidosis ear cell renal carcinoma ffuse large B-cell lymphoma adder transitional cell carcinoma cute lymphoblastic leukemia urkitts lymphoma ffuse large B-cell lymphoma lantle cell lymphoma ollicular lymphoma dney disease omerulonephritis ultiple myeloma embranous glomerulonephritis cute myeloid leukemia rohn's disease cute graft vs. host disease cute myeloid leukemia cute lymphoblastic leukemia cute promyelocytic leukemia nronic lymphocytic leukemia myelodysplastic syndrome

1 Not yet recruiting 1 Active, not recruiting 1 Withdrawn 1 Completed 1 Recruiting 1 Active, not recruiting 1 Withdrawn 1 Suspended 1 Suspended 1 Recruiting 0 Active, not recruiting 0 Recruiting 0 Active, not recruiting 1 Completed 1 Completed 1 Completed 1 Completed 1 Completed 2 Not yet recruiting 2 Recruiting 1 Completed 1 Recruiting 1 Recruiting 1 Completed 1 Completed 3 Completed 2 Terminated 2 Withdrawn 1 Completed 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03537599%22 https://clinicaltrials.gov/search?id=%22NCT04922723%22 https://clinicaltrials.gov/search?id=%22NCT03177460%22 https://clinicaltrials.gov/search?id=%22NCT03701321%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03023423%22 https://clinicaltrials.gov/search?id=%22NCT04204980%22 https://clinicaltrials.gov/search?id=%22NCT01592370%22 https://clinicaltrials.gov/search?id=%22NCT03591744%22 https://clinicaltrials.gov/search?id=%22NCT03432741%22 https://clinicaltrials.gov/search?id=%22NCT03432741%22 https://clinicaltrials.gov/search?id=%22NCT03283917%22 https://clinicaltrials.gov/search?id=%22NCT03473730%22 https://clinicaltrials.gov/search?id=%22NCT04139304%22 https://clinicaltrials.gov/search?id=%22NCT03473730%22 https://clinicaltrials.gov/search?id=%22NCT01786135%22 https://clinicaltrials.gov/search?id=%22NCT01786135%22 https://clinicaltrials.gov/search?id=%22NCT01786135%22 https://clinicaltrials.gov/search?id=%22NCT01786135%22 https://clinicaltrials.gov/search?id=%22NCT01786135%22 https://clinicaltrials.gov/search?id=%22NCT04893096%22 https://clinicaltrials.gov/search?id=%22NCT04733040%22 https://clinicaltrials.gov/search?id=%22NCT01421186%22 https://clinicaltrials.gov/search?id=%22NCT04145440%22 https://clinicaltrials.gov/search?id=%22NCT02152956%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00630643%22 https://clinicaltrials.gov/search?id=%22NCT00805909%22 https://clinicaltrials.gov/search?id=%22NCT00136084%22 http://www.whocc.no/atc_ddd_index/?code=L01XC05 https://clinicaltrials.gov/search?id=%22NCT00798213%22 https://clinicaltrials.gov/search?id=%22NCT01548911%22 https://clinicaltrials.gov/search?id=%22NCT00038831%22 https://clinicaltrials.gov/search?id=%22NCT01020539%22

CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000565
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_1000309
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	MONDO_0019457
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000222
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_1001231
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0000685
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0001359
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0002506
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0003894
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0009672
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	HP_0000999
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0001360
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	EFO_0003780
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	MONDO_0001718
CHEMBL2108707	GLEMBATUMUMAB	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000756
CHEMBL2108707	GLEMBATUMUMAB	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	MONDO_0007254
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000637
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000756
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_1000616
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000708
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	MONDO_0007254
CHEMBL2109509	HCBE-11	Antibody	Tumor necrosis factor receptor superfamily member 3 agonist	Agonist	EFO_0000616
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000191
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000309
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000565
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001378

leukemia 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00577694%22 Juvenile Myelomonocytic Leukemia 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00669890%22 therapy related acute myeloid leukem 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04915612%22 acute myeloid leukemia 0 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03568994%22 https://clinicaltrials.gov/search?id=%22NCT02258854%22,https://clinicaltrials.gov/sea 3 Terminated rheumatoid arthritis 2 Suspended https://clinicaltrials.gov/search?id=%22NCT00777816%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT00998699%22,https://clinicaltrials.gov/sea type I diabetes mellitus https://clinicaltrials.gov/search?id=%22NCT01882491%22,https://clinicaltrials.gov/sea osteoarthritis 2 Completed 2 Completed https://clinicaltrials.gov/search?id=%22NCT01498874%22 inner ear disease 2 Completed https://clinicaltrials.gov/search?id=%22NCT01950312%22 Pyoderma 2 Completed https://clinicaltrials.gov/search?id=%22NCT01882504%22 type II diabetes mellitus 1 Completed https://clinicaltrials.gov/search?id=%22NCT00513214%22,https://clinicaltrials.gov/sea 1 Withdrawn https://clinicaltrials.gov/search?id=%22NCT01211977%22 Behcet's syndrome https://clinicaltrials.gov/search?id=%22NCT01835132%22 scleritis 1 Completed 1 Completed https://clinicaltrials.gov/search?id=%22NCT00412828%22 melanoma 1 Completed https://clinicaltrials.gov/search?id=%22NCT00704158%22 breast cancer 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02487979%22 osteosarcoma https://clinicaltrials.gov/search?id=%22NCT02302339%22 2 Terminated melanoma Uveal Melanoma 2 Completed https://clinicaltrials.gov/search?id=%22NCT02363283%22 1 Terminated squamous cell lung carcinoma https://clinicaltrials.gov/search?id=%22NCT02713828%22 breast cancer 0 Withdrawn https://clinicaltrials.gov/search?id=%22NCT03473691%22 neoplasm 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00105170%22 neoplasm of mature B-cells 2 Completed https://clinicaltrials.gov/search?id=%22NCT00138086%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00577278%22 graft versus host disease 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT00012298%22 chronic lymphocytic leukemia 1 Terminated Hodgkins lymphoma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00036855%22 MALT lymphoma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00012298%22 Burkitts lymphoma 1 Completed https://clinicaltrials.gov/search?id=%22NCT00064246%22 diffuse large B-cell lymphoma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00036855%22 leukemia 1 Completed https://clinicaltrials.gov/search?id=%22NCT00048737%22 lymphoma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00372905%22 multiple myeloma 1 Completed https://clinicaltrials.gov/search?id=%22NCT00477815%22

uveitis

acne

CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkin
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000550	Splenic Margi
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001365	Lymphoma, A
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell ly
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblasti
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicularlym
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019088	post-transpla
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019465	nodal margin
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	EFO_0005547	dengue disea
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	EFO_1000637	acute respira
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	MONDO_0100096	COVID-19
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	MONDO_0100130	adult acute re
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	EFO_0000253	amyotrophic
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A c	r Cross-linking agent	EFO_1001951	colorectal car
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A c	r Cross-linking agent	EFO_0000616	neoplasm
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A c	r Cross-linking agent	EFO_0003060	non-small cel
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A c	r Cross-linking agent	EFO_0006859	head and nec
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000540	immune syste
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0004991	Myasthenia g
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0017287	lgG4-related
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chronic lympl
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0004256	neuromyeliti
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0007332	Japanese enc
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000311	cancer
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000574	lymphoma
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0001642	lymphoid neo
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0003885	multiple scle
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001993	scleroderma
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0001378	multiple mye
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000220	acute lympho

on-Hodgkins lymphoma aldenstrom macroglobulinemia lenic Marginal Zone Lymphoma nphoma, AIDS-Related antle cell lymphoma nphoblastic lymphoma licular lymphoma st-transplant lymphoproliferative d dal marginal zone B-cell lymphoma ngue disease ute respiratory distress syndrome ult acute respiratory distress syndro yotrophic lateral sclerosis orectal carcinoma n-small cell lung carcinoma ad and neck malignant neoplasia mune system disease asthenia gravis G4-related disease ronic lymphocytic leukemia fuse large B-cell lymphoma uromyelitis optica panese encephalitis mphoid neoplasm ultiple sclerosis eroderma ultiple myeloma ute lymphoblastic leukemia

1 Terminated 1 Completed 1 Terminated 1 Terminated 1 Completed 1 Terminated 1 Completed 1 Terminated 1 Completed 2 Withdrawn 2 Withdrawn 2 Recruiting 2 Terminated 1 Completed 2 Completed 1 Completed 1 Withdrawn 1 Completed 3 Recruiting 3 Recruiting 2 Completed 2 Completed 2 Completed 2 Not yet recruiting 1 Completed 1 Completed 1 Completed 1 Completed 1 Completed 0 Completed 3 Completed

https://clinicaltrials.gov/search?id=%22NCT00089284%22 https://clinicaltrials.gov/search?id=%22NCT00438880%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00012298%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00438880%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00438880%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00438880%22 https://clinicaltrials.gov/search?id=%22NCT03875560%22 https://clinicaltrials.gov/search?id=%22NCT03017547%22 https://clinicaltrials.gov/search?id=%22NCT04488081%22 https://clinicaltrials.gov/search?id=%22NCT00233207%22 https://clinicaltrials.gov/search?id=%22NCT03487263%22 https://clinicaltrials.gov/search?id=%22NCT01326000%22 https://clinicaltrials.gov/search?id=%22NCT00721266%22 https://clinicaltrials.gov/search?id=%22NCT01702714%22 https://clinicaltrials.gov/search?id=%22NCT01046266%22 http://www.whocc.no/atc_ddd_index/?code=L04AA47 https://clinicaltrials.gov/search?id=%22NCT04524273%22 https://clinicaltrials.gov/search?id=%22NCT04540497%22 https://clinicaltrials.gov/search?id=%22NCT01466153%22 https://clinicaltrials.gov/search?id=%22NCT01453205%22 https://clinicaltrials.gov/search?id=%22NCT02200770%22 https://clinicaltrials.gov/search?id=%22NCT04372615%22 https://clinicaltrials.gov/search?id=%22NCT00983619%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT02271945%22 https://clinicaltrials.gov/search?id=%22NCT01957579%22 https://clinicaltrials.gov/search?id=%22NCT01585766%22 https://clinicaltrials.gov/search?id=%22NCT00946699%22 https://clinicaltrials.gov/search?id=%22NCT01861340%22 https://clinicaltrials.gov/search?id=%22NCT00483132%22

CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanon
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003780	Behcet's
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001156	retinal v
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney c
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000574	lymphon
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	multiple
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002617	metastat
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic h
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000956	hairy cel
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000676	psoriasis
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000681	renal cel
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infe
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000558	Kaposi's
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000574	lymphor
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007147	anogenit
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007306	herpang
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000956	hairy cel
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001051	mycosis
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0018906	follicular
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infe
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	multiple
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001422	cirrhosis
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009708	metastas
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0024503	digestive
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000339	chronic r
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000349	clear cel
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000673	prostate
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000681	renal cel
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001668	human p
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002618	pancreat

3 Completed elanoma epatitis C virus infection 3 Completed ehcet's syndrome 3 Completed 3 Completed tinal vasculitis 3 Completed dney cancer 2 Terminated 2 Completed mphoma ultiple myeloma 2 Completed etastatic melanoma 2 Completed pronic hepatitis C virus infection 2 Completed airy cell leukemia 2 Completed soriasis 1 Completed enal cell carcinoma 1 Completed IV infection 1 Completed aposi's sarcoma 4 Terminated mphoma nogenital venereal wart 4 Completed erpangina airy cell leukemia ycosis fungoides 4 Unknown status ollicular lymphoma IV infection 3 Terminated ultiple myeloma 3 Completed rrhosis of liver 3 Completed 3 Completed etastasis gestive system neuroendocrine neo 3 Withdrawn nronic myelogenous leukemia 2 Recruiting ear cell renal carcinoma 2 Completed rostate adenocarcinoma 2 Recruiting enal cell carcinoma 2 Unknown status uman papilloma virus infection 2 Unknown status pancreatic carcinoma 2 Completed

https://clinicaltrials.gov/search?id=%22NCT00204529%22 https://clinicaltrials.gov/search?id=%22NCT00381953%22 https://clinicaltrials.gov/search?id=%22NCT00167583%22 https://clinicaltrials.gov/search?id=%22NCT00167583%22 https://clinicaltrials.gov/search?id=%22NCT00416429%22 https://clinicaltrials.gov/search?id=%22NCT02159482%22 https://clinicaltrials.gov/search?id=%22NCT01404936%22 https://clinicaltrials.gov/search?id=%22NCT00323505%22 https://clinicaltrials.gov/search?id=%22NCT00308607%22 https://clinicaltrials.gov/search?id=%22NCT02340962%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00001567%22 https://clinicaltrials.gov/search?id=%22NCT02763969%22 https://clinicaltrials.gov/search?id=%22NCT01513187%22 https://clinicaltrials.gov/search?id=%22NCT00000967%22,https://clinicaltrials.gov/sea http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf https://clinicaltrials.gov/search?id=%22NCT00854581%22 http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf https://clinicaltrials.gov/search?id=%22NCT03266601%22 http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf https://clinicaltrials.gov/search?id=%22NCT02323659%22 http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf https://clinicaltrials.gov/search?id=%22NCT00125814%22 https://clinicaltrials.gov/search?id=%22NCT00002556%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00273247%22 https://clinicaltrials.gov/search?id=%22NCT00221702%22 https://clinicaltrials.gov/search?id=%22NCT01860742%22 https://clinicaltrials.gov/search?id=%22NCT02001818%22 https://clinicaltrials.gov/search?id=%22NCT00101114%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03899987%22 https://clinicaltrials.gov/search?id=%22NCT01274273%22 https://clinicaltrials.gov/search?id=%22NCT02801383%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00059826%22

CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chronic h
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0000544	mucosal r
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney ca
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002691	liver canc
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008315	prostate
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0019471	adult T-ce
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000182	hepatoce
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000389	cutaneou
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000616	neoplasm
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanom
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003869	breast ne
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004197	hepatitis
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic h
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0004658	breast car
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008170	ovarian ca
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0044881	hematop
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000565	leukemia
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0007254	breast ca
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19
CHEMBL2109047	INTERFERON ALFA-N3	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000694	severe ac
CHEMBL2109047	INTERFERON ALFA-N3	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infec
CHEMBL1201557	INTERFERON ALFACON-1	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis
CHEMBL1201557	INTERFERON ALFACON-1	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic h
CHEMBL1201557	INTERFERON ALFACON-1	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007328	influenza
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003106	pneumor
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007328	influenza
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100130	adult acu
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000249	Alzheime
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000270	asthma

nronic hepatitis B virus infection 2 Completed https://clinicaltrials.gov/search?id=%22NCT00275938%22 ucosal melanoma 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03178123%22 2 Withdrawn https://clinicaltrials.gov/search?id=%22NCT00293527%22 idney cancer https://clinicaltrials.gov/search?id=%22NCT00471484%22 ver cancer 2 Unknown status 2 Terminated https://clinicaltrials.gov/search?id=%22NCT00176527%22 rostate cancer dult T-cell leukemia/lymphoma 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT02737046%22 https://clinicaltrials.gov/search?id=%22NCT00234182%22 epatocellular carcinoma 1 Completed https://clinicaltrials.gov/search?id=%22NCT00311558%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00398450%22 1 Completed itaneous melanoma 1 Completed https://clinicaltrials.gov/search?id=%22NCT00908869%22,https://clinicaltrials.gov/sea eoplasm 1 Terminated https://clinicaltrials.gov/search?id=%22NCT01409174%22 elanoma epatitis C virus infection 1 Completed https://clinicaltrials.gov/search?id=%22NCT01217359%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03066947%22 reast neoplasm 1 Completed epatitis B virus infection https://clinicaltrials.gov/search?id=%22NCT03294798%22 1 Completed nronic hepatitis C virus infection https://clinicaltrials.gov/search?id=%22NCT01194037%22,https://clinicaltrials.gov/sea 1 Completed reast carcinoma in situ 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04081389%22 arian cancer 1 Completed https://clinicaltrials.gov/search?id=%22NCT01639885%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT04379518%22 ematopoietic and lymphoid cell neor 1 Recruiting ukemia 0 Completed https://clinicaltrials.gov/search?id=%22NCT02331706%22 0 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03599453%22 reast cancer OVID-19 0 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04293887%22 evere acute respiratory syndrome 2 Completed https://clinicaltrials.gov/search?id=%22NCT00215826%22 https://clinicaltrials.gov/search?id=%22NCT00002078%22 IV infection 1 Completed 3 Completed https://clinicaltrials.gov/search?id=%22NCT00239252%22 epatitis C virus infection nronic hepatitis C virus infection 3 Completed https://clinicaltrials.gov/search?id=%22NCT00162734%22,https://clinicaltrials.gov/sea 1 Unknown status https://clinicaltrials.gov/search?id=%22NCT01227798%22 fluenza https://clinicaltrials.gov/search?id=%22NCT02735707%22 neumonia 4 Recruitina fluenza 4 Recruiting https://clinicaltrials.gov/search?id=%22NCT02735707%22 epatitis C virus infection 3 Completed https://clinicaltrials.gov/search?id=%22NCT00249860%22 dult acute respiratory distress syndro https://clinicaltrials.gov/search?id=%22NCT02622724%22 3 Terminated Izheimer's disease 2 Completed https://clinicaltrials.gov/search?id=%22NCT01075763%22 https://clinicaltrials.gov/search?id=%22NCT01126177%22,https://clinicaltrials.gov/sea 2 Completed

CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000341	chro
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000384	Croh
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000729	ulce
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000868	chro
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001373	Mult
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COV
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000712	strol
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003929	rela
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003885	mult
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000318	card
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003929	rela
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COV
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100116	Mide
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003885	mult
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000203	mon
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000220	acut
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000222	acut
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003073	asyn
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0005592	T-ce
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0044917	T-lyr
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000540	imm
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000574	lymp
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000616	neo
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001378	mult
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001642	lymp
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001264	Ane
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001951	colo
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	Orphanet_85443	ALa
CHEMBL2109348	LFB-R603	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chro
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	MONDO_0001475	neut
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000198	mye

nronic obstructive pulmonary disease 2 Recruiting rohn's disease 2 Terminated 2 Completed cerative colitis nronic inflammatory demyelinating p 2 Completed lultiple Organ Failure 2 Terminated OVID-19 2 Active, not recruiting roke 1 Completed elapsing-remitting multiple sclerosis 1 Unknown status ultiple sclerosis 0 Completed IV infection 3 Completed ardiomyopathy 2 Completed lapsing-remitting multiple sclerosis 2 Recruiting OVID-19 2 Completed liddle East respiratory syndrome 2 Completed ultiple sclerosis 1 Completed onoclonal gammopathy 2 Not yet recruiting cute lymphoblastic leukemia 2 Recruiting cute myeloid leukemia 2 Recruiting symptomatic myeloma 2 Recruiting cell leukemia 2 Terminated lymphoblastic lymphoma 2 Terminated 1 Recruiting nmune system disease mphoma 1 Active, not recruiting eoplasm 1 Active, not recruiting ultiple myeloma 1 Active, not recruiting mphoid neoplasm 1 Active, not recruiting nemia, Hemolytic, Autoimmune 1 Recruitina 1 Recruiting olorectal carcinoma amyloidosis 1 Recruiting nronic lymphocytic leukemia 1 Completed eutropenia 2 Completed yelodysplastic syndrome 1 Completed

https://clinicaltrials.gov/search?id=%22NCT03570359%22 https://clinicaltrials.gov/search?id=%22NCT00304252%22 https://clinicaltrials.gov/search?id=%22NCT00048347%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00099489%22 https://clinicaltrials.gov/search?id=%22NCT03119701%22 https://clinicaltrials.gov/search?id=%22NCT04385095%22 https://clinicaltrials.gov/search?id=%22NCT00097318%22 https://clinicaltrials.gov/search?id=%22NCT02364986%22 https://clinicaltrials.gov/search?id=%22NCT00618527%22 https://clinicaltrials.gov/search?id=%22NCT00002238%22 https://clinicaltrials.gov/search?id=%22NCT00185250%22 https://clinicaltrials.gov/search?id=%22NCT03133403%22 https://clinicaltrials.gov/search?id=%22NCT04343768%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT02845843%22 https://clinicaltrials.gov/search?id=%22NCT02474134%22 https://clinicaltrials.gov/search?id=%22NCT04614558%22 https://clinicaltrials.gov/search?id=%22NCT03860844%22 https://clinicaltrials.gov/search?id=%22NCT03860844%22 https://clinicaltrials.gov/search?id=%22NCT02960555%22 https://clinicaltrials.gov/search?id=%22NCT02999633%22 https://clinicaltrials.gov/search?id=%22NCT02999633%22 https://clinicaltrials.gov/search?id=%22NCT04294459%22 https://clinicaltrials.gov/search?id=%22NCT03769181%22 https://clinicaltrials.gov/search?id=%22NCT03637764%22 https://clinicaltrials.gov/search?id=%22NCT02514668%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT01084252%22 https://clinicaltrials.gov/search?id=%22NCT04661033%22 https://clinicaltrials.gov/search?id=%22NCT03555149%22 https://clinicaltrials.gov/search?id=%22NCT04754945%22 https://clinicaltrials.gov/search?id=%22NCT01098188%22 https://clinicaltrials.gov/search?id=%22NCT00002800%22 https://clinicaltrials.gov/search?id=%22NCT00502112%22,https://clinicaltrials.gov/sea

CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000222	acute
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000565	leuke
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0001378	multi
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_1001779	chron
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0005952	non-ŀ
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chron
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffus
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mant
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follic
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001938	B-cell
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follic
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000096	neop
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffus
CHEMBL4594518	LUTIKIZUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1000789	osteo
CHEMBL4594518	LUTIKIZUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002506	osteo
CHEMBL2109447	LYM-1	Antibody	HLA class II histocompatibility antigen, DRB1-10 beta chain othe	Other	EFO_0000574	lympl
CHEMBL2109267	M195	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000198	myel
CHEMBL2109267	M195	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000565	leuke
CHEMBL2109267	M195	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0004251	myel
CHEMBL2109337	MDX-1342	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chror
CHEMBL2109337	MDX-1342	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000685	rheur
CHEMBL2109391	MDX-447	Antibody	High affinity immunoglobulin gamma Fc receptor I cross-linking	Cross-linking agent	EFO_1000158	Centr
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0004991	Myas
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0007160	autoi
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0001378	multi
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0002690	syste
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0005140	autoi
CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-ł
CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chror
CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffus

ite myeloid leukemia 1 Not yet recruiting 1 Active, not recruiting kemia Itiple myeloma 1 Active, not recruiting onic myelomonocytic leukemia 1 Completed n-Hodgkins lymphoma 2 Recruiting onic lymphocytic leukemia 1 Recruiting ite lymphoblastic leukemia 1 Recruiting fuse large B-cell lymphoma 1 Recruiting ntle cell lymphoma 1 Recruiting licular lymphoma 1 Recruiting cell non-Hodgkins lymphoma licular lymphoma 2 Recruiting oplasm of mature B-cells 1 Not yet recruiting ite lymphoblastic leukemia 1 Terminated fuse large B-cell lymphoma 1 Not yet recruiting eoarthritis, hand 2 Completed eoarthritis 1 Completed 1 Unknown status phoma elodysplastic syndrome 1 Completed 1 Completed kemia eloproliferative disorder 1 Completed ronic lymphocytic leukemia 1 Completed eumatoid arthritis 1 Completed 1 Completed ntral Nervous System Neoplasm 2 Recruiting asthenia gravis oimmune thrombocytopenic purpu 2 Recruiting Itiple myeloma 1 Recruiting temic lupus erythematosus 1 Recruiting oimmune disease 1 Completed n-Hodgkins lymphoma 2 Terminated onic lymphocytic leukemia 1 Active, not recruiting fuse large B-cell lymphoma 1 Active, not recruiting

https://clinicaltrials.gov/search?id=%22NCT03932318%22 https://clinicaltrials.gov/search?id=%22NCT01756677%22 https://clinicaltrials.gov/search?id=%22NCT02998047%22 https://clinicaltrials.gov/search?id=%22NCT00283114%22 https://clinicaltrials.gov/search?id=%22NCT03484702%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03331198%22 https://clinicaltrials.gov/search?id=%22NCT03743246%22 https://clinicaltrials.gov/search?id=%22NCT02631044%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT02631044%22 https://clinicaltrials.gov/search?id=%22NCT02631044%22,https://clinicaltrials.gov/sea http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf https://clinicaltrials.gov/search?id=%22NCT04699461%22 https://clinicaltrials.gov/search?id=%22NCT04970901%22 https://clinicaltrials.gov/search?id=%22NCT02669264%22 https://clinicaltrials.gov/search?id=%22NCT04974996%22 https://clinicaltrials.gov/search?id=%22NCT02384538%22 https://clinicaltrials.gov/search?id=%22NCT01668511%22 https://clinicaltrials.gov/search?id=%22NCT00009776%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00014495%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00014495%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00014495%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00593944%22 https://clinicaltrials.gov/search?id=%22NCT00639834%22 https://clinicaltrials.gov/search?id=%22NCT00005813%22 https://clinicaltrials.gov/search?id=%22NCT04159805%22 https://clinicaltrials.gov/search?id=%22NCT04278924%22 https://clinicaltrials.gov/search?id=%22NCT04776018%22 https://clinicaltrials.gov/search?id=%22NCT03724916%22 https://clinicaltrials.gov/search?id=%22NCT02219256%22 https://clinicaltrials.gov/search?id=%22NCT03645395%22 https://clinicaltrials.gov/search?id=%22NCT02361346%22 https://clinicaltrials.gov/search?id=%22NCT02361346%22

CHEMBL4297789	MT-3724
CHEMBL1743048	OBINUTUZUMAE
CHEMBL2109665	OCARATUZUMA
CHEMBL2108041	OCRELIZUMAB

B-lymphocyte antigen CD20 binding agent Unknown Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent

Binding agent EFO 0004289 **Binding agent** EFO_0002690 **Binding agent** EFO_0003086 EFO_0000220 Binding agent EFO_0003060 Binding agent EFO_0005761 Binding agent EFO 0009441 Binding agent Binding agent EFO_1000956 **Binding agent** MONDO 0013730 **Binding agent** MONDO 0019088 **Binding agent** EFO_0000095 Binding agent EFO_0000096 EFO_0000183 Binding agent EFO 0000304 **Binding agent** EFO_0000309 **Binding agent Binding agent** EFO_0000311 Binding agent EFO_0000403 EFO_0000565 Binding agent EFO_0000574 Binding agent **Binding agent** EFO_0000616 Binding agent EFO_0003884 **Binding agent** EFO_0005952 **Binding agent** EFO_1001051 EFO_1001469 **Binding agent** EFO_1001480 Binding agent **Binding agent** EFO_1001951 **Binding agent** MONDO 0001023 **Binding agent** MONDO 0002083 MONDO 0018906 Binding agent MONDO_0019465 Binding agent **Binding agent** EFO_0000311 EFO 0000540 Binding agent

systemic lupus erythematosus kidney disease acute lymphoblastic leukemia non-small cell lung carcinoma lupus nephritis hairv cell leukemia graft versus host disease chronic lymphocytic leukemia neoplasm of mature B-cells Hodgkins lymphoma breast adenocarcinoma Burkitts lymphoma cancer diffuse large B-cell lymphoma leukemia lymphoma neoplasm chronic kidney disease non-Hodgkins lymphoma mycosis fungoides Mantle cell lymphoma metastatic colorectal cancer colorectal carcinoma prolymphocytic leukemia Richter syndrome follicular lymphoma cancer immune system disease

lymphoid leukemia

1 Withdrawn https://clinicaltrials.gov/search?id=%22NCT02556346%22 3 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04963296%22 3 Recruiting https://clinicaltrials.gov/search?id=%22NCT04629248%22 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04920968%22 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04880863%22 https://clinicaltrials.gov/search?id=%22NCT02550652%22 2 Active, not recruiting Waldenstrom macroglobulinemia 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02962401%22 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT03410875%22 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT02867384%22 post-transplant lymphoproliferative d 2 Withdrawn https://clinicaltrials.gov/search?id=%22NCT03086395%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT02336048%22,https://clinicaltrials.gov/sea 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT04313608%22 https://clinicaltrials.gov/search?id=%22NCT03432741%22 1 Suspended 1 Suspended https://clinicaltrials.gov/search?id=%22NCT03432741%22 https://clinicaltrials.gov/search?id=%22NCT03223610%22,https://clinicaltrials.gov/sea 1 Recruiting 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02457598%22 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT03223610%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03759184%22 1 Recruiting 1 Completed https://clinicaltrials.gov/search?id=%22NCT02729896%22,https://clinicaltrials.gov/sea 1 Completed https://clinicaltrials.gov/search?id=%22NCT02324257%22 1 Completed https://clinicaltrials.gov/search?id=%22NCT02586051%22 https://clinicaltrials.gov/search?id=%22NCT04434196%22,https://clinicaltrials.gov/sea 1 Recruiting 1 Suspended https://clinicaltrials.gov/search?id=%22NCT03432741%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02558816%22 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04826003%22 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT03866239%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02296918%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03113695%22 https://clinicaltrials.gov/search?id=%22NCT02631577%22,https://clinicaltrials.gov/sea 1 Completed nodal marginal zone B-cell lymphoma https://clinicaltrials.gov/search?id=%22NCT03432741%22 1 Suspended 1 Unknown status https://clinicaltrials.gov/search?id=%22NCT01858181%22 http://www.whocc.no/atc_ddd_index/?code=L04AA36

CHEMBL2108041	OCRELIZUMAB
CHEMBL2108041	OCRELIZUMAB
CHEMBL4298084	ODRONEXTAMAB
CHEMBL4298084	ODRONEXTAMAB
CHEMBL4298084	ODRONEXTAMAB
CHEMBL1201836	OFATUMUMAB

Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
5	B-lymphocyte antigen CD20 binding agent
Antibody	
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
, and body	b ijinphotyte unigen obzo binding ugent

inding agent	EFO_0008522	secondary p
inding agent	EFO_0002690	systemic lup
inding agent	EFO_0003840	chronic prog
inding agent	EFO_0008520	primary pro
inding agent	EFO_0003929	relapsing-re
inding agent	EFO_0007332	Japanese er
inding agent	EFO_0000685	rheumatoid
inding agent	EFO_0003885	multiple scl
inding agent	EFO_0005952	non-Hodgki
inding agent	EFO_000096	neoplasm o
inding agent	EFO_000095	chronic lym
inding agent	EFO_0000574	lymphoma
inding agent	EFO_0000616	neoplasm
inding agent	EFO_0004719	pemphigus
inding agent	EFO_1000749	pemphigus
inding agent	EFO_0000183	Hodgkins ly
inding agent	EFO_0000220	acute lymph
inding agent	EFO_0000309	Burkitts lym
inding agent	EFO_0000403	diffuse large
inding agent	EFO_0000574	lymphoma
inding agent	EFO_0000756	melanoma
inding agent	EFO_0000765	AIDS
inding agent	EFO_0003885	multiple scl
inding agent	EFO_0004255	nephrotic sy
inding agent	EFO_0004289	lymphoid le
inding agent	EFO_0009441	Waldenstro
inding agent	MONDO_0000870	childhood a
inding agent	MONDO_0000873	lymphoblas
inding agent	MONDO_0003541	adult acute
inding agent	EFO_000095	chronic lym
inding agent	EFO_0000311	cancer
inding agent	EFO_0000565	leukemia

secondary progressive multiple sclero: systemic lupus erythematosus chronic progressive multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis Japanese encephalitis rheumatoid arthritis multiple sclerosis non-Hodgkins lymphoma neoplasm of mature B-cells chronic lymphocytic leukemia pemphigus vulgaris Hodgkins lymphoma acute lymphoblastic leukemia Burkitts lymphoma diffuse large B-cell lymphoma multiple sclerosis nephrotic syndrome lymphoid leukemia Waldenstrom macroglobulinemia childhood acute lymphoblastic leuker lymphoblastic lymphoma adult acute lymphoblastic leukemia chronic lymphocytic leukemia

4 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04925557%22 3 Terminated https://clinicaltrials.gov/search?id=%22NCT00539838%22 3 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT01194570%22 3 Recruiting https://clinicaltrials.gov/search?id=%22NCT03691077%22 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04971005%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT03835728%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT02720120%22 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT03972306%22 1 Completed https://clinicaltrials.gov/search?id=%22NCT02723071%22 https://clinicaltrials.gov/search?id=%22NCT03888105%22 2 Recruiting 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT02290951%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02651662%22 http://www.whocc.no/atc_ddd_index/?code=L01XC10 3 Terminated https://clinicaltrials.gov/search?id=%22NCT01920477%22 3 Terminated https://clinicaltrials.gov/search?id=%22NCT02613910%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01195766%22 2 Terminated https://clinicaltrials.gov/search?id=%22NCT03488225%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01363128%22 https://clinicaltrials.gov/search?id=%22NCT01481272%22,https://clinicaltrials.gov/sea 2 Completed https://clinicaltrials.gov/search?id=%22NCT01613300%22,https://clinicaltrials.gov/sea 2 Completed 2 Completed https://clinicaltrials.gov/search?id=%22NCT01376713%22 https://clinicaltrials.gov/search?id=%22NCT02199184%22 2 Recruiting 2 Completed https://clinicaltrials.gov/search?id=%22NCT03560739%22,https://clinicaltrials.gov/sea 2 Completed https://clinicaltrials.gov/search?id=%22NCT02394119%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01762202%22 2 Terminated https://clinicaltrials.gov/search?id=%22NCT01536067%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01363128%22 https://clinicaltrials.gov/search?id=%22NCT01363128%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01363128%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT00742144%22,https://clinicaltrials.gov/sea 1 Completed 1 Completed https://clinicaltrials.gov/search?id=%22NCT01691807%22 1 Completed https://clinicaltrials.gov/search?id=%22NCT01110031%22

CHEMBL1201836 OFATUMUMAB OFATUMUMAB CHEMBL1201836 OFATUMUMAB CHEMBL1201836 CHEMBL1201836 OFATUMUMAB CHEMBL1201836 OFATUMUMAB CHEMBL1201836 OFATUMUMAB CHEMBL1201836 OFATUMUMAB CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 **PEGINTERFERON ALFA-2A** CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 **PEGINTERFERON ALFA-2A** CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 **PEGINTERFERON ALFA-2A** CHEMBL1201560 **PEGINTERFERON ALFA-2A** CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 **PEGINTERFERON ALFA-2A** CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 PEGINTERFERON ALFA-2A CHEMBL1201560 **PEGINTERFERON ALFA-2A** CHEMBL1201560 PEGINTERFERON ALFA-2A

Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent Antibodv B-lymphocyte antigen CD20 binding agent Protein Interferon alpha/beta receptor agonist Protein Interferon alpha/beta receptor agonist

Binding agent EFO 0000685 EFO_0005952 **Binding agent** Binding agent EFO_1001469 Binding agent MONDO 0001023 MONDO 0002083 **Binding agent Binding agent** MONDO_0013730 MONDO 0018906 Binding agent Agonist EFO_0004272 EFO_0008496 Agonist Agonist EFO_0000756 EFO_0001422 Agonist Agonist EFO_0002430 HP_0012115 Agonist MONDO 0002050 Agonist EFO_0000182 Agonist Agonist EFO_0000339 Agonist EFO_0000544 EFO 0000565 Agonist EFO_0001378 Agonist Agonist EFO_1000026 Agonist EFO_1000251 HP_0001873 Agonist MONDO 0002087 Agonist MONDO_0007254 Agonist MONDO_0008170 Agonist Agonist MONDO 0021063 Agonist MONDO 0024880 Agonist EFO_0000095 EFO 0000222 Agonist EFO_0000311 Agonist Agonist EFO 0000479 EFO 0000616 Agonist

melanoma Hepatitis infection leukemia breast cancer ovarian cancer cancer neoplasm

rheumatoid arthritis non-Hodgkins lymphoma Mantle cell lymphoma prolymphocytic leukemia Richter syndrome graft versus host disease follicular lymphoma anemia (phenotype) chronic hepatitis cirrhosis of liver primary myelofibrosis depressive disorder hepatocellular carcinoma chronic myelogenous leukemia multiple myeloma diffuse intrinsic pontine glioma Fallopian Tube Carcinoma Thrombocytopenia peritoneum cancer malignant colon neoplasm metastatic malignant neoplasm chronic lymphocytic leukemia acute myeloid leukemia essential thrombocythemia

1 Completed 1 Active, not recruiting 1 Unknown status 1 Completed 1 Completed 1 Active, not recruiting 1 Withdrawn 4 Completed 4 Recruiting 3 Completed 3 Completed 3 Unknown status 3 Completed 3 Completed 2 Completed 2 Completed 2 Completed 2 Terminated 2 Completed 2 Completed 2 Terminated 2 Completed 2 Terminated 2 Terminated 2 Terminated 2 Not yet recruiting 2 Terminated 1 Withdrawn 1 Completed 1 Completed 1 Completed 1 Completed

https://clinicaltrials.gov/search?id=%22NCT00686868%22 https://clinicaltrials.gov/search?id=%22NCT01458366%22 https://clinicaltrials.gov/search?id=%22NCT01221103%22 https://clinicaltrials.gov/search?id=%22NCT01515176%22 https://clinicaltrials.gov/search?id=%22NCT01217749%22 https://clinicaltrials.gov/search?id=%22NCT01680965%22 https://clinicaltrials.gov/search?id=%22NCT00092274%22 https://clinicaltrials.gov/search?id=%22NCT00560274%22 https://clinicaltrials.gov/search?id=%22NCT03013556%22 https://clinicaltrials.gov/search?id=%22NCT00204529%22 https://clinicaltrials.gov/search?id=%22NCT00006164%22 https://clinicaltrials.gov/search?id=%22NCT01387763%22 https://clinicaltrials.gov/search?id=%22NCT00147784%22 https://clinicaltrials.gov/search?id=%22NCT00136318%22 https://clinicaltrials.gov/search?id=%22NCT02576964%22 https://clinicaltrials.gov/search?id=%22NCT01294618%22 https://clinicaltrials.gov/search?id=%22NCT00665353%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT01392170%22 https://clinicaltrials.gov/search?id=%22NCT00323505%22 https://clinicaltrials.gov/search?id=%22NCT00036569%22 https://clinicaltrials.gov/search?id=%22NCT01773889%22 https://clinicaltrials.gov/search?id=%22NCT01355289%22 https://clinicaltrials.gov/search?id=%22NCT01773889%22 https://clinicaltrials.gov/search?id=%22NCT00227656%22 https://clinicaltrials.gov/search?id=%22NCT01773889%22 https://clinicaltrials.gov/search?id=%22NCT04798612%22 https://clinicaltrials.gov/search?id=%22NCT00227656%22 https://clinicaltrials.gov/search?id=%22NCT00962715%22 https://clinicaltrials.gov/search?id=%22NCT02328755%22 https://clinicaltrials.gov/search?id=%22NCT02174172%22 https://clinicaltrials.gov/search?id=%22NCT02407080%22 https://clinicaltrials.gov/search?id=%22NCT00253474%22

CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV i
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002429	poly
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepa
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004197	hepa
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chroi
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chroi
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007304	hepa
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009260	non-
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidne
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0044903	myel
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000479	esser
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000637	osteo
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	mult
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001422	cirrh
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002430	prim
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009708	meta
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001469	Mant
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_0012115	Нера
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000326	centi
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000389	cutar
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000565	leuke
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000574	lymp
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000658	plexi
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000707	squa
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001642	lymp
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004197	hepa
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chroi
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004243	carci
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0005221	chola
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0006859	head
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007304	hepa
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009259	skin

V infection 1 Recruitina lycythemia vera 1 Completed epatitis C virus infection 1 Terminated epatitis B virus infection 1 Completed nronic hepatitis C virus infection nronic hepatitis B virus infection 1 Unknown status epatitis D virus infection 1 Completed on-melanoma skin carcinoma 1 Unknown status 1 Completed dney cancer velofibrosis sential thrombocythemia 3 Unknown status steosarcoma ultiple myeloma 3 Completed rhosis of liver 3 Completed imary myelofibrosis etastasis 3 Completed antle cell lymphoma 3 Unknown status epatitis 3 Completed ntral nervous system cancer 2 Completed Itaneous melanoma 2 Completed ukemia 2 Completed 2 Recruitina nphoma exiform neurofibroma 2 Completed uamous cell carcinoma mphoid neoplasm 2 Recruiting epatitis B virus infection ronic hepatitis B virus infection 2 Completed rcinoid tumor 2 Completed olangiocarcinoma 2 Terminated ead and neck malignant neoplasia 2 Completed epatitis D virus infection 2 Unknown status in carcinoma

https://clinicaltrials.gov/search?id=%22NCT02471430%22 https://clinicaltrials.gov/search?id=%22NCT02407080%22 https://clinicaltrials.gov/search?id=%22NCT00277758%22 https://clinicaltrials.gov/search?id=%22NCT03294798%22 https://clinicaltrials.gov/search?id=%22NCT02057887%22,https://clinicaltrials.gov/sea 1 Unknown status https://clinicaltrials.gov/search?id=%22NCT01589952%22 https://clinicaltrials.gov/search?id=%22NCT02637999%22 https://clinicaltrials.gov/search?id=%22NCT00423397%22 https://clinicaltrials.gov/search?id=%22NCT00003542%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02742324%22 https://clinicaltrials.gov/search?id=%22NCT01387763%22 3 Unknown status https://clinicaltrials.gov/search?id=%22NCT00134030%22 https://clinicaltrials.gov/search?id=%22NCT00732641%22 https://clinicaltrials.gov/search?id=%22NCT00378599%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT01387763%22 3 Unknown status https://clinicaltrials.gov/search?id=%22NCT00221702%22 https://clinicaltrials.gov/search?id=%22NCT00209209%22 https://clinicaltrials.gov/search?id=%22NCT00039871%22 https://clinicaltrials.gov/search?id=%22NCT00047879%22 https://clinicaltrials.gov/search?id=%22NCT00049530%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00548847%22 https://clinicaltrials.gov/search?id=%22NCT04246359%22 https://clinicaltrials.gov/search?id=%22NCT00396019%22 https://clinicaltrials.gov/search?id=%22NCT02218164%22 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02634294%22 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT04189276%22 https://clinicaltrials.gov/search?id=%22NCT02332473%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00055809%22 https://clinicaltrials.gov/search?id=%22NCT02982720%22 https://clinicaltrials.gov/search?id=%22NCT00276523%22 https://clinicaltrials.gov/search?id=%22NCT03105310%22 https://clinicaltrials.gov/search?id=%22NCT02218164%22 2 Active, not recruiting

CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000209	Craniopharyngiom
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000403	Ocular Melanoma
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002974	cervical cancer
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0016691	pilocytic astrocyto
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0018079	thymic epithelial r
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0019471	adult T-cell leuker
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	Orphanet_636	Neurofibromatosi
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000180	HIV-1 infection
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000182	hepatocellular car
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000339	chronic myelogen
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000616	neoplasm
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000681	renal cell carcinon
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanoma
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infection
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000765	AIDS
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002429	polycythemia vera
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002617	metastatic melano
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus ir
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis (
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_000083	Renal insufficienc
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002087	peritoneum cance
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002158	fallopian tube can
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney cancer
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008170	ovarian cancer
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000694	severe acute respi
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003929	relapsing-remittin
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003885	multiple sclerosis
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_000083	Renal insufficienc
CHEMBL2108712	PLOVAMER ACETATE	Small mole	ec HLA class II histocompatibility antigen, DRB1-15 beta chain mo	Modulator	EFO_0003929	relapsing-remittin

raniopharyngioma 2 Terminated https://clinicaltrials.gov/search?id=%22NCT01964300%22 cular Melanoma 2 Completed https://clinicaltrials.gov/search?id=%22NCT00027742%22,https://clinicaltrials.gov/sea 2 Terminated https://clinicaltrials.gov/search?id=%22NCT00138151%22 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT02343224%22 locytic astrocytoma nymic epithelial neoplasm https://clinicaltrials.gov/search?id=%22NCT04517539%22 2 Not yet recruiting dult T-cell leukemia/lymphoma 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT02737046%22 https://clinicaltrials.gov/search?id=%22NCT04480138%22 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT00846430%22 eurofibromatosis type 1 2 Unknown status https://clinicaltrials.gov/search?id=%22NCT03588715%22 1 Active, not recruiting epatocellular carcinoma 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04943679%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00311558%22,https://clinicaltrials.gov/sea nronic myelogenous leukemia 1 Completed https://clinicaltrials.gov/search?id=%22NCT00303290%22 https://clinicaltrials.gov/search?id=%22NCT00014261%22,https://clinicaltrials.gov/sea 1 Completed enal cell carcinoma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00522249%22 https://clinicaltrials.gov/search?id=%22NCT01496807%22,https://clinicaltrials.gov/sea 1 Completed 1 Completed https://clinicaltrials.gov/search?id=%22NCT00006325%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03588715%22 https://clinicaltrials.gov/search?id=%22NCT01193699%22 olycythemia vera 1 Completed https://clinicaltrials.gov/search?id=%22NCT02379195%22 etastatic melanoma 1 Completed 1 Terminated epatitis C virus infection https://clinicaltrials.gov/search?id=%22NCT01701063%22 nronic hepatitis C virus infection 1 Completed https://clinicaltrials.gov/search?id=%22NCT00120835%22,https://clinicaltrials.gov/sea enal insufficiency 1 Completed https://clinicaltrials.gov/search?id=%22NCT01432535%22 https://clinicaltrials.gov/search?id=%22NCT00085384%22 eritoneum cancer 1 Terminated 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00085384%22 Illopian tube cancer 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00589550%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00085384%22 https://clinicaltrials.gov/search?id=%22NCT04727424%22 evere acute respiratory syndrome 3 Recruitina lapsing-remitting multiple sclerosis 3 Withdrawn https://clinicaltrials.gov/search?id=%22NCT01337427%22 3 Recruiting https://clinicaltrials.gov/search?id=%22NCT04727424%22 ultiple sclerosis https://clinicaltrials.gov/search?id=%22NCT02269930%22 1 Completed enal insufficiency 1 Completed https://clinicaltrials.gov/search?id=%22NCT01119781%22 https://clinicaltrials.gov/search?id=%22NCT01963611%22 elapsing-remitting multiple sclerosis 2 Terminated

CHEMBL1201830	RILONACEPT
CHEMBL1201830	RILONACEPT
CHEMBL1201576	RITUXIMAB

rotein	Interleukin-1 beta inhibitor
rotein	Interleukin-1 beta inhibitor
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen
ntibody	B-lymphocyte antigen CD20 binding agen

Pr

Pr

Ar

nhibitor	EFO_0000540
nhibitor	EFO_0003884
nhibitor	Orphanet_208650
nhibitor	Orphanet_47045
nhibitor	Orphanet_575
nhibitor	EFO_0002609
nhibitor	EFO_0004274
nhibitor	EFO_0007427
nhibitor	EFO_1001345
nhibitor	EFO_1001881
nhibitor	Orphanet_210115
nhibitor	Orphanet_342
nhibitor	EFO_0000404
nhibitor	EFO_0001359
nhibitor	EFO_1001999
nhibitor	EFO_0004238
linding agent	EFO_0000474
linding agent	EFO_0004194
linding agent	HP_000083
linding agent	EFO_0003929
linding agent	EFO_0004719
linding agent	EFO_0004826
linding agent	EFO_0009562
linding agent	HP_0000093
linding agent	MONDO_0000432
linding agent	EFO_0000255
linding agent	EFO_0000389
linding agent	EFO_0000540
linding agent	EFO_0000557
linding agent	EFO_0000717
linding agent	EFO_0000729
linding agent	EFO_0000765

gout pericarditis cold urticaria hearing loss epilepsy Proteinuria AIDS

immune system disease 4 Completed chronic kidney disease Cryopyrin-associated periodic syndron Familial cold urticaria 3 Completed Muckle-Wells syndrome 3 Completed juvenile idiopathic arthritis 2 Completed 2 Completed 2 Completed Hepatitis, Alcoholic 2 Completed 2 Completed Sterile multifocal osteomyelitis with p 2 Completed Familial Mediterranean fever 2 Completed diffuse scleroderma 1 Completed type I diabetes mellitus 1 Completed systemic juvenile idiopathic arthritis 1 Completed 0 Unknown status 4 Not yet recruiting IGA glomerulonephritis 4 Recruiting Renal insufficiency 4 Terminated relapsing-remitting multiple sclerosis 3 Recruiting pemphigus vulgaris 3 Completed anti-neutrophil antibody associated va 3 Completed polyneuropathy 3 Completed 3 Terminated 3 Completed lymphoplasmacytic lymphoma angioimmunoblastic T-cell lymphoma 2 Completed cutaneous melanoma 2 Unknown status immune system disease 2 Recruiting juvenile dermatomyositis 2 Completed systemic scleroderma 2 Unknown status ulcerative colitis 2 Completed 2 Recruiting

http://www.whocc.no/atc_ddd_index/?code=L04AC04 https://clinicaltrials.gov/search?id=%22NCT01663103%22 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282f4099-e848-432a-bac1 https://clinicaltrials.gov/search?id=%22NCT00288704%22 https://clinicaltrials.gov/search?id=%22NCT00288704%22 https://clinicaltrials.gov/search?id=%22NCT00534495%22 https://clinicaltrials.gov/search?id=%22NCT00610363%22 https://clinicaltrials.gov/search?id=%22NCT03980522%22 https://clinicaltrials.gov/search?id=%22NCT01903798%22 https://clinicaltrials.gov/search?id=%22NCT02171416%22 https://clinicaltrials.gov/search?id=%22NCT01801449%22 https://clinicaltrials.gov/search?id=%22NCT00582907%22 https://clinicaltrials.gov/search?id=%22NCT01538719%22 https://clinicaltrials.gov/search?id=%22NCT00962026%22 https://clinicaltrials.gov/search?id=%22NCT01803321%22 https://clinicaltrials.gov/search?id=%22NCT02828033%22 https://clinicaltrials.gov/search?id=%22NCT04542629%22 https://clinicaltrials.gov/search?id=%22NCT04525729%22 https://clinicaltrials.gov/search?id=%22NCT01312064%22 https://clinicaltrials.gov/search?id=%22NCT04578639%22 https://clinicaltrials.gov/search?id=%22NCT02383589%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT01697267%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00259974%22 https://clinicaltrials.gov/search?id=%22NCT01164098%22 https://clinicaltrials.gov/search?id=%22NCT00801281%22 https://clinicaltrials.gov/search?id=%22NCT00169156%22 https://clinicaltrials.gov/search?id=%22NCT02142335%22 https://clinicaltrials.gov/search?id=%22NCT03651518%22 https://clinicaltrials.gov/search?id=%22NCT00106184%22 https://clinicaltrials.gov/search?id=%22NCT00379431%22 https://clinicaltrials.gov/search?id=%22NCT00261118%22 https://clinicaltrials.gov/search?id=%22NCT02199184%22

CHEMBL1201576	RITUXIMAB
CHEMBL1201576	RITUXIMAB

	D kunnek an stan antinan CD20 kin din a anant
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent

Binding agent	EFO_0000772
Binding agent	EFO_0002612
Binding agent	EFO_0002689
Binding agent	EFO_0003032
Binding agent	EFO_0003100
Binding agent	EFO_0003144
Binding agent	EFO_0003780
Binding agent	EFO_0003840
Binding agent	EFO_0003860
Binding agent	EFO_0003869
Binding agent	EFO_0003897
Binding agent	EFO_0003898
linding agent	EFO_0004244
linding agent	EFO_0004254
linding agent	EFO_0004255
Binding agent	EFO_0004288
Binding agent	EFO_0004540
Binding agent	EFO_0004599
Binding agent	EFO_0005761
Binding agent	EFO_0007208
Binding agent	EFO_0007332
Binding agent	EFO_0007359
Binding agent	EFO_0009538
Binding agent	EFO_0010580
Binding agent	EFO_1000318
Binding agent	EFO_1000749
Binding agent	EFO_1000783
Binding agent	EFO_1000784
Binding agent	EFO_1000868
Binding agent	EFO_1001050
Binding agent	EFO_1001264
Binding agent	EFO_1001946

heart failure pemphigus

pneumococcal infection 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03069703%22 human herpesvirus 8 infection 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT01419561%22 antiphospholipid syndrome 2 Completed https://clinicaltrials.gov/search?id=%22NCT00537290%22 anaplastic large cell lymphoma 2 Completed https://clinicaltrials.gov/search?id=%22NCT01686165%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00006072%22 peripheral neuropathy 2 Unknown status 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT03332888%22 Behcet's syndrome 2 Completed https://clinicaltrials.gov/search?id=%22NCT00664599%22 chronic progressive multiple sclerosis 2 Completed https://clinicaltrials.gov/search?id=%22NCT02545959%22 pancreatic neoplasm 2 Completed https://clinicaltrials.gov/search?id=%22NCT00001805%22 https://clinicaltrials.gov/search?id=%22NCT00001805%22 breast neoplasm 2 Completed stomach neoplasm 2 Completed https://clinicaltrials.gov/search?id=%22NCT00001805%22 ankylosing spondylitis 2 Unknown status https://clinicaltrials.gov/search?id=%22NCT00432653%22 2 Withdrawn interstitial lung disease https://clinicaltrials.gov/search?id=%22NCT02789397%22 membranous glomerulonephritis 2 Completed https://clinicaltrials.gov/search?id=%22NCT01180036%22 https://clinicaltrials.gov/search?id=%22NCT04783675%22,https://clinicaltrials.gov/sea nephrotic syndrome 2 Recruiting colonic neoplasm 2 Completed https://clinicaltrials.gov/search?id=%22NCT00001805%22 chronic fatigue syndrome 2 Completed https://clinicaltrials.gov/search?id=%22NCT00848692%22 acute graft vs. host disease 2 Completed https://clinicaltrials.gov/search?id=%22NCT00771875%22 lupus nephritis 2 Completed https://clinicaltrials.gov/search?id=%22NCT02260934%22 Churg-Strauss syndrome 2 Terminated https://clinicaltrials.gov/search?id=%22NCT00424749%22 Japanese encephalitis 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT03274375%22 mast-cell leukemia 2 Completed https://clinicaltrials.gov/search?id=%22NCT00186628%22 chronic inflammatory demyelinating p 2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04480450%22 blastic plasmacytoid dendritic cell neo 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT04216524%22 Langerhans Cell Histiocytosis 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT03096782%22 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT04400994%22 diabetic neuropathy 2 Completed https://clinicaltrials.gov/search?id=%22NCT00050245%22 https://clinicaltrials.gov/search?id=%22NCT00104299%22 microscopic polyangiitis 2 Completed https://clinicaltrials.gov/search?id=%22NCT03864185%22 chronic inflammatory demyelinating p 2 Active, not recruiting multiple system atrophy 2 Recruiting https://clinicaltrials.gov/search?id=%22NCT04004819%22 Anemia, Hemolytic, Autoimmune 2 Completed https://clinicaltrials.gov/search?id=%22NCT00749112%22,https://clinicaltrials.gov/sea childhood B acute lymphoblastic leuke 2 Terminated https://clinicaltrials.gov/search?id=%22NCT00058461%22

CHEMBL1201576	RITUXIMAB
CHEMBL1201576	RITUXIMAB

Antihadu	D lymphonyte entires (D20 hinding egent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
5	5, 5 0 0 0 0

Binding agent HP 0012664 MONDO 0000870 **Binding agent** Binding agent MONDO 0001549 MONDO 0003541 Binding agent MONDO_0004695 Binding agent **Binding agent** MONDO_0009348 MONDO 0018170 Binding agent MONDO_0019139 Binding agent MONDO 0020743 Binding agent **Binding agent** MONDO 0021117 Binding agent MONDO 0044917 Binding agent Orphanet_232 Orphanet_238510 Binding agent **Binding agent** Orphanet_797 Orphanet_98878 **Binding agent** Binding agent EFO_0000096 Binding agent EFO_0000183 EFO_0000191 Binding agent EFO_0000198 Binding agent Binding agent EFO_0000209 Binding agent EFO_0000220 Binding agent EFO 0000222 Binding agent EFO 0000304 EFO_0000309 Binding agent EFO_0000311 Binding agent Binding agent EFO_0000339 **Binding agent** EFO 0000384 **Binding agent** EFO_0000565 EFO_0000616 Binding agent Binding agent EFO_0000685 Binding agent EFO_0000692 EFO 0000699 Binding agent

Sarcoidosis Hemophilia A cancer leukemia neoplasm schizophrenia

Reduced ejection fraction childhood acute lymphoblastic leuker hemolytic-uremic syndrome adult acute lymphoblastic leukemia liver lymphoma 2 Recruiting classic Hodgkin lymphoma idiopathic nephrotic syndrome acquired hemophilia mixed phenotype acute leukemia 2 Recruiting lung neoplasm T-lymphoblastic lymphoma Sickle cell anemia Lymphoproliferative syndrome neoplasm of mature B-cells Hodgkins lymphoma MALT lymphoma myelodysplastic syndrome T-cell acute lymphoblastic leukemia 1 Recruitina acute lymphoblastic leukemia 1 Recruiting acute myeloid leukemia breast adenocarcinoma Burkitts lymphoma chronic myelogenous leukemia Crohn's disease 1 Recruitina 1 Recruiting 1 Recruiting rheumatoid arthritis 1 Recruiting Sjogren syndrome

2 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT03332888%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT00057811%22 2 Unknown status https://clinicaltrials.gov/search?id=%22NCT00531089%22 2 Withdrawn https://clinicaltrials.gov/search?id=%22NCT02538926%22 https://clinicaltrials.gov/search?id=%22NCT04115631%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT00654732%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT01268033%22 2 Unknown status https://clinicaltrials.gov/search?id=%22NCT03700229%22 https://clinicaltrials.gov/search?id=%22NCT02135874%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT00001805%22 2 Withdrawn https://clinicaltrials.gov/search?id=%22NCT02538926%22 2 Terminated https://clinicaltrials.gov/search?id=%22NCT01279616%22 https://clinicaltrials.gov/search?id=%22NCT00869323%22 2 Terminated 2 Completed https://clinicaltrials.gov/search?id=%22NCT00855205%22 2 Completed https://clinicaltrials.gov/search?id=%22NCT00331006%22 1 Suspended https://clinicaltrials.gov/search?id=%22NCT04607772%22 https://clinicaltrials.gov/search?id=%22NCT02408042%22 1 Withdrawn 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00012298%22 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT02960646%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03808610%22 https://clinicaltrials.gov/search?id=%22NCT01371630%22,https://clinicaltrials.gov/sea 1 Completed https://clinicaltrials.gov/search?id=%22NCT02779283%22 1 Suspended https://clinicaltrials.gov/search?id=%22NCT03432741%22 https://clinicaltrials.gov/search?id=%22NCT01397825%22,https://clinicaltrials.gov/sea 1 Completed 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT00788684%22,https://clinicaltrials.gov/sea 1 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT01619761%22 https://clinicaltrials.gov/search?id=%22NCT00692939%22 https://clinicaltrials.gov/search?id=%22NCT02356159%22 https://clinicaltrials.gov/search?id=%22NCT03783403%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT03061838%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03983018%22 https://clinicaltrials.gov/search?id=%22NCT00101829%22,https://clinicaltrials.gov/sea 1 Completed

RITUXIMAB
RITUXIMAB

Antibody	P lymphosyte aptigon CD20 hinding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
. introody	

inding agent	EFO_0000707
linding agent	EFO_0000768
inding agent	EFO_0001359
inding agent	EFO_0001378
linding agent	EFO_0001423
inding agent	EFO_0001642
inding agent	EFO_0002508
inding agent	EFO_0002617
inding agent	EFO_0002690
inding agent	EFO_0003778
linding agent	EFO_0003884
linding agent	EFO_0003885
linding agent	EFO_0004145
linding agent	EFO_0004236
linding agent	EFO_0004256
linding agent	EFO_0004289
linding agent	EFO_0004991
linding agent	EFO_0005140
linding agent	EFO_0005297
linding agent	EFO_0005531
linding agent	EFO_0005952
linding agent	EFO_0007160
linding agent	EFO_0007187
linding agent	EFO_0007498
linding agent	EFO_0008520
linding agent	EFO_0008522
linding agent	EFO_0008610
inding agent	EFO_0009606
inding agent	EFO_1000131
inding agent	EFO_1000550
inding agent	EFO_1000956
inding agent	EFO_1001051

urticaria

squamous cell carcinoma 1 Completed https://clinicaltrials.gov/search?id=%22NCT04361409%22 idiopathic pulmonary fibrosis 1 Completed https://clinicaltrials.gov/search?id=%22NCT01266317%22 type I diabetes mellitus 1 Unknown status https://clinicaltrials.gov/search?id=%22NCT00798785%22 multiple myeloma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00176475%22,https://clinicaltrials.gov/sea 1 Completed https://clinicaltrials.gov/search?id=%22NCT00259805%22 encephalomyelitis lymphoid neoplasm 1 Terminated https://clinicaltrials.gov/search?id=%22NCT01596127%22 1 Recruiting Parkinson's disease https://clinicaltrials.gov/search?id=%22NCT04127578%22 metastatic melanoma 1 Terminated https://clinicaltrials.gov/search?id=%22NCT01032122%22 systemic lupus erythematosus 1 Completed https://clinicaltrials.gov/search?id=%22NCT00036491%22 https://clinicaltrials.gov/search?id=%22NCT00509678%22 psoriatic arthritis 1 Completed chronic kidney disease 1 Completed https://clinicaltrials.gov/search?id=%22NCT01178216%22,https://clinicaltrials.gov/sea 1 Terminated https://clinicaltrials.gov/search?id=%22NCT01212094%22 multiple sclerosis 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00278564%22 myopathy focal segmental glomerulosclerosis 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT03763643%22 https://clinicaltrials.gov/search?id=%22NCT00787722%22,https://clinicaltrials.gov/sea neuromyelitis optica 1 Completed lymphoid leukemia 1 Completed https://clinicaltrials.gov/search?id=%22NCT00366418%22 Myasthenia gravis 1 Completed https://clinicaltrials.gov/search?id=%22NCT00619671%22 autoimmune disease 1 Completed https://clinicaltrials.gov/search?id=%22NCT01086631%22 Granulomatosis with Polyangiitis 1 Completed https://clinicaltrials.gov/search?id=%22NCT00072592%22 1 Terminated https://clinicaltrials.gov/search?id=%22NCT00216762%22 non-Hodgkins lymphoma 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT04673617%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT01713738%22 autoimmune thrombocytopenic purpu 1 Completed bullous pemphigoid 1 Completed https://clinicaltrials.gov/search?id=%22NCT00286325%22 1 Terminated Stiff-Person syndrome https://clinicaltrials.gov/search?id=%22NCT02282514%22 primary progressive multiple sclerosis 1 Completed https://clinicaltrials.gov/search?id=%22NCT02253264%22 secondary progressive multiple sclero: 1 Completed https://clinicaltrials.gov/search?id=%22NCT02253264%22 ocular cicatricial pemphigoid 1 Completed https://clinicaltrials.gov/search?id=%22NCT00584935%22 macular degeneration 1 Completed https://clinicaltrials.gov/search?id=%22NCT02332941%22 1 Active, not recruiting Blast Phase Chronic Myelogenous Leuk https://clinicaltrials.gov/search?id=%22NCT02960646%22 Splenic Marginal Zone Lymphoma 1 Completed https://clinicaltrials.gov/search?id=%22NCT00438880%22 hairy cell leukemia 1 Recruiting https://clinicaltrials.gov/search?id=%22NCT03805932%22 mycosis fungoides 1 Suspended https://clinicaltrials.gov/search?id=%22NCT03432741%22

CHEMBL1201576	RITUXIMAB
CHEMBL1201576	RITUXIMAB

Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibodv B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibody B-lymphocyte antigen CD20 binding agent B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Antibodv B-lymphocyte antigen CD20 binding agent

Binding agent Binding agent Binding agent Binding agent Binding agent Binding agent Binding agent Binding agent **Binding agent Binding agent Binding agent** Binding agent Binding agent **Binding agent Binding agent Binding agent** Binding agent Binding agent Binding agent **Binding agent** Binding agent **Binding agent Binding agent Binding agent** Binding agent **Binding agent Binding agent Binding agent** Binding agent Binding agent Binding agent Binding agent EFO_1001365 EFO_1001383 EFO_1001466 EFO_1001486 EFO_1001779 EFO_1002048 kidney failure HP_0001871 HP_0001915 Aplastic anemia MONDO 0000873 MONDO 0001023 MONDO_0001437 MONDO_0001718 scleritis MONDO_0002083 Richter syndrome MONDO 0002334 MONDO 0002462 MONDO 0004095 B-cell neoplasm MONDO 0013730 MONDO_0015564 Castleman disease MONDO 0015760 MONDO_0018896 MONDO 0019088 MONDO 0019457 MONDO_0019465 MONDO_0024880 MONDO_0044881 MONDO 0044887 MONDO 0044889 Orphanet_1334 Orphanet_282 Orphanet_309144 Gangliosidosis Orphanet_365 Orphanet_84 Fanconi anemia

Lymphoma, AIDS-Related **Opsoclonus-Myoclonus Syndrome** Graves ophthalmopathy primary biliary cirrhosis chronic myelomonocytic leukemia Abnormality of blood and blood-formi lymphoblastic lymphoma prolymphocytic leukemia pulmonary alveolar proteinosis hematopoietic and lymphoid system n glomerulonephritis graft versus host disease T-cell non-Hodgkin lymphoma thrombotic thrombocytopenic purpura post-transplant lymphoproliferative d therapy related acute myeloid leukem nodal marginal zone B-cell lymphoma metastatic malignant neoplasm hematopoietic and lymphoid cell neor central nervous system non-hodgkin ly high grade B-cell lymphoma Chronic mucocutaneous candidosis Frontotemporal dementia Glycogen storage disease due to acid r

1 Terminated 1 Completed 1 Completed 1 Completed 1 Active, not recruiting 1 Not yet recruiting 1 Not yet recruiting 1 Active, not recruiting 1 Active, not recruiting 1 Active, not recruiting 1 Completed 1 Completed 1 Completed 1 Recruiting 1 Completed 1 Recruiting 1 Recruiting 1 Withdrawn 1 Recruiting 1 Withdrawn 1 Terminated 1 Active, not recruiting 1 Terminated 1 Terminated 1 Active, not recruiting 1 Recruitina 1 Active, not recruiting 1 Completed 1 Recruiting 1 Recruiting 1 Active, not recruiting 1 Not yet recruiting

https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00244361%22 https://clinicaltrials.gov/search?id=%22NCT00150111%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00364819%22 https://clinicaltrials.gov/search?id=%22NCT02960646%22 https://clinicaltrials.gov/search?id=%22NCT04540380%22 https://clinicaltrials.gov/search?id=%22NCT04243434%22 https://clinicaltrials.gov/search?id=%22NCT02960646%22 https://clinicaltrials.gov/search?id=%22NCT02960646%22 https://clinicaltrials.gov/search?id=%22NCT02296918%22 https://clinicaltrials.gov/search?id=%22NCT01842386%22 https://clinicaltrials.gov/search?id=%22NCT00415506%22 https://clinicaltrials.gov/search?id=%22NCT00472849%22 https://clinicaltrials.gov/search?id=%22NCT04022239%22 https://clinicaltrials.gov/search?id=%22NCT00275613%22 https://clinicaltrials.gov/search?id=%22NCT02911142%22 https://clinicaltrials.gov/search?id=%22NCT03689894%22 https://clinicaltrials.gov/search?id=%22NCT02228512%22 https://clinicaltrials.gov/search?id=%22NCT01701986%22 https://clinicaltrials.gov/search?id=%22NCT00251277%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT01619761%22 https://clinicaltrials.gov/search?id=%22NCT00012298%22 https://clinicaltrials.gov/search?id=%22NCT01596127%22 https://clinicaltrials.gov/search?id=%22NCT02367196%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT02315326%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03742258%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT01842386%22 https://clinicaltrials.gov/search?id=%22NCT04408625%22

https://clinicaltrials.gov/search?id=%22NCT03952637%22 https://clinicaltrials.gov/search?id=%22NCT02240407%22

https://clinicaltrials.gov/search?id=%22NCT04784052%22

CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocyt
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cel
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000621	neuroblastoma
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003086	kidney disease
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom mad
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000157	Central Nervous S
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000630	marginal zone B-ce
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymph
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0008315	prostate cancer
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphon
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0000479	essential thrombo
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0002429	polycythemia vera
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0000182	hepatocellular car
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0000339	chronic myelogen
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0004220	chronic hepatitis (
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0004239	chronic hepatitis E
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	Interferon alpha/beta receptor positive modulator	Positive modulator	EFO_0007304	hepatitis D virus ir
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_000096	neoplasm of matu
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_0000756	melanoma
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_0003860	pancreatic neopla
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1000044	pancreatic adenoc
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1001951	colorectal carcinor
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	MONDO_0007254	breast cancer
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_0000616	neoplasm
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000616	neoplasm
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphon
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblast
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0005952	non-Hodgkins lym
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0001023	prolymphocytic le
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chronic lymphocyt
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000096	neoplasm of matu

ronic lymphocytic leukemia 0 Completed fuse large B-cell lymphoma 0 Completed 0 Terminated 0 Completed aldenstrom macroglobulinemia 0 Completed 0 Recruitina ntral Nervous System Lymphoma arginal zone B-cell lymphoma 0 Completed antle cell lymphoma licular lymphoma 0 Completed sential thrombocythemia 3 Recruiting lycythemia vera patocellular carcinoma 1 Recruiting ronic myelogenous leukemia 1 Completed ronic hepatitis C virus infection 1 Recruiting ronic hepatitis B virus infection patitis D virus infection oplasm of mature B-cells 1 Terminated 1 Completed ncreatic neoplasm 1 Completed ncreatic adenocarcinoma 1 Completed orectal carcinoma 1 Recruiting 1 Recruiting 0 Completed licular lymphoma 3 Recruiting ute lymphoblastic leukemia 2 Terminated on-Hodgkins lymphoma olymphocytic leukemia ronic lymphocytic leukemia 1 Completed neoplasm of mature B-cells 1 Suspended

https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT00515138%22 0 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT00790413%22 https://clinicaltrials.gov/search?id=%22NCT00405340%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT03684980%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 0 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT03295240%22 0 Unknown status https://clinicaltrials.gov/search?id=%22NCT01804712%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT04285086%22 https://clinicaltrials.gov/search?id=%22NCT04182100%22,https://clinicaltrials.gov/sea 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT04233840%22 https://clinicaltrials.gov/search?id=%22NCT01933906%22 https://clinicaltrials.gov/search?id=%22NCT04774107%22 1 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT04638439%22 https://clinicaltrials.gov/search?id=%22NCT04638439%22 1 Not yet recruiting https://clinicaltrials.gov/search?id=%22NCT03892525%22 https://clinicaltrials.gov/search?id=%22NCT01103635%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00711191%22 https://clinicaltrials.gov/search?id=%22NCT01456585%22 https://clinicaltrials.gov/search?id=%22NCT03555149%22 https://clinicaltrials.gov/search?id=%22NCT03424005%22 https://clinicaltrials.gov/search?id=%22NCT02157831%22 http://www.whocc.no/atc_ddd_index/?code=L01XC35 https://clinicaltrials.gov/search?id=%22NCT04680052%22 https://clinicaltrials.gov/search?id=%22NCT01685021%22 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT01685008%22 https://clinicaltrials.gov/search?id=%22NCT02005289%22 2 Active, not recruiting https://clinicaltrials.gov/search?id=%22NCT01161511%22 https://clinicaltrials.gov/search?id=%22NCT04607772%22

CHEMBL4298047	TAFASITAMAB
CHEMBL4298047	TAFASITAMAB
CHEMBL3301574	TISAGENLECLEUCEL
CHEMBL1201604	TOSITUMOMAB
CHEMBL3833304	TOSITUMOMAB 131
CHEMBL3833304	TOSITUMOMAB 131
CHEMBL3833304	TOSITUMOMAB 131
CHEMBL3833304	TOSITUMOMAB 1311
CHEMBL3833304	TOSITUMOMAB 1311
CHEMBL3833304	TOSITUMOMAB 1311
CITEMDE3033304	

Antibody	B-lymphocyte antigen CD19 binding agent
Antibody	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Cell	B-lymphocyte antigen CD19 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent

Binding agent	EFO_0000403	diffuse large
Binding agent	EFO_0000574	lymphoma
Binding agent	EFO_0000616	neoplasm
Binding agent	EFO_000096	neoplasm of
Binding agent	EFO_0004289	lymphoid le
Binding agent	EFO_0005952	non-Hodgki
Binding agent	EFO_1001469	Mantle cell I
Binding agent	MONDO_0000873	lymphoblast
Binding agent	MONDO_0018906	follicularlyr
Binding agent	EFO_000094	B-cell acute
Binding agent	EFO_000095	chronic lym
Binding agent	EFO_0000220	acute lymph
Binding agent	EFO_0000222	acute myelo
Binding agent	EFO_0000565	leukemia
Binding agent	EFO_0001378	multiple my
Binding agent	EFO_1000157	Central Nerv
Binding agent	EFO_0000183	Hodgkins lyr
Binding agent	EFO_0000403	diffuse large
Binding agent	EFO_0000574	lymphoma
Binding agent	EFO_0002618	pancreatic c
Binding agent	EFO_000095	chronic lymp
Binding agent	EFO_0000574	lymphoma
Binding agent	EFO_1001469	Mantle cell I
Binding agent	EFO_000096	neoplasm of
Binding agent	EFO_0005952	non-Hodgkir
Binding agent	MONDO_0018906	follicularlyn
Binding agent	EFO_0000574	lymphoma
Binding agent	EFO_0001378	multiple my
Binding agent	EFO_0003032	anaplastic la
Binding agent	EFO_000095	chronic lymp
Binding agent	EFO_000096	neoplasm of
Binding agent	EFO_0000183	Hodgkins lyr

diffuse large B-cell lymphoma neoplasm of mature B-cells ymphoid leukemia non-Hodgkins lymphoma Mantle cell lymphoma ymphoblastic lymphoma follicular lymphoma 3-cell acute lymphoblastic leukemia chronic lymphocytic leukemia acute lymphoblastic leukemia acute myeloid leukemia multiple myeloma Central Nervous System Lymphoma Hodgkins lymphoma diffuse large B-cell lymphoma pancreatic carcinoma chronic lymphocytic leukemia Mantle cell lymphoma neoplasm of mature B-cells non-Hodgkins lymphoma follicular lymphoma multiple myeloma anaplastic large cell lymphoma chronic lymphocytic leukemia neoplasm of mature B-cells Hodgkins lymphoma

1 Active, not recruiting 1 Not yet recruiting 2 Unknown status 2 Active, not recruiting 2 Active, not recruiting 2 Recruiting 2 Unknown status 2 Active, not recruiting 1 Unknown status 1 Recruiting 1 Terminated 1 Recruiting 1 Recruiting 1 Completed 1 Recruiting 0 Terminated 0 Not yet recruiting 0 Completed 0 Unknown status 2 Completed 2 Completed 2 Completed 1 Completed 1 Completed 1 Completed 2 Completed 2 Active, not recruiting 2 Completed 1 Unknown status 1 Completed 1 Completed

https://clinicaltrials.gov/search?id=%22NCT04134936%22 https://clinicaltrials.gov/search?id=%22NCT04882163%22 http://www.whocc.no/atc_ddd_index/?code=L01XX71 https://clinicaltrials.gov/search?id=%22NCT03391726%22 https://clinicaltrials.gov/search?id=%22NCT02435849%22 https://clinicaltrials.gov/search?id=%22NCT03610724%22 https://clinicaltrials.gov/search?id=%22NCT04234061%22 https://clinicaltrials.gov/search?id=%22NCT03321123%22 https://clinicaltrials.gov/search?id=%22NCT03568461%22 https://clinicaltrials.gov/search?id=%22NCT02924753%22 https://clinicaltrials.gov/search?id=%22NCT03853616%22 https://clinicaltrials.gov/search?id=%22NCT01551043%22 https://clinicaltrials.gov/search?id=%22NCT03896854%22 https://clinicaltrials.gov/search?id=%22NCT03614858%22 https://clinicaltrials.gov/search?id=%22NCT02135406%22 https://clinicaltrials.gov/search?id=%22NCT04134117%22 https://clinicaltrials.gov/search?id=%22NCT02624258%22 https://clinicaltrials.gov/search?id=%22NCT04890236%22 https://clinicaltrials.gov/search?id=%22NCT02476734%22 https://clinicaltrials.gov/search?id=%22NCT03497819%22 https://clinicaltrials.gov/search?id=%22NCT00476047%22 https://clinicaltrials.gov/search?id=%22NCT00107380%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00992992%22 https://clinicaltrials.gov/search?id=%22NCT00434629%22 https://clinicaltrials.gov/search?id=%22NCT00434629%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00315731%22 https://clinicaltrials.gov/search?id=%22NCT00006695%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00135200%22 https://clinicaltrials.gov/search?id=%22NCT00073918%22 https://clinicaltrials.gov/search?id=%22NCT00022880%22 https://clinicaltrials.gov/search?id=%22NCT00434629%22 https://clinicaltrials.gov/search?id=%22NCT00484874%22

CHEMBL3833304	TOSITUMOMAB 131
CHEMBL3833304	TOSITUMOMAB 131
CHEMBL1743083	TREGALIZUMAB
CHEMBL1743083	TREGALIZUMAB
CHEMBL1743083	TREGALIZUMAB
CHEMBL4297845	TRU-015
CHEMBL4297845	TRU-015
CHEMBL4297845	TRU-015
CHEMBL2108354	UBLITUXIMAB
CHEMBL3137347	VARLILUMAB

Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	T-cell surface antigen CD4 agonist
Antibody	T-cell surface antigen CD4 agonist
Antibody	T-cell surface antigen CD4 agonist
Unknown	B-lymphocyte antigen CD20 binding agent
Unknown	B-lymphocyte antigen CD20 binding agent
Unknown	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	B-lymphocyte antigen CD20 binding agent
Antibody	CD27 antigen agonist

Binding agent EFO 0000309 **Binding agent** EFO_0000403 Binding agent EFO_0005952 Binding agent EFO_0009441 EFO_1000550 Binding agent **Binding agent** EFO_1001469 MONDO 0000873 Binding agent MONDO_0018906 Binding agent MONDO 0019465 **Binding agent** Agonist EFO_0000685 Agonist EFO_1001494 MONDO_0004784 Agonist EFO_0000685 Binding agent EFO 0000574 Binding agent EFO_0002690 **Binding agent** Binding agent EFO_0000403 Binding agent EFO_0003885 EFO_0003929 **Binding agent** MONDO_0018906 **Binding agent** Binding agent EFO_0000095 Binding agent EFO_0000096 Binding agent EFO_0004256 Binding agent EFO_0009441 EFO_1001469 Binding agent EFO_0000519 Agonist Agonist EFO_1001961 Agonist EFO 0000272 Agonist EFO_0000574 EFO_0000630 Agonist EFO_0000632 Agonist EFO 0000681 Agonist EFO_0000756 Agonist

Ivmphoma astrocytoma lymphoma melanoma

Burkitts lymphoma diffuse large B-cell lymphoma non-Hodgkins lymphoma Waldenstrom macroglobulinemia Splenic Marginal Zone Lymphoma Mantle cell lymphoma lymphoblastic lymphoma follicular lymphoma nodal marginal zone B-cell lymphoma rheumatoid arthritis psoriasis vulgaris allergic asthma rheumatoid arthritis systemic lupus erythematosus diffuse large B-cell lymphoma multiple sclerosis relapsing-remitting multiple sclerosis follicular lymphoma chronic lymphocytic leukemia neoplasm of mature B-cells neuromyelitis optica Waldenstrom macroglobulinemia Mantle cell lymphoma glioblastoma multiforme intrahepatic cholangiocarcinoma oligoastrocytoma oligodendroglioma renal cell carcinoma

1 Completed 2 Completed 2 Completed 2 Recruiting 2 Terminated 1 Terminated 1 Terminated 2 Recruiting 2 Completed 2 Active, not recruiting 2 Recruiting 1 Recruitina 1 Recruiting 1 Completed 1 Completed 1 Completed 2 Recruiting 2 Not yet recruiting 1 Active, not recruiting 1 Active, not recruiting 1 Active, not recruiting 1 Active, not recruiting 1 Terminated 1 Terminated

https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT00434629%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT00110071%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00110071%22 https://clinicaltrials.gov/search?id=%22NCT01481493%22 https://clinicaltrials.gov/search?id=%22NCT01072383%22 https://clinicaltrials.gov/search?id=%22NCT04673591%22 https://clinicaltrials.gov/search?id=%22NCT00634933%22 https://clinicaltrials.gov/search?id=%22NCT00521638%22 https://clinicaltrials.gov/search?id=%22NCT00479622%22 https://clinicaltrials.gov/search?id=%22NCT02793583%22 https://clinicaltrials.gov/search?id=%22NCT02738775%22 https://clinicaltrials.gov/search?id=%22NCT03381170%22 https://clinicaltrials.gov/search?id=%22NCT03828448%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03671590%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT03804996%22 https://clinicaltrials.gov/search?id=%22NCT02276963%22 https://clinicaltrials.gov/search?id=%22NCT01744912%22 https://clinicaltrials.gov/search?id=%22NCT01744912%22 https://clinicaltrials.gov/search?id=%22NCT03688178%22 https://clinicaltrials.gov/search?id=%22NCT04941287%22 https://clinicaltrials.gov/search?id=%22NCT02924038%22 https://clinicaltrials.gov/search?id=%22NCT03307746%22 https://clinicaltrials.gov/search?id=%22NCT02924038%22 https://clinicaltrials.gov/search?id=%22NCT02924038%22 https://clinicaltrials.gov/search?id=%22NCT02386111%22 https://clinicaltrials.gov/search?id=%22NCT02413827%22

CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0003060	non-small ce
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0003863	urogenital ne
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000685	rheumatoid a
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lympl
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000220	acute lympho
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkin
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007160	autoimmune
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000432	lymphoplasm
CHEMBL1743088	VELTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lym
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000565	leukemia
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003032	anaplastic lar
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730	graft versus h
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0044887	central nervo
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183	Hodgkins lym
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000191	MALT lympho
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000309	Burkitts lymp
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001378	multiple mye
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkin:
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000550	Splenic Margi
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001365	Lymphoma, A
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblasti
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019088	post-transpla
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019465	nodal margin
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lympl
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000630	marginal zone
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell ly
		5				,

on-small cell lung carcinoma 1 Recruiting rogenital neoplasm 1 Terminated eumatoid arthritis 2 Terminated nronic lymphocytic leukemia 1 Completed cute lymphoblastic leukemia 1 Unknown status ffuse large B-cell lymphoma 1 Withdrawn 1 Completed on-Hodgkins lymphoma 1 Completed Itoimmune thrombocytopenic purpu 1 Terminated mphoplasmacytic lymphoma 1 Completed ollicular lymphoma 1 Terminated 2 Active, not recruiting aplastic large cell lymphoma 2 Withdrawn aft versus host disease 2 Active, not recruiting entral nervous system non-hodgkin ly 2 Terminated eoplasm of mature B-cells 1 Completed odgkins lymphoma 1 Terminated ALT lymphoma 1 Terminated urkitts lymphoma 1 Completed 1 Completed ultiple myeloma 1 Completed on-Hodgkins lymphoma 1 Unknown status plenic Marginal Zone Lymphoma 1 Terminated mphoma, AIDS-Related 1 Terminated mphoblastic lymphoma 1 Terminated ost-transplant lymphoproliferative d 1 Completed 1 Terminated odal marginal zone B-cell lymphoma nronic lymphocytic leukemia 0 Completed ffuse large B-cell lymphoma 0 Completed /aldenstrom macroglobulinemia 0 Completed arginal zone B-cell lymphoma 0 Completed antle cell lymphoma 0 Completed

https://clinicaltrials.gov/search?id=%22NCT04081688%22 https://clinicaltrials.gov/search?id=%22NCT02386111%22 https://clinicaltrials.gov/search?id=%22NCT01390545%22 https://clinicaltrials.gov/search?id=%22NCT00546793%22 https://clinicaltrials.gov/search?id=%22NCT01279707%22 https://clinicaltrials.gov/search?id=%22NCT01101581%22 https://clinicaltrials.gov/search?id=%22NCT00989586%22 https://clinicaltrials.gov/search?id=%22NCT00596804%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00547066%22 https://clinicaltrials.gov/search?id=%22NCT00546793%22 https://clinicaltrials.gov/search?id=%22NCT01147393%22 https://clinicaltrials.gov/search?id=%22NCT00577278%22 https://clinicaltrials.gov/search?id=%22NCT00310128%22 https://clinicaltrials.gov/search?id=%22NCT00577278%22 https://clinicaltrials.gov/search?id=%22NCT01973062%22 https://clinicaltrials.gov/search?id=%22NCT00761384%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00012298%22 https://clinicaltrials.gov/search?id=%22NCT00064246%22 https://clinicaltrials.gov/search?id=%22NCT00058292%22,https://clinicaltrials.gov/sea https://clinicaltrials.gov/search?id=%22NCT00477815%22 https://clinicaltrials.gov/search?id=%22NCT00807196%22 https://clinicaltrials.gov/search?id=%22NCT00012298%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00036855%22 https://clinicaltrials.gov/search?id=%22NCT00064246%22 https://clinicaltrials.gov/search?id=%22NCT00012298%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22 https://clinicaltrials.gov/search?id=%22NCT00017381%22

0 Completed

https://clinicaltrials.gov/search?id=%22NCT00017381%22

FinnGen Full Name Aarno Palotie

Affiliation

aarno.palotie@helsinki. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Mark Daly Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, mark.daly@helsinki.fi Bridget Rilev-Gills Abbvie, Chicago, IL, United States bridget.rileygillis@abbvi Howard Jacob Abbvie, Chicago, IL, United States howard.jacob@abbvie.c Dirk Paul dirk.paul@astrazeneca. Astra Zeneca, Cambridge, United Kingdom Athena Matakidou Astra Zeneca, Cambridge, United Kingdom athena.x.matakidou@g Adam Platt Astra Zeneca, Cambridge, United Kingdom adam.platt@astrazened Heiko Runz Biogen, Cambridge, MA, United States heiko.runz@biogen.com Sally John Biogen, Cambridge, MA, United States sally.john@biogen.com George Okafo Boehringer Ingelheim, Ingelheim am Rhein, Germany george.okafo@boehring Nathan Lawless Boehringer Ingelheim, Ingelheim am Rhein, Germany nathan.lawless@boehrij Robert Plenge Bristol Myers Squibb, New York, NY, United States robert.plenge@bms.con Joseph Maranville Bristol Myers Squibb, New York, NY, United States joseph.maranville@bms Mark McCarthy Genentech, San Francisco, CA, United States mccarthy.mark@gene.c Julie Hunkapiller Genentech, San Francisco, CA, United States hunkapiller.julie@gene. Margaret G. Ehm meg.g.ehm@gsk.com GlaxoSmithKline, Collegeville, PA, United States Kirsi Auro GlaxoSmithKline, Espoo, Finland kirsi.m.auro@gsk.com Simonne Longerich Merck, Kenilworth, NJ, United States simonne.longerich@me Caroline Fox Merck, Kenilworth, NJ, United States caroline.fox@merck.cor Anders Mälarstig Pfizer, New York, NY, United States anders.malarstig@pfize Katherine Klinger Translational Sciences, Sanofi R&D, Framingham, MA, USA katherine.klinger@sano Deepak Raipal Translational Sciences, Sanofi R&D, Framingham, MA, USA deepak.raipal@sanofi.c Eric Green Maze Therapeutics, San Francisco, CA, United States egreen@mazetx.com Robert Graham Maze Therapeutics, San Francisco, CA, United States rgraham@mazetx.com rvang31@its.jnj.com Robert Yang Janssen Biotech, Beerse, Belgium Chris O'Donnell Novartis Institutes for BioMedical Research, Cambridge, MA, United States chris.odonnell@novartis Tomi P. Mäkelä HiLIFE, University of Helsinki, Finland, Finland tomi.makela@helsinki.t Jaakko Kaprio Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland jaakko,kaprio@helsinki, Petri Virolainen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland petri.virolainen@tvks.fi Antti Hakanen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland antti.hakanen@tvks.fi

.fi
ie.com
com
.com
sk.com
ca.com
n
1
ger-ingelheim.com
inger-ingelheim.com
m
s.com
com
com
erck.com
m
er.com ofi.com
com
s.com fi
i.fi

E-mail

Role 1

Steering Committee Steering Committee Steering Committee Steering Committee **Steering Committee Steering Committee**

Role 2

Steering Committee Steering Committee

Pharmaceutical companies University of Helsinki & Biobanks University of Helsinki & Biobanks University of Helsinki & Biobanks University of Helsinki & Biobanks

Terhi Kilpi	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	terhi.kilpi@thl.fi	Ş
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perola@thl.fi	ç
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki,	jukka.partanen@veripalvelu.fi	ç
	Finland		
Anne Pitkäranta	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	anne.pitkaranta@hus.fi	\$
Juhani Junttila	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	juhani.junttila@ppshp.fi	ç
	Oulu, Finland		
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	raisa.serpi@ppshp.fi	ç
	Oulu, Finland		
Tarja Laitinen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	tarja.laitinen@pshp.fi	ç
	Tampere, Finland		
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,	veli-matti.kosma@uef.fi	Ş
	Kuopio, Finland		
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,	jari.laukkanen@ksshp.fi	Ş
	Jyväskylä, Finland		
Marco Hautalahti	FINBB - Finnish biobank cooperative	marco.hautalahti@finbb.fi	Ş
Outi Tuovila	Business Finland, Helsinki, Finland	outi.tuovila@businessfinland.fi	Ş
Raimo Pakkanen	Business Finland, Helsinki, Finland	raimo.pakkanen@businessfinland.fi	ç
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com	ç
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com	ç
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com	ç
loanna Tachmazidou	Astra Zeneca, Cambridge, United Kingdom	ioanna.tachmazidou@astrazeneca.com	ç
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com	ç
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com	Ş
Zhihao Ding	Boehringer Ingelheim, Ingelheim am Rhein, Germany	zhihao.ding@boehringer-ingelheim.com	Ş
Marc Jung	Boehringer Ingelheim, Ingelheim am Rhein, Germany	marc_oliver.jung@boehringer-ingelheim.com	Ş
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	Shameek.Biswas@bms.com	
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	\$
Julie Hunkapiller	Genentech, San Francisco, CA, United States	hunkapiller.julie@gene.com	Ş
Margaret G. Ehm	GlaxoSmithKline, Collegeville, PA, United States	meg.g.ehm@gsk.com	\$
David Pulford	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulford@gsk.com	\$
Neha Raghavan	Merck, Kenilworth, NJ, United States	neha.raghavan@merck.com	\$
Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States	adriana.huertas.vazquez@merck.com	ç
Jae-Hoon Sul	Merck, Kenilworth, NJ, United States	jae.hoon.sul@merck.com	ç
Anders Mälarstig	Pfizer, New York, NY, United States	anders.malarstig@pfizer.com	

Steering Committee
Steering Committee
Steering Committee

Steering Committee Steering Committee

Steering Committee

Steering Committee

Steering Committee

Steering Committee

Steering Committee Steering Committee Steering Committee Scientific Committee University of Helsinki & Biobanks Other Experts/ Non-Voting Members Other Experts/ Non-Voting Members Pharmaceutical companies

Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies Pharmaceutical companies

Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com	
Katherine Klinger	Translational Sciences, Sanofi R&D, Framingham, MA, USA	katherine.klinger@sanofi.com	
Robert Graham	Maze Therapeutics, San Francisco, CA, United States	rgraham@mazetx.com	
Eric Green	Maze Therapeutics, San Francisco, CA, United States	egreen@mazetx.com	
Sahar Mozaffari	Maze Therapeutics, San Francisco, CA, United States	smozaffari@mazetx.com	
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com	
Nicole Renaud	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	nicole.renaud@novartis.com	
Ma´en Obeidat	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	maen.obeidat@novartis.com	
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	samuli.ripatti@helsinki.fi	
Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi	
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perola@thl.fi	
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki,	mikko.arvas@veripalvelu.fi	
	Finland		
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi	
Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	reetta.hinttala@oulu.fi	
	Oulu, Finland		
Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	johannes.kettunen@oulu.fi	
	Oulu, Finland		
Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,	arto.mannermaa@uef.fi	
	Kuopio, Finland		
Katriina Aalto-Setälä	Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland	katriina.aalto-setala@tuni.fi	
Mika Kähönen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	mika.kahonen@uta.fi	
	Tampere, Finland		
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,	jari.laukkanen@ksshp.fi	
	Jyväskylä, Finland		
Johanna Mäkelä	FINBB - Finnish biobank cooperative	johanna.makela@finbb.fi	
Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland	reetta.kalviainen@kuh.fi	
Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland	valtteri.julkunen@kuh.fi	
Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland	hilkka.soininen@uef.fi	
Anne Remes	Northern Ostrobothnia Hospital District, Oulu, Finland	anne.remes@oulu.fi	
Mikko Hiltunen	University of Eastern Finland, Kuopio, Finland	mikko.hiltunen@uef.fi	
Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland	jukka.peltola@pshp.fi	
Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	minna.raivio@geri.fi	
Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pentti.tienari@hus.fi	
Juha Rinne	Hospital District of Southwest Finland, Turku, Finland	juha.rinne@tyks.fi	

Scientific Committee Scientific Committee

Scientific Committee Scientific Committee

Scientific Committee

Scientific Committee

Scientific Committee Scientific Committee

Scientific Committee

Scientific Committee Clinical Groups Clinical Groups

Pharmaceutical companies University of Helsinki & Biobanks Neurology Group Neurology Group

Roosa Kallionpää	Hospital District of Southwest Finland, Turku, Finland
Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Ali Abbasi	Abbvie, Chicago, IL, United States
Adam Ziemann	Abbvie, Chicago, IL, United States
Nizar Smaoui	Abbvie, Chicago, IL, United States
Anne Lehtonen	Abbvie, Chicago, IL, United States
Susan Eaton	Biogen, Cambridge, MA, United States
Heiko Runz	Biogen, Cambridge, MA, United States
Sanni Lahdenperä	Biogen, Cambridge, MA, United States
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Edmond Teng	Genentech, San Francisco, CA, United States
Rion Pendergrass	Genentech, San Francisco, CA, United States
Fanli Xu	
David Pulford	GlaxoSmithKline, Brentford, United Kingdom GlaxoSmithKline, Stevenage, United Kingdom
Kirsi Auro	GlaxoSmithKline, Stevenage, Gnited Kingdom GlaxoSmithKline, Espoo, Finland
Laura Addis	GlaxoSmithKline, Brentford, United Kingdom
John Eicher	GlaxoSmithKline, Brentford, United Kingdom
Qingqin S Li	Janssen Research & Development, LLC, Titusville, NJ 08560, United States
Karen He	Janssen Research & Development, LLC, Spring House, PA, United States
Ekaterina Khramtsova	Janssen Research & Development, LLC, Spring House, PA, United States
Neha Raghavan	Merck, Kenilworth, NJ, United States
Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Sampsa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland
Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland
Timo Blomster	Northern Ostrobothnia Hospital District, Oulu, Finland
Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland
Markku Voutilainen	Hospital District of Southwest Finland, Turku, Finland
Mark Daly	Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,
	Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital
Ali Abbasi	Abbvie, Chicago, IL, United States
Jeffrey Waring	Abbvie, Chicago, IL, United States

roosa.kallionpaa@tyks.fi juulia.partanen@helsinki.fi ali.abbasi@abbvie.com adam.ziemann@abbvie.com nizar.smaoui@abbvie.com anne.lehtonen@abbvie.com susan.eaton@biogen.com heiko.runz@biogen.com sanni.lahdenpera@biogen.com shameek.biswas@bms.com hunkapiller.julie@gene.com bowersn1@gene.com teng.edmond@gene.com penders2@gene.com chun-fang.2.xu@gsk.com david.x.pulford@gsk.com kirsi.m.auro@gsk.com laura.x.addis@gsk.com john.d.eicher@gsk.com QLi2@its.jnj.com khe2@its.jnj.com ekhramts@its.jnj.com neha.raghavan@merck.com martti.farkkila@hus.fi jukka.koskela@helsinki.fi sampsa.pikkarainen@hus.fi airi.jussila@pshp.fi katri.kaukinen@tuni.fi timo.blomster@ppshp.fi mikko.kiviniemi@kuh.fi markku.voutilainen@tyks.fi mark.daly@helsinki.fi

ali.abbasi@abbvie.com jeff.waring@abbvie.com **Clinical Groups Clinical Groups**

Clinical Groups Clinical Groups Neurology Group Gastroenterology Group

Gastroenterology Group Gastroenterology Group

Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Tim Lu	Genentech, San Francisco, CA, United States	lut8@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom	linda.c.mccarthy@gsk.com
Amy Hart	Janssen Research & Development, LLC, Spring House, PA, United States	ahart13@its.jnj.com
Meijian Guan	Janssen Research & Development, LLC, Spring House, PA, United States	mguan4@its.jnj.com
Jason Miller	Merck, Kenilworth, NJ, United States	jason.miller4@merck.com
Kirsi Kalpala	Pfizer, New York, NY, United States	, kirsi.kalpala@pfizer.com
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	kari.eklund@hus.fi
Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland	ajpalo@utu.fi
Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland	pia.isomaki@pshp.fi
Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland	laura.pirila@fimnet.fi,laura.pirila@tyks.fi
Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland	oili.kaipiainen-seppanen@kuh.fi
Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland	johanna.huhtakangas@kuh.fi
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
Ali Abbasi	Abbvie, Chicago, IL, United States	ali.abbasi@abbvie.com
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Apinya Lertratanakul	Abbvie, Chicago, IL, United States	apinya.lertratanakul@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
David Close	Astra Zeneca, Cambridge, United Kingdom	david.close@astrazeneca.com
Marla Hochfeld	Bristol Myers Squibb, New York, NY, United States	mhochfeld@celgene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom	jorge.x.esparza-gordillo@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com
Fabiana Farias	Merck, Kenilworth, NJ, United States	fabiana.farias@merck.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com

Clinical Groups Clinical Groups

Gastroenterology Group Rheumatology Group

Nan Bing	Pfizer, New York, NY, United States	nan.bing@pfizer.com
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland	margit.pelkonen@kuh.fi
Paula Kauppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	paula.kauppi@hus.fi
Hannu Kankaanranta	University of Gothenburg, Gothenburg, Sweden/ Seinäjoki Central Hospital, Seinäjoki, Finland/	hannu.kankaanranta@tuni.fi
	Tampere University, Tampere, Finland	
Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland	terttu.harju@oulu.fi
Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland	rilahes@utu.fi
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Alex Mackay	Astra Zeneca, Cambridge, United Kingdom	alex.mackay@astrazeneca.com
Glenda Lassi	Astra Zeneca, Cambridge, United Kingdom	glenda.lassi@astrazeneca.com
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton@biogen.com
Hubert Chen	Genentech, San Francisco, CA, United States	chenh37@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom	joanna.c.betts@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom	rajashree.x.mishra@gsk.com
Majd Mouded	Novartis, Basel, Switzerland	majd.mouded@novartis.com
Debby Ngo	Novartis, Basel, Switzerland	debby.ngo@novartis.com
Teemu Niiranen	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	teemu.niiranen@thl.fi
Felix Vaura	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	fechva@utu.fi
Veikko Salomaa	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	veikko.salomaa@thl.fi
Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland	kaj.metsarinne@tyks.fi
Jenni Aittokallio	Hospital District of Southwest Finland, Turku, Finland	jemato@utu.fi
Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland	mika.kahonen@uta.fi
Jussi Hernesniemi	Pirkanmaa Hospital District, Tampere, Finland	jussi.hernesniemi@tuni.fi
Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	daniel.gordin@hus.fi
Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	juha.sinisalo@hus.fi
Marja-Riitta Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	marja-riitta.taskinen@helsinki.fi
Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tiinamaija.tuomi@hus.fi
Timo Hiltunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	timo.hiltunen@hus.fi
Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland	jari.laukkanen@ksshp.fi

Clinical Groups Clinical Groups Clinical Groups Clinical Groups Clinical Groups Clinical Groups Clinical Groups

Clinical Groups Clinical Groups

Clinical Groups

Clinical Groups

Rheumatology Group Rheumatology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group

Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Pulmonology Group Cardiometabolic Diseases Group

Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	aelliott@broadinstitute.org
Mary Dat Daars	Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston,	
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•
Sanni Ruotsalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Benjamin Challis	Astra Zeneca, Cambridge, United Kingdom	benjamin.challis@astrazeneca.com
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@astrazeneca.com
Julie Hunkapiller	Genentech, San Francisco, CA, United States	hunkapiller.julie@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom	audrey.y.chu@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Dermot Reilly	Janssen Research & Development, LLC, Boston, MA, United States	dreill11@its.jnj.com
Mike Mendelson	Novartis, Boston, MA, United States	mike.mendelson@novartis.com
Jaakko Parkkinen	Pfizer, New York, NY, United States	jaakko.parkkinen@pfizer.com
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com
Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuomo.meretoja@hus.fi
Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	heikki.joensuu@hus.fi
Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	olli.carpen@helsinki.fi
Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	johanna.mattson@hus.fi
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi
Annika Auranen	Pirkanmaa Hospital District, Tampere, Finland	anaura@utu.fi
Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland	peeter.karihtala@oulu.fi
Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland	paivi.auvinen@kuh.fi
Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland	klaus.elenius@utu.fi
Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mark.daly@helsinki.fi
Mark Daly	Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	
Relja Popovic	Abbvie, Chicago, IL, United States	relja.popovic@abbvie.com
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Jennifer Schutzman	Genentech, San Francisco, CA, United States	schutzman.jennifer@gene.com
Julie Hunkapiller	Genentech, San Francisco, CA, United States	hunkapiller.julie@gene.com
· ·		

Clinical Groups

Clinical Groups Clinical Groups

Clinical Groups Clinical Groups Clinical Groups Clinical Groups Clinical Groups

Cardiometabolic Diseases Group

Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Cardiometabolic Diseases Group Oncology Group Oncology Group **Oncology Group Oncology Group Oncology Group Oncology Group** Oncology Group **Oncology Group Oncology Group Oncology Group Oncology Group Oncology Group** Oncology Group Oncology Group

Oncology Group Oncology Group Oncology Group **Oncology Group Oncology Group**

Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom	diptee.a.kulkarni@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Alessandro Porello	Janssen Research & Development, LLC, Spring House, PA, United States	APorrell@ITS.JNJ.com
Andrey Loboda	Merck, Kenilworth, NJ, United States	andrey_loboda@merck.com
Heli Lehtonen	Pfizer, New York, NY, United States	heli.lehtonen@pfizer.com
Stefan McDonough	Pfizer, New York, NY, United States	stefan.McDonough@pfizer.com
Sauli Vuoti	Janssen-Cilag Oy, Espoo, Finland	svuoti@its.jnj.com
Kai Kaarniranta	Northern Savo Hospital District, Kuopio, Finland	kai.kaarniranta@uef.fi
Joni A Turunen	Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group,	joni.turunen@helsinki.fi
	Folkhälsan Research Center, Helsinki, Finland	
Terhi Ollila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	terhi.ollila@hus.fi
Hannu Uusitalo	Pirkanmaa Hospital District, Tampere, Finland	hannu.uusitalo@tuni.fi
Juha Karjalainen Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland juha.karjalainen@helsinki.fi		
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d esa.pitkanen@helsinki.fi
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com
Stephanie Loomis	Biogen, Cambridge, MA, United States	stephanie.loomis@biogen.com
Erich Strauss	Genentech, San Francisco, CA, United States	strauss.erich@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Hao Chen	Genentech, San Francisco, CA, United States	haoc@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Kaisa Tasanen	Northern Ostrobothnia Hospital District, Oulu, Finland	kaisa.tasanen-maatta@oulu.fi
Laura Huilaja	Northern Ostrobothnia Hospital District, Oulu, Finland	laura.huilaja@oulu.fi
Katariina Hannula-Jouppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	katariina.hannula-jouppi@hus.fi
Teea Salmi	Pirkanmaa Hospital District, Tampere, Finland	teea.salmi@pshp.fi
Sirkku Peltonen	Hospital District of Southwest Finland, Turku, Finland	sipelto@utu.fi
Leena Koulu	Hospital District of Southwest Finland, Turku, Finland	leena.koulu@tyks.fi
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
David Choy	Genentech, San Francisco, CA, United States	choy.david@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com

Clinical Groups Clinical Groups

Clinical Groups Clinical Groups

Clinical Groups

Oncology Group Oncology Group

Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Opthalmology Group Dermatology Group **Dermatology Group** Dermatology Group Dermatology Group **Dermatology Group** Dermatology Group Dermatology Group **Dermatology Group** Dermatology Group **Dermatology Group** Dermatology Group **Dermatology Group**

Kirsi Kalpala Ying Wu Pirkko Pussinen Aino Salminen Tuula Salo David Rice Pekka Nieminen Ulla Palotie Maria Siponen Liisa Suominen Päivi Mäntylä Ulvi Gursoy Vuokko Anttonen Kirsi Sipilä Rion Pendergrass Hannele Laivuori Venla Kurra Laura Kotaniemi-Talonen Oskari Heikinheimo Ikka Kalliala Lauri Aaltonen Varpu Jokimaa Johannes Kettunen Marja Vääräsmäki Outi Uimari Laure Morin-Papunen Maarit Niinimäki Terhi Piltonen Katja Kivinen Elisabeth Widen Taru Tukiainen	Pfizer, New York, NY, United States Pfizer, New York, NY, United States Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Northern Savo Hospital District, Kuopio, Finland Hospital District of Southwest Finland, Turku, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland; Medical Research Center, Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland Genentech, San Francisco, CA, United States Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu	venla.kurra@tuni.fi laura.kotaniemi-talonen@tuni.fi oskari.heikinheimo@helsinki.fi ilkka.kalliala@hus.fi lauri.aaltonen@helsinki.fi varpu.jokimaa@utu.fi Johannes.Kettunen@oulu.fi marja.vaarasmaki@oulu.fi outi.uimari@oulu.fi Imp@cc.oulu.fi maarit.niinimaki@oulu.fi terhi.piltonen@oulu.fi katja.kivinen@helsinki.fi
		•
Elisabeth Widen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elisabeth.widen@helsinki.fi
Taru Tukiainen		
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	5
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@helsinki.fi
	Finianu, bioau institute of with and halvaru, wassachusetts General hospital	

Clinical Groups Clinical Groups

Clinical Groups Clinical Groups

Clinical Groups

Dermatology Group Dermatology Group Odontology Group

Odontology Group

Women's Health and Reproduction Group Women's Health and Reproduction Group

Niko Välimäki	University of Helsinki, Helsinki, Finland	niko.valimaki@helsinki.fi
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi
Jaakko Tyrmi	University of Oulu, Oulu, Finland / University of Tampere, Tampere, Finland	jaakko.tyrmi@oulu.fi
Heidi Silven	University of Oulu, Oulu, Finland	heidi.silven@student.oulu.fi
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi
Riikka Arffman	University of Oulu, Oulu, Finland	riikka.arffman@oulu.fi
Susanna Savukoski	University of Oulu, Oulu, Finland	susanna.savukoski@oulu.fi
Triin Laisk	Estonian biobank, Tartu, Estonia	triin.laisk@ut.ee
Natalia Pujol	Estonian biobank, Tartu, Estonia	natalia.pujolgualdo@oulu.fi
, Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Janet Kumar	GlaxoSmithKline, Collegeville, PA, United States	janet.x.kumar@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
liris Hovatta	University of Helsinki, Finland	iiris.hovatta@helsinki.fi
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com
Erkki Isometsä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	erkki.isometsa@hus.fi
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi
Jaana Suvisaari	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	jaana.suvisaari@thl.fi
Thomas Damm Als	Aarhus University, Denmark	tda@biomed.au.dk
Antti Mäkitie	Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and	antti.makitie@helsinki.fi
	Helsinki University Hospital, Helsinki, Finland	
Argyro Bizaki-Vallaskanga	s Pirkanmaa Hospital District, Tampere, Finland	argyro.bizaki-vallaskangas@tuni.fi
Sanna Toppila-Salmi	University of Helsinki, Finland	sanna.salmi@helsinki.fi
Tytti Willberg	Hospital District of Southwest Finland, Turku, Finland	tytti.willberg@tyks.fi
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarentaus@helsinki.fi
Antti Aarnisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	antti.aarnisalo@hus.fi
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi
Elisa Rahikkala	Northern Ostrobothnia Hospital District, Oulu, Finland	elisa.rahikkala@ppshp.fi
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kettunen@oulu.fi
Kristiina Aittomäki	Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland	kristiina.aittomaki@helsinki.fi
Fredrik Åberg	Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University,	fredrik.aberg@helsinki.fi
	Helsinki, Finland	

Clinical Groups Clinical Groups

Clinical Groups Women's Health and Reproduction Group Depression group ENT (ear, nose and throath) Group

ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group ENT (ear, nose and throath) Group

Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mkurki@broadinstitute.org	Fi
	Finland; Broad Institute, Cambridge, MA, United States		
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l samuli.ripatti@helsinki.fi	F
Mark Daly	Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mark.daly@helsinki.fi	Fi
	Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital		
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	^l juha.karjalainen@helsinki.fi	F
Aki Havulinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aki.havulinna@helsinki.fi	F
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l juha.mehtonen@helsinki.fi	F
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@helsinki.fi	F
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlanc	shabbeer.hassan@helsinki.fi	F
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlanc	pietro.dellabriottaparolo@helsinki.fi	F
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org	F
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org	F
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org	F
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	shabbeer.hassan@helsinki.fi	F
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lemmela@helsinki.fi	F
Manuel Rivas	University of Stanford, Stanford, CA, United States	mrivas@stanford.edu	F
Mari E. Niemi	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mari.e.niemi@helsinki.fi	F
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aarno.palotie@helsinki.fi	F
Aoxing Liu	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aoxing.liu@helsinki.fi	F
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	arto.lehisto@helsinki.fi	F
Andrea Ganna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aganna@broadinstitute.org	F
Vincent Llorens	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	vincent.llorens@helsinki.fi	F
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivuori@helsinki.fi	F
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	taru.tukiainen@helsinki.fi	F
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi	F
Henrike Heyne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hheyne@broadinstitute.org	F
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi	F
Joel Rämö	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	ijoel.ramo@helsinki.fi	F
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarentaus@helsinki.fi	F
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi	F
Rodos Rodosthenous	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rodos.rodosthenous@helsinki.fi	F
Satu Strausz	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		F
Tuula Palotie	University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.palotie@helsinki.fi	F
Kimmo Palin	University of Helsinki, Helsinki, Finland	kimmo.palin@helsinki.fi	F

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi	F
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi	F
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi	F
Jiwoo Lee	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	jiwoo.lee@helsinki.fi	F
Kristin Tsuo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	kristintsuo@fas.harvard.edu	F
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston,	aelliott@broadinstitute.org	F
Kati Kristiansson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristiansson@thl.fi	F
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	mikko.arvas@veripalvelu.fi	F
Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland	kati.hyvarinen@veripalvelu.fi	F
Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland	jarmo.ritari@veripalvelu.fi	F
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi	F
Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	johannes.kettunen@oulu.fi	F
	Oulu, Finland		
Katri Pylkäs	University of Oulu, Oulu, Finland	katri.pylkas@oulu.fi	F
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi	F
Minna Karjalainen	University of Oulu, Oulu, Finland	minna.k.karjalainen@oulu.fi	F
Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	tuomo.mantere@oulu.fi	F
Eeva Kangasniemi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	eeva.kangasniemi@pshp.fi	F
Sami Heikkinen	University of Eastern Finland, Kuopio, Finland	sami.heikkinen@uef.fi	F
Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	arto.mannermaa@uef.fi	F
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi	F
Nina Pitkänen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	Niina.Pitkanen@tyks.fi	F
Samuel Lessard	Translational Sciences, Sanofi R&D, Framingham, MA, USA	samuel.lessard@sanofi.com	F
Clément Chatelain	Translational Sciences, Sanofi R&D, Framingham, MA, USA	clement.chatelain@sanofi.com	F
Perttu Terho	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	perttu.terho@tyks.fi	B
Sirpa Soini	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sirpa.soini@thl.fi	B
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	•	B

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grouFinnGen Analysis working grouFinnGen Analysis working groupFinnGen Analysis working grouFinnGen Analysis working groupFinnGen Analysis working grouFinnGen Analysis working groupBiobank directorsBiobank directorsBiobank directorsBiobank directorsBiobank directorsBiobank directors

Eero Punkka	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	eero.punkka@hus.fi	Biobank directors	Biobank directors
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District	, raisa.serpi@ppshp.fi	Biobank directors	Biobank directors
	Oulu, Finland			
Sanna Siltanen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	sanna.siltanen@pshp.fi	Biobank directors	Biobank directors
	Tampere, Finland			
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,	veli-matti.kosma@uef.fi	Biobank directors	Biobank directors
	Kuopio, Finland			
Teijo Kuopio	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,	teijo.kuopio@ksshp.fi	Biobank directors	Biobank directors
	Jyväskylä, Finland			
Anu Jalanko	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d anu.jalanko@helsinki.fi	FinnGen Teams	Administration
Huei-Yi Shen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d huei-yi.shen@helsinki.fi	FinnGen Teams	Administration
Risto Kajanne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d risto.kajanne@helsinki.fi	FinnGen Teams	Administration
Mervi Aavikko	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d mervi.aavikko@helsinki.fi	FinnGen Teams	Administration
Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mkurki@broadinstitute.org	FinnGen Teams	Analysis
	Finland; Broad Institute, Cambridge, MA, United States			
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d juha.karjalainen@helsinki.fi	FinnGen Teams	Analysis
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d pietro.dellabriottaparolo@helsinki.fi	FinnGen Teams	Analysis
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d arto.lehisto@helsinki.fi	FinnGen Teams	Analysis
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d juha.mehtonen@helsinki.fi	FinnGen Teams	Analysis
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org	FinnGen Teams	Analysis
Masahiro Kanai	Broad Institute, Cambridge, MA, United States	mkanai@broadinstitute.org	FinnGen Teams	Analysis
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org	FinnGen Teams	Analysis
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org	FinnGen Teams	Analysis
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d hannele.laivuori@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Aki Havulinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d aki.havulinna@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d susanna.lemmela@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d tuomo.kiiskinen@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
L. Elisa Lahtela	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d laura.lahtela@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Mari Kaunisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d mari.kaunisto@helsinki.fi	FinnGen Teams	Communication
Elina Kilpeläinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d elina.kilpelainen@helsinki.fi	FinnGen Teams	E-Science
Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d timo.p.sipila@helsinki.fi	FinnGen Teams	E-Science
Oluwaseun Alexander Dao	اء Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		FinnGen Teams	E-Science
Awaisa Ghazal	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		FinnGen Teams	E-Science
Anastasia Kytölä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		FinnGen Teams	E-Science
Rigbe Weldatsadik	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d rigbe.weldatsadik@helsinki.fi	FinnGen Teams	E-Science

Kati Donner Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Anu Loukola	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	anu.loukola@hus.fi
Päivi Laiho	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	paivi.laiho@thl.fi
Tuuli Sistonen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tuuli.sistonen@thl.fi
Essi Kaiharju	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	essi.kaiharju@thl.fi
Markku Laukkanen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markku.laukkanen@thl.fi
Elina Järvensivu	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	elina.jarvensivu@thl.fi
Sini Lähteenmäki	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sini.lahteenmaki@thl.fi
Lotta Männikkö	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	lotta.mannikko@thl.fi
Regis Wong	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	regis.wong@thl.fi
Auli Toivola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	auli.toivola@thl.fi
Minna Brunfeldt	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	minna.brunfeldt@thl.fi
Hannele Mattsson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	hannele.mattsson@thl.fi
Kati Kristiansson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristiansson@thl.fi
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Sami Koskelainen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sami.koskelainen@thl.fi
Tero Hiekkalinna	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tero.hiekkalinna@helsinki.fi
Teemu Paajanen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	teemu.paajanen@thl.fi
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Kalle Pärn	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	kalle.parn@helsinki.fi
Mart Kals	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mart.kals@helsinki.fi
Shuang Luo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	shuang.luo@helsinki.fi
Vishal Sinha	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	vishal.sinha@helsinki.fi
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Marianna Niemi	University of Tampere, Tampere, Finland	marianna.niemi@tuni.fi
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi
Javier Gracia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi
Mika Helminen	University of Tampere, Tampere, Finland	mika.helminen@tuni.fi
Tiina Luukkaala	University of Tampere, Tampere, Finland	tiina.luukkaala@tuni.fi
lida Vähätalo	University of Tampere, Tampere, Finland	iida.vahatalo@epshp.fi
Jyrki Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	jyrki.pitkanen@helsinki.fi
Marco Hautalahti	Finnish Biobank Cooperative - FINBB	marco.hautalahti@finbb.fi

FinnGen Teams FinnGen Teams **FinnGen Teams FinnGen Teams** FinnGen Teams FinnGen Teams **FinnGen Teams FinnGen Teams** FinnGen Teams **FinnGen Teams FinnGen Teams** FinnGen Teams **FinnGen Teams FinnGen Teams** FinnGen Teams **FinnGen Teams FinnGen Teams FinnGen Teams FinnGen Teams**

Genotyping Genotyping Sample Collection Coordination Sample Logistics **Registry Data Operations Registry Data Operations** Sequencing Informatics Sequencing Informatics Sequencing Informatics Sequencing Informatics Sequencing Informatics Trajectory Trajectory Trajectory Trajectory Trajectory Trajectory Trajectory Trajectory Trajectory Data protection officer FINBB - Finnish biobank cooperative Johanna Mäkelä Sarah Smith Tom Southerington

Finnish Biobank Cooperative - FINBB Finnish Biobank Cooperative - FINBB Finnish Biobank Cooperative - FINBB

johanna.makela@finbb.fi sarah.smith@finbb.fi tom.southerington@finbb.fi FinnGen Teams FinnGen Teams FinnGen Teams FINBB - Finnish biobank cooperative FINBB - Finnish biobank cooperative

FINBB - Finnish biobank cooperative